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Abstract
Effect of CNTF derived peptide, P021 on cognition and pathology in 3xTg-AD mouse
model of Alzheimer’s disease
By
Narjes Baazaoui

Advisor: Dr Khalid Iqbal
Studies

described

in

this

thesis

deal

with

the

preventive

effects

of

a

neurogenic/neurotropic peptidergic compound, P021, on neurogenesis and synaptic deficits,
neurodegeneration, cognitive impairment, and A and tau pathologies in a 3xTg-AD mouse
model of Alzheimer’s disease (AD).
Background: AD is a chronic progressive neurodegenerative disease. Its multifactorial nature
and the heterogeneity make its treatment especially challenging. Although it is a major burden in
society, at present there is no drug that can stop or slow down the progression of the disease.
Currently, the only available treatments are symptomatic and for mild to severe stages. The
development of a drug that can prevent AD at its early stages would be of major importance. The
use of neurotrophic factors mimetic for the treatment of AD is an exciting therapeutic strategy. It
focuses mainly on boosting synaptic plasticity and neurogenesis which lead to shifting the
balance from neurodegeneration to regeneration of the brain as well as preventing A and tau
pathologies. Herein, I present the preventive effects of P021 treatment in 3xTg-AD mice that is
initiated very early in the disease during the period of synaptic compensation and is continued
for the lifespan of the animal.
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Aims: The specific aims were: 1) to study the presence of the synaptic compensation
phenomenon in the brain as a self-repairing mechanism in 3xTg-AD mice; 2) to study the
preventive effects of P021 on cognitive deterioration when administered during the
compensation period; 3) to study the preventive effects of P021 on amyloid beta (A) and tau
pathologies; and 4) to study the effect of P021 on synaptic deficit, neuronal degeneration and
neurogenesis.
Methods: A battery of behavioral tests was conducted to assess the cognitive performance in
3xTg-AD mice with and without treatment with P021 at different disease stages.
Immunohistochemical and biochemical analyses were performed to determine the levels of
synaptic protein expression as well as A and tau pathologies at different time points that
correspond to different stages of disease progression. Neurodegeneration was studied
immunohistochemically

with

Fluorojade

C

staining.

Neurogenesis

was

studied

immunohistochemically with DCX (double cortin) and Ki-67 staining.
Results: The 3xTg-AD mice at the age of 12 weeks were found to be cognitively impaired and
showed a decrease in multiple synaptic and neuronal markers. This decrease was compensated
by the brain until ~16 weeks of age. Beyond 16 weeks the brain was found to fail to compensate
for the synaptic deficit. P021 intervention, started at 14 weeks of age, prevented cognitive
impairment 9 months post-treatment, as tested by the Morris Water maze task. At 15-17 months
post-treatment P021 was able to rescue short-term spatial reference memory as well as episodic
memory, as determined by the novel object location and the novel object recognition tasks. The
treatment with P021 also prevented A and tau pathologies during 9-18 months post-treatment.
P021 was able to rescue synaptic deficit and neurodegeneration 9-18 months post-treatment and
boost neurogenesis at 9 months post-treatment. P021 treatment increased survival from 41% in
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3xTg-AD-vh to 87% in 3xTg-AD-P021 mice. In the entire study I did not find any severe side
effects of P021 including loss of appetite or body weight.
Conclusions: Early intervention with P021 during the period of synaptic compensation of the
brain was successful in preventing cognitive impairment in 3xTg-AD mice. The P021 treatment
prevented synaptic and neurogenesis deficits, neurodegeneration, and A and tau pathologies.
These findings provide a proof of principle of the potential therapeutic effect of P021 on several
major features of AD.
Key Words: Aβ pathology, Alzheimer’s disease, brain derived neurotrophic factor, cognitive
impairment, neurodegeneration, neurogenesis, neurotrophic factor, mortality, synaptic plasticity,
tau pathology, therapeutic prevention, 3xTg-AD.
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Introduction
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States and the
most common form of dementia; it accounts for 60-80% of dementia cases. Although AD is
known as a disease of old age, with more than 95% of AD sporadic cases occurring at an age of
>65 years, the remaining <5% are familial cases and have early onset, usually around the age of
40 to 50 years. AD is a progressive neurodegenerative disease with a slow memory loss at early
stages followed by severe cognitive impairment and memory loss at later stages along with
personality changes and susceptibility to infectious diseases such as pneumonia, which is the
major cause of death at later stages. It is a non-linear disease in which the first brain changes
occur more than a decade before the appearance of clinical symptoms. AD is characterized by
two histopathological hallmarks, β-amyloidosis and neurofibrillary degeneration, which are the
biological basis for dementia. The oligomeric forms of tau and amyloid beta (Aβ) are believed to
be most toxic to neurons because they, respectively, sequester normal tau and bind to cell surface
receptors and contain β conformation that ends up in  sheets which make them resistant to
degradation. A accumulation is believed to disrupt the communication between neurons
through the synapses, which leads to synaptic death and later to neuronal death. The intracellular
accumulation of tau as neurofibrillary tangles (NFT) is believed to disrupt the axonal transport,
which leads to synaptic death followed by neuronal death. Indeed, the brain atrophy seen in AD
is consistent with neurodegeneration seen in patients with severe AD.
Because of the increase in lifespan in the developed countries, AD has increasingly
become a major health problem and burden to society. Worldwide, AD currently affects 44
million people and this number is expected to increase to 135 million by 2050 with the aging of
the baby boomer generation. The costs for health care in the US alone are estimated to be about
1

$217 billion (Alzheimer's Assocation 2015) in addition to social and emotional costs. Because
AD has a multifactorial nature and the neuropathological insults that, at present, cannot be
reliably detected in living individuals start more than a decade before the appearance of the first
clinical symptoms, it makes it difficult to develop a drug that can stop or at least slow down the
progression of the disease. Currently there is no treatment for AD. The six approved drugs are
able only to temporarily improve the clinical symptoms; they do not stop or slow down the
disease. The majority of the approved drugs for AD are cholinesterase inhibitors such as Tacrine
(rarely prescribed today), Donepezil for all AD stages, Galantamine for mild to moderate stages,
and Rivastagmine for mild to moderate stages. Memantine is an NMDA receptor antagonist and
has beneficial symptomatic effect only during moderate to severe stages of AD. Namzaric is a
combination of donepezil and memantine. All of these drugs act by increasing neurotransmitter
release. Tacrine, Galantamine and memantine have also been reported to increase neurogenesis
(Jin et al., 2006). From 2002-2012, the only new drug approved by the Food and Drug
Administration (FDA) was memantine. Namzaric was approved in late 2014. A major problem
that faces drug development is that it is a lengthy process with a 95% chance of failure, and the
average time for a development of a drug from the discovery to approval in the market requires
an average of 10-15 years (Schneider et al., 2014).
Because of the repeated failures in the development of a drug to treat AD, several
therapeutic approaches have been developed in recent years in an attempt to design an effective
drug for AD. There are two major approaches; the first one is to inhibit neurodegeneration and
disease progression and the second one is to reverse neurodegeneration and prevent cognitive
impairment by boosting the regenerative capacities of the brain. In most disease modifying
strategies the first approach used to attempt to inhibit neurodegeneration was to remove toxic
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protein aggregates such as A aggregates, A plaques, tau aggregates and NFT. However, the
phase III clinical trials of the drugs targeting Aβ showed that this approach is ineffective at least
in patients with an advanced stage of the disease. This has led to conducting human clinical trials
with Aβ passive immunotherapy at mild and prodromal stages of the disease and to tau-based
therapeutic approaches, especially immunotherapies (Iqbal et al., 2016). The other promising
approach in developing and designing AD drugs is to reverse synaptic loss and
neurodegeneration and to boost neurogenesis, focusing mainly on treating the pathophysiological
features of the disease rather than directly targeting Aβ and tau pathologies. Indeed, previous
studies showed that synaptic loss is more tightly related to neurodegeneration and the
progression of the disease than NFT or A plaques (Terry et al., 1991). The use of a small
neurotrophic peptide mimetic that has neurogenic/neurotrophic effect, is able to cross the bloodbrain barrier (BBB), is bioavailable and biostable, and is safe, with minimal or no side effects,
represents a promising strategy to reverse neurodegeneration. This strategy has a wide
therapeutic window compared to toxin clearance approaches and, because of the
neurogenic/neurotrophic effect, can be used even at a later stage of the disease to stop or slow
down its progression. Because of the lack of early diagnosis and the unavailability of efficient
biomarkers, AD is discovered only after significant pathological changes have happened in the
brain. Indeed, in individuals with disease-causing autosomal dominant mutations, who are at a
very high risk to develop AD, A deposition starts 15-20 years before the appearance of any
clinical symptoms (Lu et al., 2013; Sperling et al., 2014).
In our lab we adopted the approach of boosting the regenerative capacity of the brain
using a neurogenic/neurotrophic peptidergic compound mimetic, named P021 (Ac-DGGLAGNH2). P021 is derived from the most active region of the ciliary neurotrophic factor (CNTF) (Li
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et al., 2010). It has a plasma half life of > 3 h, is 100% stable in the intestinal fluid during 2 h,
and ~90% stable in gastric juice during 30 min (Kazim et al., 2014). P021 is adamantylated on its
C-terminal to protect it from degradation by carboxypeptidases and increase its blood brain
barrier (BBB) permeability. Previously we showed that P021 increases neurogenesis and
neuronal plasticity (Blanchard et al., 2010b, Bolognin et al., 2012, Kazim et al., 2014). The
neurogenic and neurotrophic effects of P021 are due to its competitive inhibition with Leukemia
inhibitory factor (LIF) through the decrease in the phosphorylation of pSTAT3 (Li et al., 2010,
Kazim et al., 2014). It decreases tau phosphorylation through the increase in BDNF expression
mainly through enhancing its transcription (Bolognin et al., 2012, Bolognin et al., 2014). The
increase in BDNF expression leads to an increase in the phosphorylation of GSK3β at serine 9
which leads to its inactivation. Since GSK 3β is the major serine/threonine kinase that
phosphorylates tau at many different sites such as Ser199, Ser202, Thr205, Ser396, and Ser404,
its inactivation results in a decrease in the level of phosphorylation, hence to a global decrease in
tau pathology. Besides, P021 also has an effect on decreasing A pathology through the decrease
in the generation of A (Kazim et al., 2014). This P021 effect is thought to occur also through
the inhibition of GSK3β, which is also implicated in A mediated neuritic damage (DaRochaSouto et al., 2012), APP processing and A deposition (Phiel et al., 2003).
Several reports in the literature emphasize the presence of a compensatory mechanism
during the early stages of AD to slow down neurodegeneration, synaptic loss and cognitive
deterioration. The compensatory phenomenon was shown to work by enhancing neurogenesis to
replace the lost neurons (Li et al, 2008) and increase the production of neurotrophic factors such
as the brain derived neurotrophic factor (BDNF) (Faria, et., 2014) or synaptic plasticity either by
an increase in the level of expression of synaptic proteins or in the size of the surviving synapses
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to compensate for synaptic loss (Scheff et al, 2006). It is believed that this compensation is
present in healthy aging, but it is defective in AD and it occurs only during early stages where
there is minimal brain insult (Bertoni-Freddari et al., 1988, Barnes, 1994, Brown et al., 1998,
Mukaetova-Ladinska et al., 2000). Probably that is why there is a slow progression of the
disease. In contrast, once the brain damage reaches a certain threshold, the compensation
phenomenon fails and the cognitive deterioration and clinical symptoms show a drastic and
dramatic decline. Therapeutic intervention during the compensation period is believed to boost
compensation and help prevent cognitive impairment, neurodegeneration and synaptic loss.
The specific objective of this study was (i) to investigate the presence of the
compensation phenomenon at a very early stage of the disease akin to AD in 3xTg-AD mice and
(ii) to start the treatment with P021 when the compensatory phenomenon is still effective to
investigate the effect of the compound on the prevention of the disease. The specific aims were:
1) to study the presence of the synaptic compensation phenomenon in the brain as a selfrepairing mechanism in 3xTg-AD mice; 2) to study the preventive effects of P021 when
administered during the compensation period on cognitive deterioration; 3) to study the
preventive effects of P021 on amyloid beta (A) and tau pathologies; and 4) to study the effect
of P021 on synaptic deficit, neuronal degeneration and neurogenesis.
I present and discuss the data of this study at four different time points: the first one is at
3 months of age before the treatment with P021; the other time points are 9 months (12 months
of age), 15 months (18 months of age) and at 18 months after treatment (21 months of age).
This work is presented as a chapter-based dissertation: Introduction, Background
(Chapter 1), Material and Methods (Chapter 2), synaptic compensation study in 3xTg-AD mice
(Chapter 3), the effect of early intervention with P021 on cognitive impairment (Chapter 4), on
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A and tau pathologies (Chapter 5), and on neuroregeneration and neurodegeneration (Chapter
6), and a general discussion (Chapter 7).
With this research I am aiming to answer the following questions: 1) would early
treatment with P021 be effective on boosting the compensatory mechanism? 2) Would early
intervention be effective in preventing cognitive impairment? 3) Would it prevent A and tau
pathologies? And 4) would it prevent neuronal and synaptic loss? Finally, 5) does P021 have the
potential to be considered for further drug development as a promising novel therapeutic
approach for AD?
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Chapter 1. Background
1.1

Alzheimer’s disease classification, prevalence, and public cost

1.1.1 AD classification
AD is classified into two major categories: 1) The sporadic or late onset form, which
represents the vast majority of AD cases (more than 95%) and tends to develop at the age of > 65
years with an unknown etiology; and 2) the familial or early onset form, which represents the
remaining ~5 % of cases. The familial AD is genetically inherited through mutations in one of
the three genes, the amyloid precursor protein (APP), presenilin 1 or presenilin 2. Generally
early onset AD or the inherited form tends to progress faster and follows a Mendelian pattern of
inheritance (Reitz and Mayeux, 2014). Mutations in APP or presenilin 1 are associated with
complete penetrance, meaning that any individual who has one of the mutations is guaranteed to
have an early onset of the disease. Presenilin 2 mutation has only 95% penetrance, thus not
everyone who has the mutation will develop AD. Individuals that have mutation in any of these
genes tend to have an early onset of AD, sometimes as early as 30 years of age (Alzheimer's
Assocation 2015) .
1.1.2 Prevalence and epidemiology
AD is the major cause of dementia; it represents 60-80 % of all dementia cases with
about half involving only AD. The incidence of AD increases with age, doubling every 5 years.
The prevalence also increases with age from 3% at the age of 65 to ~50% at the age of 85 or
older. Because of the decrease in birth rate and the increase in life expectancy, the percentage of
elderly people in the US is expected to increase from 12.4% (35 million) in 2000 to 19.6% (71
million) in 2030. Worldwide the number of people that are 65 years or older is expected to
increase more than double from 420 million in 2000 to 973 million in 2030 (Castellani et al.,
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2010). In the US alone there are around 5.3 million people that have AD, with 5.1 million aged
65 years or older and approximately 200,000 with early onset. This number is projected to
increase up to ~15 million in 2050. Women represent almost two thirds of the AD cases in the
US. Indeed, out of the 5.1 million affected, 3.2 million are women. Currently in the US every 67
seconds there is a new case of AD and by 2050 it will be every 33 seconds. With the increase in
life expectancy and the aging of the baby boomer generation, the number of elderly people may
even increase. Because aging is a high risk factor for AD, the number of people who develop AD
would even increase.
AD is the sixth leading cause of death in the US and the fifth leading cause of death in
individuals 65 years and older. Between 2000-2013 deaths ascribed to AD increased by 71%
while deaths attributed to heart disease (the most frequent cause of death) decreased by 14%. In
the US AD rose from the 25th most burdensome disease in 1990 to the 12th most burdensome
disease in 2010 (Alzheimer's Assocation 2015). In 2005, the highest prevalence of dementia was
recorded in the US and Western Europe, affecting 6.4 and 5.4% of the population at age 60,
followed by Latin America and China (Mayeux and Stern, 2012).
1.1.3 Public cost
The financial cost of AD is large. Indeed, the lifetime cost per AD person is estimated to
be $174,000 (Castellani et al., 2010). In 2015, the estimated total health care and hospital
services for people that are 65 years or older with dementia was $226 billion. The contribution
from family members and other unpaid caregivers was estimated to be 17.9 billion hours of
caregiving, which is valued at more than $217 billion. By 2050 the national cost of AD could
reach $1 trillion. Beyond financial costs AD also causes major social and emotional distress to
the patient and his/her family (Alzheimer's Association 2015).
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1.2

AD diagnostics and symptoms, risk factors and preventive factors

1.2.1 Diagnostics and symptoms
Diagnostic criteria
Diagnostic criteria for AD were proposed in 1984 by a group of experts put together by the
National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease
and Related Disorders Association .These criteria combine both clinical and neuropathological patterns to
classify AD as possible (for typical clinical syndrome without intervening issues) , probable (for
diagnosis complicated by other disorders intervening with dementia) and definite (for autopsy confirmed
disease) AD and they were considered reliable for diagnosing AD for more than three decades. AD is
considered as a continuum with a broad spectrum starting with an asymptomatic stage at early adulthood
to definite AD late in life at the age of 65 years or older. The pathological features of AD include not only
A and tau pathologies but also synaptic deficit, neuronal loss, unsuccessful neurogenesis and
microgliosis (Mayeux and Stern, 2012, Reitz and Mayeux, 2014).

Symptoms
The early symptoms of AD are mainly difficulty remembering new conversations, names or
events. It is often accompanied by depression and apathy. This mild cognitive impairment (MCI) is an
intermediate stage between the expected cognitive decline of normal aging and the more serious decline
of dementia. It can involve problems with memory, language, thinking and judgment that are greater than
normal age-related changes but does not interfere notably with the activities of daily life (Gauthier et al.,
2006). In AD this MCI stage leads to symptoms that are mainly related to disorientation, difficulty
swallowing, walking or carrying a conversation, poor judgment and personality change (Fig. 1). How fast
the symptoms change from mild to moderate to severe varies among patients (Alzheimer's Association
2015).
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Fig. 1: Model of the clinical trajectory of AD (Sperling et al., 2011).
1.2.2 Risk factors
Age
Age is a major risk factor to develop AD. Usually people who are 65 years or older are more
susceptible to develop AD. However, age alone does not cause AD and AD is not part of normal aging
(Alzheimer's Association 2015).

APOE4
Inheritance of the APOE4 allele is a major genetic risk factor for developing AD. The
APOE4 allele is located on the chromosome 19q13. APOE is a lipid-binding protein that is
expressed in three isoforms in humans: APOE2, APOE3, and APOE4. These isoforms are coded
by the same gene locus and consist of 299 amino acids; the only structural difference is a single
amino acid change. APOE3 has Cys-112 and Arg-158, whereas APOE4 has arginines at both
sites, and APOE2 has cysteines at both sites. APOE2 has a frequency of ~8.4% in the general
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population and it is believed to have a protective effect against AD. APOE3 is the most
common allele (frequency of ~77.9%) and it is believed to have a neutral effect in developing
AD. APOE4 is present in ~14% of the population and in ~40% of the late onset of AD cases
(Wikipedia). People who inherit one copy of the allele APOE4 have a three fold higher risk of
AD while people who have two copies of the APOE4 have 8-15 fold higher risk of having AD
and they are more likely to have it than people who carry the APOE2 or the APOE3 alleles.
Approximately 2% of the US population carry APOE4. Out of all the cases of AD 40-60% of
people who are diagnosed with AD carry one or two copies of APOE4 (Alzheimer's Assocation
2015). Each copy of the APOE4 allele lowers the age of onset of AD by 6-7 years. However,
the presence of the 4 allele is not sufficient or necessary to develop AD (Reitz and Mayeux,
2014).
Other factors
An increasing number of studies link heart diseases to brain diseases, which is why
cerebrovascular diseases such as hemorrhagic infarcts, small and large ischemic infarcts and
vasculopathies are considered to be a risk for having AD. Stroke increases the risk of having
dementia by 4-12 times and the mechanism is unknown. High blood pressure in mid-life has
been shown to increase the risk of cognitive impairment and dementia in later life. Having type
II diabetes doubles the risk of having AD for as yet unknown reasons. The increase in cholesterol
level has been controversial as being a risk factor for AD. However, the increase of cholesterol in
mid-life is suspected to have a damaging effect in later life (Reitz and Mayeux, 2014). The risk
of AD is 2.3 times higher in people who experience moderate traumatic brain injury (TBI) and
4.7 times higher for people who experience severe TBI compared to non injured individuals
(www.alz.org). People with mild cognitive impairment (MCI) are at higher risk for developing
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AD, especially if the MCI is accompanied by memory problems, which will more likely lead to
early AD. 10-20% of people that are more than 65 years old have MCI and among those who had
serious symptoms 15% develop early AD. However, some MCI cases can reverse to normal
cognition or the MCI can remain stable and not proceed to AD (Alzheimer's Assocation 2015).
1.2.3 Preventive factors:
Exercise
It has been well documented that physical exercise increases the level of the brain derived
neurotrophic factor (BDNF) and increases neurogenesis (van Praag et al., 1999) and neuronal
plasticity. Exercise may also increase brain vascularization (Black et al, 1990), neuronal survival
and resistance to brain insult (Carro et al., 2001).
Diet
Recently it was shown that the Mediterranean diet is associated with a lower risk of
developing AD and a lower mortality rate in AD patients. The Mediterranean diet is mostly
composed of vegetables, cereals, fish, a low to moderate intake of dairy products and a low to
moderate intake of poultry and meat (Castellani et al., 2010). In contrast, the consumption of a
high fat diet was associated with an increase of cholesterol and an increased risk of vascular
disease in the brain (Mayeux and Stern, 2012).
Brain and cognitive reserve
The fact that some patients have AD neuropathological lesions that are not accompanied
by cognitive impairment led to the suggestion that these people are resilient and they have high
cognitive or brain reserve. Brain reserve encompasses both brain size and cognitive reserve. The
cognitive reserve refers to the ability of the brain to use alternative neuronal networks or
cognitive strategies to overcome the cognitive impairment and it was associated with a higher
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level of education (Alzheimer's Association 2015). Thus, a high brain reserve, it is suggested,
could exert a compensatory and a protective effect against AD. Compensation would be effective
for a long period of time to protect from cognitive decline. However, once a certain threshold of
damage was reached, the compensation would fail and the cognitive decline would be more rapid
and drastic compared to AD non-resilient patients (Sperling et al., 2014). In a large longitudinal
cohort study consisting of AD, amnestic mild cognitive impairment patients (aMCI) and healthy
controls, a larger intracranial volume was found to attenuate the effect of atrophy and APOE4 in
aMCI but it did not correlate with the severity of clinical symptoms or worsening of atrophy.
However, this protective effect was found to be efficient only during early stages of AD. Once a
neurodegeneration threshold is reached, brain size is no longer protective (Guo et al., 2013). This
argues in favor of a role of brain reserve in compensation for neuronal loss instead of
neuroprotection

1.3

The three common hypotheses of AD
The exact cause of AD remains to be established. Several hypotheses concerning the

etiopathogenesis have evolved over the years but to date none of them have been found to
explain all aspects of the disease. The three major hypotheses are the cholinergic, Aβ cascade,
and tau hypotheses, as follows.
1.3.1 Cholinergic Hypothesis
Previously AD was considered to be a cholinergic disease associated with severe loss of
central cholinergic neurons and the level of cognitive impairment was correlated with the level of
cholinergic loss. Indeed, the cholinergic hypothesis states that the cognitive impairment in AD is
caused by the degeneration of basal forebrain cholinergic neurons due to aberrant signaling of
the neurotrophin P75 receptor through the increase in proNGF level and decrease in NGF level
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in AD patients. The increase in proNGF level was shown to stimulate cell death through the P75
receptor (Podlesniy et al., 2006). This hypothesis led to the development of cholinomimetics like
Tacrine, Donepezil and Rivastigmine that are being used for the symptomatic treatment of AD.
1.3.2 A hypothesis
APP is an integral membrane protein that acts as a signaling receptor. It is produced due
to alternative splicing of its transcripts as three different isoforms: APP695, APP751, and APP770.
The three mRNA isoforms are present in almost every tissue in different ratios. It is the mRNA
and the protein expression of APP695 that is more prominent in neurons. APP is metabolized
through two different pathways: amyloidogenic and non amyloidogenic (Fig. 2). In the non
amyloidogenic pathway APP is first cleaved by -secretase in the A region between Lys16 and
Leu17 and the resulting carboxy-terminal fragment is further cleaved by γ-secretase enzyme.
This pathway precludes the production of A. However, in the amyloidogenic pathway APP is
sequentially cleaved by - and γ-secretases to produce a soluble monomeric A fragment. The
most commonly produced A isoforms are A1-40 and A1-42. A1-40 is more prone to
deposit in brain blood vessels, as seen in cerebral amyloid angiopathy, whereas A1-42 is more
prone to form insoluble aggregates because of its hydrophobic nature. Since A is a normal
metabolite of APP it is believed that an imbalance between the rate of production and clearance
of A is what leads to A plaque deposition. The enzyme BACE1 is responsible for -secretase
activity, while PS1 and PS2 are part of the γ-secretase complex. The -secretase activity is
mediated by the ADAM family, especially ADAM10 and ADAM17 (Hicks et al., 2012,
Tarasoff-Conway et al., 2015).
Certain APP mutations that are causative of familial Alzheimer’s disease (FAD) also
result in the increase of A synthesis. Since PS1 and PS2 have γ-secretase activity, certain
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mutations in either of these proteins can also increase A production. However, it is well
established that A load does not correlate with cognitive impairment in AD. The A hypothesis
then places the accumulation of A as the major cause and the earliest key event in the AD
pathophysiological process, followed later on by NFT and neuronal loss. However, this
hypothesis remains controversial and challenged mainly because all the clinical trials based on
anti-A therapies failed to treat AD (Sperling et al., 2014).
1.3.3 Tau hypothesis
The tau hypothesis is that abnormally hyperphosphorylated tau is causative of the
disease. In AD the dementia correlates with the density of tau pathology. For instance, the
severity of dementia correlates better with the increase in the accumulation of NFT and the level
of hyperphosphorylated tau in the CSF correlates better with cognitive impairment (Rafii and
Aisen, 2015). It is hypothesized that due to aberrant signaling of tau protein kinases and/or
phosphatases, tau becomes hyperphosphorylated and aggregated into NFT, leading to abnormal
cellular trafficking and disruption of the microtubule-based cytoskeleton, followed by cell death.
After cell death the oligomeric forms of tau are released to the extracellular environment, which
stimulates microglial cells, leading to further prion-like spread of tau pathology and
neurodegeneration. So far the closest approximation to cognitive impairment in AD is the tau
hypothesis. The strongest support for the tau hypothesis comes from the fact that certain
mutations in the tau gene cause frontotemporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17). Furthermore, several tauopathies are characterized by accumulation
of abnormally hyperphosphorylated tau in the absence of Aβ pathology. NFT and neuropil
threads are common pathological features shared between various tauopathies such as
frontotemporal dementia, Pick’s disease, progressive supranuclear palsy and corticobasal
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degeneration (Brunden et al., 2009). The fact that all tauopathies share abnormal
hyperphosphorylated tau inclusions as a common pathological feature that is followed by
neurodegeneration and clinical phenotype strongly supports the idea that tau by itself can cause
neurodegeneration without the presence of Aβ.

1.4

Underlying pathologies
The neuropathological hallmarks of AD are grouped into so-called “negative” and

“positive lesions”. The negative lesions mainly represent synaptic and neuronal loss and the
positive lesions mainly represent A plaques and NFT. Plaques are primarily localized in the
cerebral cortex and NFT are primarily localized in the limbic and cortical association areas
(Serrano-Pozo et al., 2011a).
1.4.1 A plaques
Amyloid beta (A) plaques (Fig. 2) are extracellular, spherical deposits of A (10-200
µm in diameter) in the cerebral cortex. They are classified as dense core or diffuse plaques.
Dense-core plaques are thioflavin S and congo-red positive, usually associated with dystrophic
neurites, reactive astrocytes and synaptic loss, and they are considered to be pathological. They
are mainly composed of A 42 and their presence is generally associated with cognitive
impairment. Diffuse plaques are thioflavin S and congo-red negative, with amorphous shape, not
accompanied with dystrophic neurites or synaptic loss, and they are not considered for a
pathological diagnosis of AD because they are also found in the brains of healthy individuals.
The spatio-temporal pattern of the staging of the plaque pathology, unlike NFT, is far less
predictable but it is generally classified into three stages: first in isocortical areas, then in
allocortical or limbic areas, and finally in subcortical areas (Serrano-Pozo et al., 2011a). A
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deposition does not correlate with the severity of cognitive symptoms. In fact, it was shown
previously that the A deposition reaches a plateau in the isocortex right after the onset of
cognitive symptoms even in the preclinical stages of the disease (Ingelsson et al., 2004, SerranoPozo et al., 2011b).

Fig. 2. App processing pathways: amyloidogenic and non-amyloidogenic pathways
(Hicks et al., 2012).
1.4.2 NFT
Tau is a microtubule associated protein that is abundant in neurons; its main function is to bind
to and stabilize microtubules to facilitate axonal transport. In the normal physiological condition
tau is seen mainly localized in the axons and it is phosphorylated by several kinases to
destabilize microtubules and promote plasticity. Normal adult human brain tau contains 2-3
moles of phosphate, while in the AD brain tau is 3-4 times more hyperphosphorylated (Iqbal et
al., 2010). Tau hyperphosphorylation happens either because of hyperactive kinases or
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hypoactive phosphatases. Pathological tau in AD patients is found to be localized in the
somatodendritic compartment. Hyperphosphorylation of tau leads to destabilization of
microtubules and sequestration of normal tau by the pathological protein and its self-assembly
into paired helical filaments (PHF) as neuropil threads and NFT. NFT (Fig. 3) are intraneuronal
aggregates of hyperphosphorylated tau and misfolded tau and they are seen after neuronal death
as “ghost” tangles in the extracellular space. NFT have a spatiotemporal spread that correlates
with the severity of cognitive impairment and they parallel synaptic and neuronal loss. The
topographic staging of AD is used for the diagnosis of AD. Early NFT formation starts in the
entorhinal/perirhinal cortex, followed by the hippocampus, the association cortex and finally the
primary cortex (Braak and Braak, 1991, Serrano-Pozo et al., 2011a, Glass and Arnold, 2012).
NFT are classified as pre-NFT with diffuse and sometimes punctuate staining in normal-looking
neurons. Mature or intraneuronal NFT are found in the cytoplasm and they push the location of
the nucleus to the periphery. The shape of dendrites and the proximal axon looks distorted.
Extracellular or ghost NFT are found when tangle-bearing neurons are dead and they are
identified by the absence of a nucleus and stainable cytoplasm (Serrano-Pozo et al., 2011a). NFT
are localized mainly in the neuron clusters of feed-forward and feed-back connections between
cortical and subcortical areas, leading to a disconnection between the hippocampus and the
neocortex and between the neocortical association areas. This disconnection results in the
impairment of intellectual functioning (Armstrong, 1993, Terry et al., 1994).
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Fig. 3: A plaques and NFT in a Bielchowsky silver stained section of AD hippocampus.
From Iqbal et al., in “An Atlas of Alzheimer’s Disease”; edited by Mony J. DeLeon and Heiko
Braak, Parthenon Publishers Group, June 15, 1999.

1.4.3 Changes in synaptic plasticity
Synaptic loss
The process of neurodegeneration is mainly accompanied by synaptic loss as an early
event in AD (Masliah and Terry, 1993, Masliah, 2000). In fact synaptic loss is the best correlate
of cognitive impairment in AD patients and a major contributor to cortical atrophy. The level of
expression of synaptophysin in the midfrontal and inferior parietal lobes in AD patients and
cognitive scores prior to death show that synaptophysin loss strongly correlates with cognitive
impairment as compared to A plaques or NFT (Terry et al., 1991). Synaptic loss is colocalized
with neuronal loss and sometimes exceeds neuronal loss and this indicates that synaptic loss
probably precedes neuronal loss. That is why synaptic density is a better correlate of cognitive
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decline than neuronal loss (Terry et al., 1991, Masliah and Terry, 1993). Furthermore, it was
shown that synaptic loss in AD does not happen only because of neuronal death but also in living
neurons (Coleman and Yao, 2003).
In AD, the hippocampus and the frontal and parietal cortices are among the brain regions
that are severely affected with synaptic loss while the other brain regions such as the occipital
cortex are relatively spared (Honer, 2003). A previous study reported that synaptophysin-like
immunoreactivity dramatically decreased in the hippocampus and the entorhinal cortex in
autopsies of brains of patients with definite AD compared to controls or multi-infarct dementia
patients (Heinonen et al., 1995).
Synaptic loss occurs later than A deposition but represents a better correlate of disease
progression (Terry et al., 1991, Selkoe, 2002, Shankar and Walsh, 2009). In autopsied brains of
patients with moderate to severe AD, evident synaptic loss was found in the hippocampus,
frontal, inferior parietal and entorhinal cortices 2-4 years after the onset of clinical symptoms. In
the CA1 region of the hippocampus, synaptic loss was reported to be 18% in MCI subjects
compared to 55% in mild AD subjects. Stereological investigation of the number of synapses
revealed that evident synaptic loss was correlated with impaired episodic memory in MCI
patients (Lu et al., 2013). Studies from animal models of AD also corroborated these findings. In
the 3xTg-AD mouse model, for example, a progressive loss of dendritic spines in the
somatosensory cortex was reported as early as 4 months of age in layer III neurons and it
coincided with soluble A and tau hyperphosphorylation at 13 months (Bittner et al., 2010).
Similar data were reported in Tg2576 mice, which showed that the loss of synapses occurs in a
region and age-dependent manner (Dong et al., 2007). Furthermore, brain imaging studies using
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functional MRI (fMRI) showed that in AD patients global disruption of functional connectivity
was associated with cognitive decline (Supekar et al., 2008).
Synaptic loss is highly correlated with the number of NFT in the same brain regions, and
regional differences in the amount of synaptic loss in the cerebral cortex match the pattern of
neurofibrillary degeneration as shown by BRAAK stages. A detailed study reported a decrease in
the synaptophysin mRNA level in tangle-bearing neurons compared to healthy ones. However,
the correlation between plaque numbers and synaptic loss was found to be less consistent and
failed to establish such a relationship (Arendt, 2009).
Synaptic compensation
A transient increase in the level of synaptic markers at the early stages of AD as a
compensation for synaptic loss is known to occur. It has been shown that the levels of
synaptophysin and other synaptic proteins increase in the early stages of AD prior to NFT
formation (BRAAK stage III) and then decrease again when the disease progresses, suggesting a
phenomenon of synaptic compensation (Mukaetova-Ladinska et al., 2000). An increase in the
level of PSD-95 in AD patients (Leuba et al., 2008a, Leuba et al., 2008b ) and the presynaptic
cholinergic bouton density in the midfrontal gyrus of MCI patients was reported (Bell et al.,
2007). Early studies showed that synaptic loss in AD is accompanied by an increase of the
synaptic size to compensate for synaptic loss. Indeed, in several neocortical areas the increase in
synaptic size compensates for the significant loss of synapses by maintaining a constant total
synaptic contact area. However, when the disease progresses and synaptic loss becomes more
and more dramatic in these areas, the compensation phenomenon is no longer effective. The
failure in synaptic compensation is more apparent in the neocortical areas that are known to be
implicated early in synaptic loss such as Brodmann area 9 (Scheff and Price, 2006). These
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findings were corroborated with results from fMRI studies that suggest there may be a biphasic
stage in the prodromal stage of the disease in which there is a period of increased brain activation
which is reduced later during the disease process (Sperling, 2007). In AD, however, although the
compensatory phenomenon is present early in the disease process it becomes defective at
advanced pathological stages. This phenomenon may help in slowing the cognitive deterioration
seen in early AD stages and that may be why we do not see a linear relationship between brain
pathology and functional measures (Arendt, 2009).
Altered neurogenesis
In the brain neurogenesis takes place in the subgranular zone (SGZ) of the DG and the
subventricular zone (SVZ) (Fig. 4). Neurogenesis is essential for several aspects of learning and
memory especially the formation of adult-born neurons is essential for pattern separation (Lacar,
et al., 2014). Neurogenesis is also essential for the plasticity of the hippocampus and, especially
in rodents, the olfactory system. Indeed, hippocampal neurogenesis in the CNS contributes to
information storage and retrieval. Thus an impaired neurogenesis may interfere with synaptic
and neuronal plasticity as well as normal neuronal function. In AD several studies reported that
neurogenesis is disrupted very early in the process of the disease, with some reports claiming an
increase while others claim a decrease in the level of neurogenesis. In autopsied brains an
increase in neurogenesis was reported. Indeed, the expression of markers of immature neurons
such as DCX, which signals the birth of new neurons, polysialylated nerve cell adhesion
molecule , neurogenic differentiation factors and TUC-4 in the SVZ, granular layer of DG (site
of neurogenesis) and the CA1 region (principal site of hippocampal pathology) were shown (Jin
et al., 2004b). Similarly, studies employing J20 transgenic mice reported an increase in
neurogenesis in the SGZ of the DG and the SVZ. Indeed, the number of BrdU positive cells and
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immature neuronal marker proteins increased by 2-fold at the age of 3 months, where there was
no neuronal loss or A deposition in these mice. Studies on neurogenesis in human autopsied
brains and transgenic mice led to the hypothesis that it is stimulated by the disease itself and not
by the confounding clinical factors. The increase in neurogenesis may serve to generate new
neurons to replace the degenerated ones and this may provide a unique approach to AD treatment
(Jin et al., 2004a).
Neurogenesis was shown to increase after other pathological conditions such as global
and focal experimental cerebral ischemia transiently and bilaterally in the SGZ and the SVZ by
12 fold, followed by normal level in 2-3 weeks. After one month it was shown that the newly
born neurons migrate into the granular zone of the DG and express the calcium-binding protein
(Liu et al., 1998, Jin et al., 2001, Yagita et al., 2001, Taupin, 2006). However, the
aforementioned attempt of the CNS to self-repair after severe pathological insult remains
unsuccessful. This may be explained in part by the fact that newly born neurons cannot
differentiate into fully mature cells either because they do not develop into the right type of
neurons or that they cannot integrate into the surviving circuitry. In support of this hypothesis it
was previously reported that neurogenesis is unsuccessful because the newly born neurons
cannot make it to become fully mature in AD brains. Indeed the levels of MAP2 a and b
(markers of mature neurons) decrease dramatically in the DG of AD brains. However, the total
expression of MAP2 including MAP2c (a marker of immature neurons) was less affected. These
findings suggest that although in AD there is an increase in neuronal proliferation, the newborn
neurons do not fully mature in the DG (Li et al., 2008). The failure of the maturation process in
AD is suggested to be because of the imbalance in neurotrophic factors, including an increased
level of FGF2 and decreased levels of BDNF and neurotrophin-4 (Stopa et al., 1990, Hock et al.,
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2000). In fact, it was previously shown that the increase in the level of FGF-2 drives the
hippocampal progenitor neurons to stay in an undifferentiated actively dividing developmental
stage. Thus a promotion of the maturation of the newly born-neurons may help improve
cognition and represents a potential therapeutic strategy.
Collectively, these studies then suggest that impairment in neurogenesis cannot be only
the consequence of the disease but can be a cause of cognitive impairment observed in AD
(Rodriguez and Verkhratsky, 2011).
The discrepancies seen among the results in the literature could be explained by the fact
that neurogenesis does not follow a uniform pattern in AD and it varies between stages and
between brain regions (Perry et al., 2012). The difference in several other parameters could also
be involved. PS1 mutation for example, is known to have a negative effect on the generation of
newborn neurons, while a non mutated PS1 would enhance cell proliferation and differentiation
(Lazarov and Marr, 2010).

Fig. 4. The Process of Neurogenesis (Aimone et al., 2014).
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1.4.4

Imbalance of neurotrophic factors

Neurotrophic factors are secreted molecules that play a crucial role in synaptic and
neuronal growth, proliferation, maturation, pruning and survival (Budni et al., 2015). Insufficient
trophic factors in the crucial regions of the brain like the hippocampus would lead to
neurodegeneration and also leave them unprotected from pathological insults. The initial
embryonic expression of neurotrophins approximately coincides with neurogenesis. NT-3 is
mostly expressed in the immature regions of the CNS and the expression level dramatically
decreases with their maturation. In contrast the expression level of BDNF is low in immature
regions of the brain and it increases as these regions mature. The level of expression of NGF
varies during the development of brain regions in an inconsistent manner. All three
neurotrophins have a high mRNA expression level in the hippocampus, with the BDNF mRNA
level 50 times higher than NGF (Hofer et al., 1990, Maisonpierre et al., 1990).
The process of adult neurogenesis generates too many newborn neurons but only a few of
them survive to undergo the process of neuronal maturation and become integrated into the
neuronal circuit. The selection of the neurons that will survive is based on the availability of
neurotrophic factors in the target neurons. Neurotrophic factors are released by target neurons in
an activity-dependent manner. A neuron that is not well connected to a target neuron would
receive an insufficient amount and die, while the best connected would receive a sufficient
amount and survive to become mature neurons. This ensures that the established connections and
networks are synaptically active. Synaptic loss and axonal transport dysfunction are among the
early events that happen in AD. The loss of synapses results in the loss of connection between
the innervating neuron and the target neuron, and the axonal transport dysfunction leads to a
defect in the retrograde transport of the neurotrophic factor. Both of these phenomena can lead to
the death of the innervating neurons because they are not receiving the trophic factor from their
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target counterpart. This is consistent with what was reported in the literature, that pro-NGF level
increased in AD patients because of a defect in retrograde transport. So this suggests that
neurodegeneration may be caused by disconnection between the neuron and its target rather than
being a consequence of it (Castren and Tanila, 2006).
During the process of AD there is an imbalance in the level of neurotrophic factors,
which may explain the failure of maturation of newborn neurons and synaptic loss. In fact,
employing autopsied brains it has been reported that there is a decrease in the level of expression
of BDNF in the hippocampus and the parietal cortex accompanied by a decrease in the ratio of
BDNF/NT-3 in the frontal and the parietal cortices compared to control groups. However, the
levels of NGF and NGF/NT-3 were significantly increased in the hippocampus and the frontal
cortex in AD. The levels of NT-4/5 and NT-4/NT-3 were slightly reduced in the hippocampus
and the cerebellum in the AD group compared to control cases. The level of NT-3, however, was
unchanged in all the brain regions studied. The decrease of BDNF expression could then explain
the lack of trophic support, which results in the degeneration of specific neuronal populations
such as the cholinergic neurons. In NFT bearing neurons BDNF was not expressed, while it was
expressed in tangle-free neurons, implicating its protective effect against neurodegeneration
(Lanni et al., 2010).
BDNF
BDNF is synthesized in the entorhinal cortex and retrogradely transported to the
hippocampus, where it regulates LTP and LTD, axonal sprouting, synaptic plasticity,
proliferation of dendritic arbor and neuronal differentiation (Murer et al., 2001, Tyler et al.,
2002). It is a vital component of synaptic plasticity and memory function. LTP provides the
cellular mechanism of memory formation and consolidation and it is facilitated by BDNF
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through binding to its TrkB receptor. TrkB receptors are found mainly in the hippocampus and
some of them in the basic cholinergic neurons to support cholinergic function. TrKA receptors
that respond to NGF are found mainly in the basal forebrain cholinergic neurons. Thus, any
imbalance in the level of BDNF or NGF in the brain would affect memory formation and lead to
neurodegeneration. Indeed, the level of expression of these two neurotrophins and their receptors
is affected very early in AD. The level of BDNF expression was reported to be decreased by 23
% in AD compared to normal controls in the frontal cortex. Pro-BDNF level also was shown to
slightly progressively decrease from MCI (21%) to AD (30%) in the parietal cortex (Ferrer et al.,
1999, Fahnestock et al., 2002, Michalski and Fahnestock, 2003, Peng et al., 2005, Allen et al.,
2011). However, in other studies an increase in the BDNF level has been reported in the AD
brain compared to MCI and control brains. TrkB levels also were reported to increase in the CA1
region of patients at early AD stage (Kao et al., 2012, Faria et al., 2014). The increase in BDNF
level happened early in the disease stage and it might be as a compensation to slow down the loss
of memory. However, later in the process of the disease the compensation mechanism becomes
unsuccessful and the levels of BDNF are decreased dramatically. Thus, possibly for this reason
the memory loss and cognitive deterioration are marked in the later stages of the disease.
Alteration in BDNF level might result in insufficient differentiation of neurons, synaptic
loss and cognitive dysfunction (Song et al., 2015). Indeed, a previous study correlated the
decrease in BDNF and Pro-BDNF levels to a decline in cognitive abilities very early in the
disease stage (Peng et al., 2005). A recent study in the oldest old, the 90+ study, reported that the
level of BDNF and Aβ 42 correlated with dementia in Brodmann areas 7 and 9. BDNF mRNA
level was decreased in demented vs non-demented subjects regardless of pathology. Soluble Aβ
42 level was increased in AD subjects with or without dementia (Michalski et al., 2015).
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NGF
NGF is synthesized in the hippocampus and it reaches its neuronal targets in the forebrain
through a retrograde transport. In AD the level of NGF is reported to be decreased. However, the
NGF level is unchanged or increased in the hippocampus, which argues in favor of a clear defect
in the retrograde transport or an inefficient uptake of NGF to NGF-sensitive neurons.
Neurodegeneration leads to an insufficient amount of NGF to reach the soma of the basal
forebrain neurons, which leads to further degeneration (Hock et al., 2000, Price et al., 2007).
Later studies, however, showed that the level of Pro-NGF is actually increased and the level of
NGF decreased in the postmortem AD brains, and that the increase in Pro-NGF level is
associated with poorer cognitive performance. The predominant form of NGF in the brain is the
immature form (Pro-NGF), which is cleaved by plasmin to give the mature form (NGF). In AD
the level of plasmin decreases and the Pro-NGF cannot mature into NGF. In addition, the
degradation of mature NGF is increased. This is believed to be most likely a mechanism that
initiates neurodegeneration of the basic forebrain neurons (Allen et al., 2011).
FGF-2
The brain level of FGF-2 or basic FGF is increased in AD compared to control cases and
this increase is associated with the presence of neuritic plaques and NFT (Stopa et al., 1990) and
with the increase in tau phosphorylation through the increase in the level of GSK3β and tau itself
(Schindowski et al., 2008). The concentration of FGF-2 is 50 times more than NGF (Siegel and
Chauhan, 2000) and it is well established that FGF-2 has a promitotic role in neurogenesis.
Studies on FGF receptor 1 conditional knockout mice (a major receptor of FGF-2) suggested its
involvement in neurogenesis, LTP, memory consolidation but not spatial memory (Zhao et al.,
2007). FGF-2 enhances adult rat hippocampal progenitor cell division and nestin level but
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inhibits neuronal fate commitment and maturation of these cells in culture. FGF-2 drives the
cells toward an undifferentiated actively dividing developmental stage (Chohan et al., 2011).
GDNF
The level of GDNF expression was reported to be increased in the cerebrospinal fluid and
decreased in the sera of AD patients compared to controls, while another study showed that the
level of GDNF increased in the plasma of AD patients as an adaptive compensatory mechanism
from the brain (Marksteiner et al., 2011, Straten et al., 2011). However, postmortem studies
showed that there is a dramatic decrease of mature GDNF in the medial temporal gyrus in AD
patients. These findings were corroborated by another study that showed that the level of GDNF
decreased in the sera of MCI and AD patients (Airavaara et al., 2011, Forlenza et al., 2015).
IGF-1
IGF-1 has been implicated in the development of late onset AD. In this context, IGF-1
was reported to have an effect on the metabolism and clearance of Aβ as well as the formation of
NFT. It is even proposed that the IGF-1 receptor (IGF-1R) may promote Aβ production.
Previous data also showed that the level of IGF-1R inversely correlates with cognitive
impairment (Lanni et al., 2010). Indeed, a recent study reported that blocking IGF-1R signaling
in adult APP/PS1 mice results in a significant delay of AD pathology through clearance of toxic
Aβ (Gontier et al., 2015). In a subsequent study, however, it was reported that the levels of IGF1R and insulin receptors were decreased in AD neurons, suggesting that neurons that undergo
neurodegeneration could be resistant to IGF-1/IR (insulin receptor) signaling (Moloney et al.,
2010).
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1.5

Current AD therapeutics and therapeutic approaches

1.5.1 Current AD therapeutics
Currently there are six FDA-approved drugs for AD. These drugs increase
neurotransmitter release and temporarily improve AD symptoms without stopping or slowing the
progression of the disease. Five of these drugs are acetyl cholinesterase inhibitors. The general
efficacy of cholinesterase inhibitors is considered to be moderate with 2 or 3 points on the
standard cognitive outcome (Schneider et al., 2014). Based on the cholinergic theory the first
cholinesterase inhibitor drug, Tacrine, was developed in 1993 but nowadays it is rarely
prescribed because of possible liver damage and its low bioavailability. In 1996, Donepezil was
developed and it is used for treatment of all stages of AD. Rivastigmine was developed in 2000
to treat mild to moderate stages of AD. Galantamine was approved by the FDA in 2001 to treat
mild to moderate stages of the disease. In 2003, Memantine, an NMDA mild to moderate
antagonist, was approved by the FDA for moderate to severe stages of AD to improve memory,
attention and simple skills. However, Memantine failed to show any significant benefit when
administered to patients with mild AD. From 2002-2012, out of 244 drugs tested for AD, only
Memantine completed clinical trials and was approved. Late in 2014, in a second U.S-controlled
clinical trial, a combination of Donepezil and Memantine (Namzaric) decreased cognitive
deterioration and decline in daily activities with minimal new behavioral symptoms in AD
patients when compared to placebo and was approved as a therapeutic drug for AD (Schneider et
al., 2014; Alzheimer's Association 2015).
1.5.2 Anti-Aβ therapeutics
Based on the amyloid beta hypothesis several clinical trials were conducted using passive
immunotherapy. Solanezemub, a monoclonal antibody against the mid-domain of Aβ, recognizes
only soluble monomeric Aβ. A Phase III clinical trial using this antibody showed it to be safe but
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had no improvement in primary outcome measures; Crenezumab, another antibody directed
against all forms of Aβ, showed no difference between the placebo and the treatment group in
the primary cognitive outcome measures; and Gantenerumab, a monoclonal antibody designed
against a conformational epitope of the fibrillar Aβ, was stopped in phase II/III clinical trials
because of the lack of a perceived efficacy (Rafii and Aisen, 2015).
Active immunization using a synthetic fragment of Aβ peptide named AN1792 showed
exciting data in mice harboring APP mutation. Indeed, it decreased Aβ plaques and improved
cognition in mice. However, when advanced to clinical trials in patients with mild to moderate
AD, the active immunization was stopped because of severe side effects such as
meningoencephalitis with no benefits in AD symptoms. Following AN1792 immunization, 6%
of the treated patients developed meningoencephalitis. Postmortem analysis determined the
cause to be an increase in CD4+ infiltration, suggesting a T-cell response to Aβ (Serrano-Pozo et
al., 2011b). Based on the results of this clinical trial the National Institute on Aging (NIA)
proposed that passive immunization might be a safer immunotherapeutic strategy than active
immunization.
To date in clinical trials of mild to moderate AD, anti- Aβ therapy was able to clear Aβ
without slowing down or stopping cognitive impairment. The repeated failures of the thousands
of trials using anti-Aβ therapies are thought to be because the treatment was probably initiated
too late to be effective. Indeed, it is believed that therapeutic interventions would be useless once
dementia is established. Because Aβ deposits precede dementia by an average of 10-15 years, the
current approach is to start treating patients during the pre-symptomatic stage and during MCI.
MCI is characterized by a mild cognitive impairment without dementia, while the presymptomatic stage is characterized by an intact cognition that is associated with amyloid
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deposition. Several large prevention studies such as the A4, DIAN, and API are being conducted
targeting mainly the prodromal and the pre-symptomatic stages of AD.
Several BACE inhibitors also were tested for their therapeutic efficacy. MK-8931 is one
of them. In a Phase I clinical trial this drug was well tolerated with 92% reduction of Aβ from
CSF and is now undergoing Phase II/III clinical trials. Some active antibodies to A also were
used.
Current research now is focused mainly on developing a drug that can slow or prevent
disease progression. The anti-amyloid therapeutic strategy focuses on decreasing amyloid
production, inhibiting β and γ-secretases, α secretase promotors, removal of amyloid, active and
passive immunization, blocking Aβ signaling and inhibiting Aβ aggregation. The anti-tau
therapies focus mainly on inhibition of hyperphosphorylation, passive and active immunization
and inhibition of aggregated tau. Growth factors, insulin sensitization and anti-aging drugs are
being tried as therapies (Waite, 2015).
1.5.3 Tau immunotherapies
Despite the critical role that tau plays in several neurodegenerative diseases most tautargeted drug discoveries are still in early stages and are not advanced as much as A therapies.
This is because the whole AD drug discovery field was focused mainly on anti-A therapies due
to the presence of the autosomal dominant APP mutations PS1 and PS2 in FAD cases. Several
active and passive tau immunotherapeutic approaches were tested in different mouse strains and
showed reduction of tau tangles and improvement in cognition (Ingelsson et al., 2004, SerranoPozo et al., 2011a). Different phosphotau peptides were used for active immunization while antitau antibodies were used for passive immunization (see Iqbal et al., 2016).
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1.5.4 Prevention strategies
Based on what is commonly known — that the development of neuropathological lesions
start in the brain of the presymptomatic AD patient at least a decade before developing the
clinical symptoms — four large secondary prevention trials were initiated. The main goal of a
secondary prevention trial is to target people who already have the neuropathological changes
without the clinical symptoms and treat them to prevent progression to clearly diagnostic AD.
These trials target especially high risk people such as those who carry the autosomal dominant
mutations or two copies of the APOE4 allele. The Dominantly Inherited Alzheimer’s Network
(DIAN) study is testing two anti-A antibodies, Solanezumab and Gantenerumab, in a cohort of
people that have a mutation in PSEN-1 or PSEN-2 or APP; it is currently in a Phase II biomarker
trial. The Alzheimer’s Prevention Initiative (API) trial is testing Crenezemab in the large
Columbian family cohort with an autosomal dominant genetic mutation in PSEN-1. Within the
next two years the API is also planning to recruit people who are homozygous to APOE4 to test
active vaccination against A and BACE inhibitors. The TOMORROW trial (a clinical trial
designed to delay the onset of AD) aims to test Pioglitazone to treat glucose metabolism defects
in carriers of the TOMM-40 gene. The Anti-amyloid Treatment in Asymptomatic Alzheimer’s
Disease (A4) study is planning to recruit people who have a high risk of cognitive impairment
based on the accumulation of A but with or without memory complaints. Older people aged 6585 will be recruited in a double blind Phase III clinical trial for Solanezumab vs placebo
(Sperling et al., 2014, Rafii and Aisen, 2015). However, as stated above, all the prevention trials
that are initiated are mainly based on anti-A therapies, while there is growing evidence now that
tau spread starts even from the MCI stage, which makes it more reasonable to use a combination
therapy for anti-amyloid and anti-tau in the pre-symptomatic AD patients.
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1.5.5 Use of neurotrophic factors in AD treatment and the limits of their applications in
clinical trials
Several neurotrophic factors such as NGF, BDNF, neurotrophin-3 (NT-3), neurotrophin-4
(NT-4) and CNTF exhibit similar structure and function. Each of these factors plays an important
role in neural development, maturation, proliferation, differentiation and survival of neurons.
This makes the use of these factors a promising and exciting therapeutic strategy. However, their
relatively big size (120Aa), short bioavailability, poor blood brain barrier (BBB) permeability
and adverse side effects have led to disappointing results and limit their use in clinical trials
(Saragovi and Gehring, 2000).
NGF
In the 1990s a small phase I clinical trial was conducted in Sweden where a mouse NGF
was administered intracerebroventricularly (ICV) to three AD patients. The first two AD patients
were infused with a 6.6 mg dose of mouse NGF over three months and the third patient with
three doses of NGF (<0.25 mg) given separately for a total of 22 weeks. The first two patients
showed slight improvement in cognitive scores while the third patient showed no improvement.
However, all patients complained of lumbar pain after 11 days of treatment and two of them
showed weight loss and loss of appetite. All these symptoms ceased after stopping NGF infusion
(Olson et al., 1992, Eriksdotter Jonhagen et al., 1998). Another study was conducted on rats by
ICV administration of a recombinant human NGF over 12 weeks. However, hyperplasia because
of the proliferation of Schwann cells was a major side effect. The hyperplasia was mainly
explained by the high dose of NGF infused into the ventricles and the effect was mediated
through the p75NTR receptor (Winkler et al., 1997). Because of the problems encountered in the
administration of NGF to the brain other means were developed and another phase I clinical
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study was conducted using AD patients’ genetically modified fibroblasts with a retroviral vector
to produce NGF and injection of these cells into the basal forebrain. Two of the patients were
affected by the severity of the surgical intrusion and the rest showed a slowing in cognitive score
deterioration by 3 points per year instead of 6 points in the MMSE score (Tuszynski et al., 2005).
Another method of NGF delivery was developed to overcome the previously mentioned
problems through CERE-110; CERE-110 is a gene therapy product designed to deliver NGF to
the brain through an adeno-associated virus (AAV), specifically to the nucleus Basilis of
Meynert. It is administered surgically in the brain. NGF is a neurotrophic factor that enhances
the survival and death of cholinergic neurons and increases acetylcholine production (Rafii and
Aisen, 2015). A Phase I clinical study was successfully completed using CERE-110; it showed
that CERE-110 was safe and well tolerated for two years with a long-term biologically active
NGF (Rafii et al., 2014). The Phase II clinical study is currently ongoing (Mandel, 2010, Rafii
and Aisen, 2015).
BDNF
The major limitation of the use of BDNF as a therapeutic agent for AD is that it is not
biologically stable (serum half-life 10 min) and it cannot cross the blood brain barrier (BBB),
which restricts its oral, subcutaneous or intravenous delivery. ICV injection of BDNF showed
beneficial effects on memory and neurodegeneration in animal studies. However, because this
approach is invasive it is used only for animal model studies and not for human clinical trials.
Injecting the right dose of BDNF is of major importance because a low dose will not have any
beneficial effects and a high dose will cause serious side effects (Peng et al., 2005). No human
clinical trials have been conducted in AD, Parkinson’s disease or Huntington’s disease with
BDNF. Five clinical trials were conducted (four with ALS and one with diabetic neuropathy) and

35

all of them were discouraging (Lu et al., 2013). In one amyotrophic lateral sclerosis (ALS)
clinical trial, methionyl human BDNF was infused subcutaneously or intrathetically to patients.
BDNF was well tolerated but it failed to show any significant effects on patients’ survival
because of the small number of patients and the contradictory results. The major problem faced
was that BDNF penetration was limited to the superficial layers and did not go through the
parenchyma of the brain and spinal cord (Beck et al., 2005, Nagahara and Tuszynski, 2011). The
most challenging problem in the use of BDNF as a drug is to deliver it directly to its target with
minimal exposure to undamaged tissues.
CNTF
CNTF is a 22.7 KDa protein synthesized by astrocytes and Schwann cells. It is a member
of the neurokine superfamily. CNTF expression develops during the second postnatal week and
is almost exclusively limited to the nervous system (Hagg, 2009). In the peripheral nervous
system, CNTF is synthesized in muscles and released by the motor neuron terminals and then
retrogradely transported to the cell bodies. It is considered to be an autocrine and paracrine signal
that is involved in the activation of astrocytes and responsible for hypertrophy in case of injury to
the intact nervous system. In fact its retrograde transport increases with nerve lesion. After nerve
lesion, CNTF prevents atrophy of skeletal muscles but has no effect on healthy innervated
muscles, suggesting its mobilization only in a pathological state. It has been found to be
decreased in the human sciatic nerve in motor neuron diseases. CNTF acts by binding primarily
to the GPI-anchored alpha subunit of the CNTF receptor complex alpha (CNTFR). This
induces the recruitment of two other transmembrane receptor proteins, LIFR and gp130,
resulting in their dimerization and tyrosine phosphorylation. This leads to the activation of the
JAN kinase/ STAT signaling pathway (Siegel and Chauhan, 2000). STAT proteins then
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translocate to the nucleus where they bind specific DNA sequences responsible for the
transcription of responsive genes (Lanni et al., 2010).
In a previous study using cultured basal forebrain cholinergic neurons isolated from 2week-old rats CNTF was shown to act synergistically with BDNF and promote the survival of
choline acetyl transferase-positive neurons. BDNF alone induced a three-fold increase of
neuronal survival. However, when CNTF was added to the culture, the number of survived
neurons increased to eight fold. When applied alone, CNTF has very little effect on neuronal
survival. The synergetic effect was localized only to basal forebrain cholinergic neurons and not
to the hippocampus, basal forebrain or cerebellum. CNTF also enhanced neuronal protection
synergistically with NT-4 but not NGF. In addition BDNF mediated protection was enhanced by
the LIF and not IL-6. This suggests the involvement of TrkB and CNTFR  receptors in the
synergetic effects (Hashimoto et al., 1999).
When applied after motor neuron injury to animal models of neuromuscular disease,
CNTF prevented neuronal death and partially restored motor function. Since CNTF is expressed
mainly by glia cells in the PNS and the CNS, it has been implicated in neural stem cell fate
determination and survival as well as neuronal and glia differentiation and development (Siegel
and Chauhan, 2000, Lanni et al., 2010). In a recent study it has been shown that CNTF enhances
forebrain neurogenesis and it is expressed in the astrocytes in the subventricular zone, the brain
area where dopaminergic neurons regulate neural precursor cell proliferation. These findings
suggest a link between CNTF, neurogenesis and dopamine. This link was further supported by
the findings that CNTF is an endogenous regulatory component of Dopamine D2-receptordependent neurogenesis in the subventricular zone and the dentate gyrus in adult mice (Mori et
al., 2008, Yang et al., 2008). Indeed, the dopminergic pathway to the striatum regulates CNTF
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expression and regulates neurogenesis only through CNTF (Yang et al., 2008). It was shown
that CNTF supported neuronal survival in vivo and in vitro in models of neurodegeneration (Ip
and Yancopoulos, 1996). However, attempts to use CNTF as a therapeutic drug were
unsuccessful. Axokine, a modified version of human CNTF, with a 15 amino acid truncation at
the C-terminus and substitution of two amino acids, was shown to be 5 times more potent and
stable than the original CNTF in vivo and vitro (Lanni et al., 2010); when administered
systematically to patients with ALS it yielded disappointing results. CNTF delivery failed to
achieve sufficient concentration in the brain, with no significant efficacy; too many adverse side
effects such as weight loss, muscle pain and anorexia occurred. However, despite these
disappointing results CNTF clinical trials showed promising effects in Huntington disease and
retinal degeneration (Lanni et al., 2010). NT-501 is a drug that consists of encapsulated human
cells that are genetically modified to secrete CNTF; this drug showed significant effects in a
Phase II clinical trial of retinitis pigmentosa (a photoreceptor degeneration that eventually leads
to blindness) (Talcott et al., 2011).

1.6

Use of peptide mimetics to overcome the limitations of neurotrophic factor
therapeutics
In neurodegenerative diseases such as AD the compensation mechanism, by increasing

neurogenesis and synaptic plasticity, should at least slow down the progression of the disease at
the early stages. This makes boosting neurogenesis and synaptic plasticity to treat AD a very
important and exciting therapeutic approach. The design of small peptide mimetics that are
biostable, able to cross the BBB and not easily degraded by peptidases can offer the opportunity
to stimulate the secretion of neurotrophic factors and/or mimic their neurotrophic/neurogenic
activities.
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A currently approved drug, Memantine, which inhibits neuronal death, addresses only the
symptoms of AD and slows down cognitive deterioration without stopping or reversing it. Since
neuronal loss plays a pivotal role in cognitive impairment, one might expect that a small
molecule that has a dual function of promoting neurogenesis and neuroprotection could stop the
sharp and fast cognitive decline and reverse the disease state (Kelleher-Andersson, 2004).
Several clinical trials were conducted using neurotrophic factors such as NGF, CNTF or BDNF
as described above in sections 1.5.4 and 1.5.5. However, the major problems have been how to
deliver them to the brain and how much should be delivered so that it can reach the target
neurons, the severe side effects, and how the mechanism of neurotrophin signaling is integrated
in the disease mechanisms (Longo and Massa, 2004). Because of the multiple effects of the
neurotrophic factors on neuronal activity major side effects such as pain and gastrointestinal
symptoms have been reported after BDNF delivery. More severe side effects such as fever, pain
and anorexia were also reported after using CNTF in clinical trials, which limited the doses
investigated (Thoenen and Sendtner, 2002). The use of small molecule neurotrophic factor
mimetics can overcome the blood brain barrier permeability and stability problems encountered
in the delivery of the full-length proteins.
In ligand mimetics large polypeptides are reduced to small functional units that contain
the site of interaction in which the molecule can block or activate specific receptors. What
makes mimetics useful is that the protein-protein interaction occurs only in a few key regions or
“hot-spots” instead of the overall protein surface. Two approaches have been used to develop
small peptide mimetics. The first one is to mimic antibodies for neurotrophin receptors and the
second one is to mimic the ligand itself (neurotrophins). Both antibodies and neurotrophin
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mimetics should bind to the same receptor as the original molecule from which they are derived
(Saragovi and Gehring, 2000).
NGF peptide mimetics
A previous study reported the development of a promising small molecule non-peptide
ligand of p75NTR that promotes survival-related signaling, inhibits A induced neurodegeneration
and reduces neurodegeneration in A treated neuronal cultures. The molecule, named LM11A31, is a water soluble amino acid derivative that crosses the BBB and works as an antibody
analog of NGF. It has a structure similar to the NGF1 loop domain that interacts with p75NTR and
it prevents neurodegeneration through the activation of the PI3 kinase/AKT signaling pathway
(Longo et al., 1997). Previous work also showed that when this molecule was administrated early
in the process of AD pathology right after appearance of A plaques in a mouse model of AD it
prevented cognitive impairment and atrophy of the basal forebrain cholinergic neurons.
Administration of the molecule late in the process of AD pathology in two AD mouse models,
Thy-1 hAPP Lond/Swe (APPL/S) and Tg2576, was able to reverse atrophy in the cholinergic
neurons of the basal forebrain, reduced cortical atrophy and normalized the increased levels of
p75NTR in the basal forebrain (Simmons et al., 2014). In another study a small molecule -turn
analog of an antibody directed against the extracellular domain of the TrkA receptor was
developed and behaved pharmacologically as a partial agonist (Maliartchouk et al., 2000).
BDNF mimetics
The BDNF molecule has a moderate size and charge, which limits its ability to cross the
BBB and its peripheral administration (Nagahara and Tuszynski, 2011). The use of a small
molecule mimetic of BDNF that could be applied locally or systematically can overcome the
limitations to the application of the full length BDNF molecule. It avoids the adverse side effects
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of the invasive methods of delivery and uncontrolled doses, and improves BDNF diffusion
(Zuccato and Cattaneo, 2009).
A small molecule that acts as a TrKB receptor agonist or modulator and could imitate the
biological activity of BDNF by binding with higher affinity to TrkB and p75 NTR and have
neuroprotective effects through its downstream pathways would present a potential therapeutic
drug for AD. One of the most remarkable BDNF mimetics that has appeared in the literature is
7,8- dihydroxyflavone (7, 8-DHF), which showed a high affinity to the TrkB receptor, imitated
BDNF biological activity, reduced A toxicity and synaptic dysfunction, and prevented
cognitive impairment in animal models. This molecule has a high bioavailability and penetration
of the BBB.

However, further investigations are required to determine the stability and

specificity of the drug and the agents that can interfere with its activity (Zhang et al., 2014, Song
et al., 2015).
In our lab 5 different tetra peptides corresponding to different active regions of BDNF
were screened. All five tetra peptides were found to be nontoxic and induce the expression of
neuronal markers in mouse E18 primary hippocampal cell culture. Two of the five peptides (B3
and B5) were found to function as partial agonists/antagonists and to compete with BDNF to
activate the TrkB receptor in a dose dependent manner. The primary results of this screening
showed that these two peptidomimetics have neurogenic/ neurotrophic effects, can modulate
BDNF signaling in a partial agonistic/antagonistic manner, and can be promising therapeutic
agents for AD and other diseases where BDNF level is altered (Cardenas-Aguayo M. del et al.,
2013).
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P021- a CNTF peptide mimetic
Employing

neutralizing

antibodies,

our

lab

showed

previously

that

the

neurogenic/neurotrophic effect of an anti-dementia drug, Cerebrolysin, in AD patients was due to
the presence of CNTF, FGF-2, GDNF, IGF-1 and IGF-2. CNTF, however, had the strongest
neurogenic/neurotrophic characteristics, and could counteract the mitogenic effect of FGF-2 and
decrease the number of nestin positive cells (Chen et al., 2007). Based on these findings an
epitope mapping of the neutralizing antibodies was carried out to help identify the most
biologically active region of CNTF. An 11-mer peptide, peptide 6 (Aa 146-156, AcVGDGGLFEKKL-NH2), was discovered. Studies on C57BL6 mice showed that this peptide
boosted neurogenesis by increasing the number of proliferating and differentiated hippocampal
neurons. It also improved hippocampal spatial memory when administered peripherally via slow
release bolus. Moreover, the peptide was found to increase synaptic plasticity by increasing in
the level of expression of synaptophysin and MAP2 (Chohan et al., 2011). Peptide 6 contains a
putative leukemia inhibitory factor receptor (LIFR)-binding sequence of CNTF and acts by
competitively inhibiting LIF. It is BBB permeable and it has a plasma half-life of more than 6 h.
In an attempt to test Peptide 6 as a potential drug in AD another study was conducted in our lab
in a 3xTg-AD mouse model of AD, which harbors three mutated transgenes (APPSwe, tau P301L
and PS1 M146V) and shows AD like pathological features. The study was conducted on 6-7
month old animals in the mild stages of the disease process before development of any overt A
plaques or NFT. Peripheral administration of peptide 6 by intraperitoneal injection for one month
induced neurogenesis, reduced ectopic birth in the DG, enhanced synaptic plasticity in the
hippocampus and cerebral cortex and improved cognition (Blanchard et al., 2010b).

In a

subsequent study an experimental rat model (AAV1-I2NTF-CTF infected brain) of the sporadic
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form of AD was treated with peptide 6 for 40 days by daily intraperitoneal injection. Peptide 6
administration was found to rescue neurodegeneration and cognitive impairment in 2.5 month
old I2NTF-CTF rats, increasing DG neurogenesis, the mRNA levels of BDNF and synaptic
plasticity as determined by the increase in synaptic and dendritic marker expression, especially in
the CA1 and CA3 areas of the hippocampus (Bolognin et al., 2012). Peptide 6 was used in the
Ts65Dn mouse model of Down’s syndrome. Subcutaneous administration through a slow release
pellet with a continuous dosing for 30 days enhanced neurogenesis and neuronal plasticity and
inhibited cognitive impairment in these mice (Blanchard et al., 2011). Furthermore, Peptide 6
treatment of neuronal cell culture and newborn Wistar rats injected with autism sera reduced
neuronal death and oxidative stress and restored the balance of neurotrophic factors (Kazim et
al., 2015).
The active region of Peptide 6 was further narrowed down and a four amino acid peptide
(Ac-DGGL-NH2) called Peptide 6c that corresponds to the CNTF amino acids 148-151 was
generated. Peptide 6c was administered subcutaneously in a continuous dose for 30 days to C57
BL6 mice. The results showed that Peptide 6c, like its parent molecule, increases neurogenesis,
synaptic plasticity and cognition without weight loss or any apparent side effects such as
anorexia or muscle pain. Peptide 6c acts like its parent Peptide 6 by competitively inhibiting the
LIF through the JAK/STAT pathway. LIF acts by increasing self-renewal and proliferation of
neural progenitor cells. By inhibiting this activity Peptide 6c would promote proliferation and
maturation of neural precursor cells through CNTF signaling and thus boost neurogenesis
(Blanchard et al., 2010a). Peptide 6c was adamantylated on its c-terminal to increase its
lipophilicity to cross the BBB and to decrease its degradation by carboxy peptidases to make it
more druggable. The pentamer Peptide-021 (P021) thus was generated (Fig. 5) with the sequence
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Ac-DGGLAG-NH2. When administered peripherally to normal WT mice, P021 increased
neurogenesis and neuronal plasticity, as shown by the increase in the expression of
synaptophysin and synapsin1, and it significantly improved cognition by enhancing short-term
memory encoding in the novel object recognition task and spatial memory in the Morris Water
Maze task. P021 acts the same as peptide 6c by competitively inhibiting LIF through the slight
inhibition of the LIF-induced STAT3 phosphorylation in a dose-dependent manner (Li et al.,
2010).
Because aging is a great risk factor for AD, the effect of P021 was studied in a rat model
of cognitive aging decline. Oral administration of P021 to 22-24 month old Fisher rats
significantly reduced cognitive decline related to aging, increased neurogenesis and neuronal
plasticity, increased the level of BDNF expression and significantly decreased the level of
hippocampus myoinositol, a metabolite that increases with age (Bolognin et al., 2014). Recently
another study was conducted in which P021 was administered in diet to 9-10 month old 3xTgAD mice for 12 months. A significant decrease in tau pathology, probably through the increase
in BDNF expression level and the inhibition of GSK3, was found in these animals at moderate
to severe stage of the disease. Furthermore, a decrease in soluble A levels and a trend toward
decrease in A plaques load were found. P021 also increased neurogenesis and neuroplasticity
and reversed cognitive impairment in these mice (Kazim et al., 2014).
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Fig. 5. Steps in the design of Peptide 021 (Li et al., 2010)

1.7

The triple transgenic mouse model of AD, 3xTg-AD
The use of animal models in preclinical studies to test the effect of the drugs and their

efficacy has been of great importance in advancing the drug discovery field. In AD especially
several mouse models were used and they helped in better understanding molecular mechanisms
of the disease and to design more efficient therapeutic approaches in attempts to cure it. The
3xTg-AD mouse model developed by Oddo et al. (Oddo et al., 2003b) harbors three mutated
transgenes: APPSwe mutation, tau P301L mutation and PS1 M146V knock-in. It is abiologically
relevant mouse model to AD because it develops A and tau pathologies in a time and
topographic manner which closely mimics the human pathological distribution. Indeed, the Aβ
pathology starts in the neocortex at ~ 6 months and expands to the hippocampus at ~12 months;
NFT start at around 12 months in this model (Oddo et al., 2003a, Oddo et al., 2003b). Cognitive
impairment starts as early as 3 months of age, with synaptic dysfunction preceding the onset of
A and tau pathologies which also mimic early cognitive impairment in AD patients. This shows
the relevance of this mouse model to study AD-like pathologies compared to, for instance, the
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double transgenic mouse Tg2576xJNPL3 (APPSwe), which fails to develop early behavioral
impairment (Rodriguez and Verkhratsky, 2011).
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Chapter 2. Materials and Methods
2.1

Animals and housing
The homozygous 3xTg-AD mice express two mutated human transgenes, APPSwe and

P301L, and human PS1 M146V knock-in. Breeding pairs of these mice were obtained from Dr.
Frank LaFerla through the Jackson laboratory (New Harbor, ME, USA). Wild type (WT) agematched control from the same background strain, hybrid 129/Sv x C57BL/6, were also obtained
from the Jackson Laboratory. Animals were housed and bred according to approved protocols
from our Institutional Animal Care and Use Committee (IACUC), according to the PHS Policy
on Human Care and Use of Laboratory Animals (revised January, 2013). Animals were housed 5
animals/cage with a 12:12 h light/dark cycle and with free access to food and water. They were
given a period of acclimatization of 45 min to 1 h before any behavioral test was performed.
Only young adult female 3xTg-AD mice and age-matched WT control mice were used in this
study because it has been shown previously that female 3xTg-AD have more aggressive
pathology than males. They show more A deposition, worse cognitive performance and a
higher deficit in neurogenesis than males (Clinton et al., 2007, Hirata-Fukae et al., 2008, Carroll
et al., 2010). To exclude any effect of behavioral studies on neurogenesis, animals other than
those used for behavioral studies were employed for immunohistochemical/biochemical studies
(Table 1).
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Project

Synaptic compensation

P021-prevention study

Animals used
Immunohistochemistry and Western blots
28 WT; 26 3xTg-AD-vh
10 weeks (WT, n = 5; Tg-AD, n = 3)
12 weeks (WT, n = 5; Tg-AD, n = 4)
13 weeks (WT, n = 4; Tg-AD, n = 4)
14 weeks (WT, n = 5; Tg-AD, n = 6)
15 weeks (WT, n = 4; Tg-AD, n = 4)
16 weeks (WT, n = 5; Tg-AD, n = 5)
Immunohistochemistry and Western blots
21 WT; 20 3xTg-AD-vh; 22 3xTg-AD-P021
3 months (WT, n = 6; Tg-AD-vh, n = 6)
12 months (WT, n = 5; Tg-AD-vh, n = 5; Tg-ADP021, n = 5)
18 months (WT, n = 5; Tg-AD-vh, n = 4; Tg-ADP021, n = 5)
21 months (WT, n = 5; Tg-AD-vh, n = 5; Tg-ADP021, n = 5)

Table 1. Total animals used in the study.
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Behavior
20 WT; 15 3xTg-ADvh; 14 3xTg-AD-P021

2.2

P021 treatment
After the Morris Water Maze task at ~ 3 months of age, the animals were divided into

three groups; one group of 3xTg-AD-P021 (n= 36) treated with 60 nmole of P021/g feed in diet;
another group of 3xTg-AD-vh (n = 35) treated with the same diet but without P021; and a third
group of WT (n=40) treated with the same diet but without P021. P021 was formulated by
Research Diets (New Brunswick, NJ). Food consumption was recorded every two weeks and
body weight every month. The average mouse food consumption was  2.7 g feed/day. Animals
were tested behaviorally at four different time points: 0 (before treatment), 9, 15, and 16-17
months (post-treatment). 15 3xTg-AD-vh, 14 3xTg-AD P021 and 20 WT mice were used for
behavioral studies. The rest of the animals were used for immunohistochemical and biochemical
studies at the above time points.
2.2.1 Design and synthesis of P021
The chemical structure of P021 is shown in Fig. 6. It is a pentapeptide (Ac-DGGLAGNH2; mol. wt. of 578.3) generated by the addition of adamantylated glycine at the C-terminus of
CNTF tetrapeptide (amino acid residues 148–151). The adamantylated glycine was added to
P021 to increase its BBB permeability and decrease its degradation by carboxy peptidases
(Blanchard et al., 2010a, Li et al., 2010, Chohan et al., 2011). P021 was synthesized and purified
by reverse phase HPLC to > 96% purity as described previously (Li et al., 2010). The sequence
of the P021 was confirmed by mass spectrometry.
2.2.2 P021 stability in plasma and gastric and intestinal juices and blood–brain barrier
permeability
P021 has >95% stability in artificial gastric juice during 30 minutes, ~100% stability in
intestinal fluid during 120 minutes, a plasma stability of >3 hours and is BBB permeable (Kazim
et al., 2014).
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Fig. 6. Chemical Structure of P021.

2.3

Behavioral Procedures

2.3.1 Elevated Plus Maze
The elevated plus maze is a test for anxiety/emotionality in mice. The test apparatus was
composed of four arms (30 x 5 cm) connected together by a 5x5 cm central zone. There were
two opposite facing closed arms (CA) covered by 20 cm high walls of opaque plexiglass and two
opposite facing open arms (OA). The entire plus-maze was elevated on a pedestal to a height of
82 cm above floor level in a separate room from the investigator. The luminosity of the room
was kept at 60 lx so that light would not exert any anxiogenic effect on the mice. Each animal
was put in the center zone facing one of the open arms and it was automatically recorded for a
total of 8 min using the ANY-Maze software tracking system (ANY-Maze software, version 4.5,
Stoelting Co., Wood Dale, IL, USA). After each session the mouse was removed and returned to
its cage. The floor was cleaned of feces with 70% alcohol to remove any olfactory cues. For each
animal the time spent in CA, OA, and the total time spent in the OA + CA were recorded.
Because mice prefer CA to OA, the percent of time spent in the OA was analyzed to evaluate
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anxiety-like behavior. The percentage of time in OA was calculated as the percentage of time
spent in the OA over the total time spent in the OA + CA, i.e., [OA/(OA+CA)] × 100.
2.3.2 Open-field test
The open field test was used to assess anxiety-like behavior and locomotor activity in
mice. An open field apparatus (a PVC square arena, 50 x 50 cm, with walls 40 cm high) was put
in a separate room from the experimenter and 60 lx of light was used to avoid the anxiogenic
effects of light on mice. Each animal was allowed to explore the arena for 15 min and
automatically recorded using the ANY-Maze software tracking system (ANY-Maze software,
version 4.5, Stoelting Co., Wood Dale, IL, USA). After each session the animal was removed
and returned to its home cage. The floor was cleaned of feces using 70% alcohol to remove any
olfactory cues. Movements of the animal were recorded using a camera that surmounted the
open field apparatus; the camera was connected to a computer equipped with tracking software
The time spent in the central zone and the distance traveled were recorded using the ANY-Maze
software. The anxiety was measured by the analysis of the percentage of time spent in the central
zone and the locomotor/exploratory behavior by the total distance traveled during the 15 min
duration of the test.
2.3.3 Accelerating Rota-rod test
Rota-rod is a test of locomotor activity in rodents. During a test trial each animal was put
in one of the four chambers in the apparatus. The motor of the apparatus was set up in an
accelerating mode (factory setting) at a rate of 0.02 cm/s, from 4 to 40 rpm. Each animal was put
through two sessions of three trials and the fall latency was measured.
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2.3.4 Prehensile traction test
This test was used to measure grip strength. The apparatus consisted of a horizontal wire
60 cm above the ground. Animals were made to grab the wire with their forepaws and then the
latency to fall was recorded to a maximum of 60 s.
2.3.5 Morris Water Maze task
The Morris Water Maze task is a test of reference memory, which is a measure of hippocampal
function. The test was a modification of the original procedure by Morris et al. (Morris et al., 1982).
Animals were divided into three groups: 15 3xTg-AD-vh, 14 3xTg-AD-P021 and 20 age-matched wild
type (WT) control mice. The procedure was performed in a circular pool tank, 180 cm in diameter. A 13
cm escape platform was submerged 1 cm below the surface of opaque water in the Northwest quadrant.
The water was made opaque by the addition of a white non-toxic chalk to make the escape platform
invisible to mice. Spatial cues were set up in the test room to help the animals find the platform from the
distant cues. The temperature of the water was kept at 21± 1°C. In each trial the animal was given 90 s to
find the escape platform. If the animal did not find the escape platform it was gently guided to it. Each
animal was left for 20 s on the escape platform and then it was returned to its cage. In each trial the mouse
was released from a different quadrant with its back toward the center of the tank and the starting point
was changed each day so that the animal would not learn the place of the platform without using the
spatial cues. The acquisition trials were conducted for four consecutive days. The retention test or probe
trial, in which the escape platform was removed and the animal was allowed to swim for 60 s, was
conducted 24 h after the last acquisition trial. The measure of acquisition was the time and distance swum
to reach the escape platform. The measures of retention were the percent of time spent in the target
quadrant and the number of entries into the target zone. Behavior of the animal in the Morris Water Maze
was recorded using a Samsung digital camera (SDC 4304) mounted on the ceiling; SMART version
2.0.14 software (Pan Lab/San Diego Instruments) was used for tracking and timing of each trial.
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2.3.6 Object location task
The object location task in the open field is a test for short-term spatial memory, which is
mainly hippocampal dependent. In this test the 18 month old animals were required to identify
the location of the object as novel or familiar based on a previous experience. The test consists of
a habituation phase, a sample phase and a test phase. During the habituation phase animals
underwent a total of 6 sessions, 2 sessions/day, and each session lasted 10 min within 2 h of
inter-trial interval. Neophobia measurements, in which an object was put in the center of the
arena and the amount of exploration time was recorded, were done during the first habituation
phase. Twenty four hours after the last habituation session the sample phase and the test phase of
the Novel object location were conducted. During the sample phase two identical objects were
placed symmetrically in two different places, each 15 cm away from the corner, and animals
were allowed to explore them for 5 min. One hour later, in the test phase, one of the two objects
was moved to a new location 15 cm away from the corner, in a symmetrical position to the
familiar one, and the time spent exploring each object was recorded. To evaluate cognitive
performance a discrimination index was calculated as follows: [(time exploring the new location
– time exploring familiar location)/ total time exploring both locations] x 100. Mice were
considered to be impaired if they spent more time investigating the familiar location than the
novel one. After each trial the objects were removed and cleaned with 70% alcohol to remove
any olfactory cues.
2.3.7 Object recognition task
The novel object recognition task is a test used to evaluate short-term episodic memory,
which depends on the entorhinal cortex, hippocampus and frontal cortex. In this task the 19-20
month old mice were required to identify an object as familiar or novel based on a previous
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experience with one of the two objects they encountered before in the open field. The general
procedure of the test consists of three different phases: a familiarization phase, a sample phase
and a test phase. The familiarization phase consists of four sessions of 10 min each, one session
per day for four days. During each session each animal was allowed to explore the arena for 10
min, then was put back into the cage. On the 5th day animals were subjected to the sample phase
and each two identical objects were symmetrically placed in the center of the arena 15 cm away
from each corner. After 15 min delay in which the mouse was returned to its home cage, the
animal was reintroduced to the arena to perform the test phase. The mouse was then presented to
a familiar object (previously seen during the sample phase) and a novel object in the same
location as in the sample phase. The object discrimination index was calculated as (time spent
close to the new object)/(time close to both old and new objects) during the test phase. Animals
were considered to be impaired if they had a discrimination index (DI) ≤ 0.5. A discrimination of
0.5 means that the animal discovered both objects in a similar time and had no preference for
novelty.

2.4

Tissue processing
Animals were anesthetized using an overdose of avertin and transcardially perfused using

0.1 M PBS. The brain was immediately removed from the skull. The right hemisphere was
immersion fixed with 4% paraformaldehyde in 0.1 M PBS for at least 24 h at 4°C then
transferred to 30% sucrose; the left hemisphere was dissected into hippocampus, fore, mid, and
hind brains, and stored at -80C for biochemical studies. After fixation and cryoprotection, the
right hemisphere was sectioned into 40 um sagittal sections, then saved at -20°C in antifreeze
solution (ethylene glycol, glycerol and 0.1 M PBS in 3:3:4 ratio) until further processing.
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2.5

Immunohistochemistry
For immunohistochemistry 3-5 animals/group were chosen randomly. Every tenth

section, 5 to 6 sections/mouse, were used for staining intensity-scanning analysis. For
immunofluorescence, sections recovered from the glycol antifreeze solution were washed three
times, 1X PBS for 15 min then incubated in 0.5% Triton-X100 in PBS for 15 min. Sections were
then washed 3 times in 1X PBS for 15 min each and blocked in 5% normal goat serum
containing 0.05% Tween-20 and 0.05% Triton X-100 for 45 min. Sections were then incubated
overnight at 4C with the corresponding primary antibodies (see Table 2 for all the antibodies
that were used in this study). Treatment with the primary antibody was followed by treatment
with the corresponding secondary fluorescent antibody, either Alexa 488-conjugated goat antimouse IgG antibody (1:500, Molecular Probes, Carlsbad, CA, USA) or CY3-conjugated goat
anti-rabbit antibody (1:500, Jackson Laboratory, Bar Harbor, Maine, USA), for 2 h at RT and
protected from light. Sections were washed 3 times with 1X PBS for 20 min each and then
mounted on microscope slides with fluorogel mounting medium (Electron microscopy, Hatfield,
PA). All the slides were then covered with coverslips and stored at 4C until analyzed by
confocal microscopy under identical conditions. For all the stainings maximum projection
images were generated using the average of 15 Z-stacks using the 20X objective of a Nikon 90i
fluorescent microscope equipped with a Nikon C1 three-laser confocal system and a Nikon DS
U1 digital camera. The entire area of the DG, CA1, CA3, parietal association and frontal cortices
were analyzed. Mean pixel intensity was measured for each brain region using the Image J
software package (NIH).
For A staining an extra step of antigen retrieval was added right after the washes of the
sections from the glycol anti-freeze solution. Briefly, 5-6 sections per mouse were put in a petri
dish glass container containing 0.01 M citrate buffer and heated for 2 min until boiling. Sections
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were then left to cool down at RT and treated with 50% formic acid for 5-7 min. Sections were
then washed one time in 1X PBS for 15 min and then incubated in 0.5% Triton X-100 and the
same procedure was followed as stated above.
To study neurogenesis the DCX and Ki67 double immunostaining were performed
immunohistochemically. Primary antibodies for DCX (mouse monoclonal IgG) and Ki-67 (goat
polyclonal IgG) are stated on Table 2. The corresponding secondary antibodies were used:
Alexa-555 conjugated goat anti-mouse IgG antibody (1:500, Invitrogen, Camarillo, CA, USA)
and Alexa-488 conjugated donkey anti-goat IgG (1:500, Invitrogen, Camarillo, CA, USA). The
same procedure as stated above was used for the immunohistochemical staining with the addition
of the extra step of the antigen retrieval. Sections were then counterstained with the nuclear
staining TO-PRO-3 iodide (1:1000, Invitrogen, Camarillo, CA, USA) for 30 min and then
washed two times for 20 min. 5 mice per group and 5 sections (every 10th section) per brain per
mouse were analyzed. All sections were carefully investigated for the DCX positive staining and
the Ki67 positive staining. Labeled cells in the granule cell layer and the hilus of the DG of the
hippocampus were manually quantified using a 40x oil objective of a Nikon 90i fluorescent
microscope. The number of DCX+ staining cells and Ki-67+ cells was reported as percent of
control. DCX is a marker of immature adult-born neurons and Ki-67 is a marker of cell
proliferation.

2.6

Western Blots
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The brain tissue stored at -80C from each mouse was homogenized using a Teflon-glass
homogenizer to generate 10% (w/v) homogenate. The pre-chilled homogenization buffer
contained 50 mM Tris.HCl (pH 7.4), 8.5% sucrose, 2 mM EDTA, 2 mM EGTA, 10 mM βmercaptoethanol plus the following protease and phosphatase inhibitors: 0.5 mM AEBSF, 10
μg/ml aprotinin, 10 μg/ml leupeptin, 4 μg/ml pepstatin, 5 mM benzamidine, 20 mM βglycerophosphate, 50 mM sodium fluoride, and 1 mM sodium orthovanadate. Protein
concentration of each brain homogenate was determined by the Pierce 660 nm protein assay kit
(Pierce Biotechnology, Rockford, IL USA). The tissue homogenates were boiled in Laemmli’s
buffer for 5 min and then subjected to 7.5 % or 10% SDS-polyacrylamide gel electrophoresis
followed by transfer of separated proteins on 0.45 µm Immobilon-P membrane (Millipore,
Bedford, MA, USA). The blots were developed using the corresponding primary antibodies
(Table 2). Rabbit monoclonal anti-GAPDH (1:2,000; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) was used for the development of the blots as a loading control. The corresponding
horseradish peroxidase-conjugated affinity-pure goat anti-mouse IgG (H+L) and anti-rabbit IgG
(H+L) secondary antibodies were used (1:5,000; Jackson Immuno Research Laboratories, Inc.,
West Grove, PA, USA). The blots were visualized using enhanced chemiluminescence (ECL)
reagents (Pierce, Rockford, IL, USA). The ECL films of the blots were scanned and then
analyzed using Image J (NIH) and Multigauge softwares (Fuji Photo Film, Co., Ltd). Each
protein’s band intensity quantification was the result of the subtraction of the background
intensity from the original intensity of the band. Finally, the intensity of each band minus the
background was normalized over the intensity of the GAPDH band minus the background.
Statistical analysis was conducted using either the GraphPad Prism software package, version 5.0
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(GraphPad Software Inc., La Jolla, CA, USA), or the Stata 13 statistical package (StataCorp,
College Station, TX)

Antibody

Dilution

company

Catalog #

IHC

WB

GluR1

1:300 IHC
1:1000 WB

EMD Millipore

AB1504

yes

yes

Synaptophysin

1:500 IHC
1:3000 WB

Millipore

5258

yes

yes

MAP2

1:1000 IHC
1:4000 WB

Covance

SMI-52R

yes

yes

Covance

PRB-435P

yes

yes

Sigma
Cell signaling

P-246 (IHC)
3450S (WB)

yes

yes

MN1020

yes

no

-III tubulin
PSD95

1: 1000 IHC
1:10000 WB
1: 1000 WB
1:100 IHC

AT8

1:500 IHC

ThermoScientific

PHF1

1:200 IHC
1:500 WB

Kind gift from Dr. Peter Davies

yes

yes

43D

1:1000

BioLegend

816601

no

yes

NR1

1:200 IHC
1:500 WB

ABCAM

ab17345

yes

yes

GluR 2/3

1:2000

ABCAM

52896

no

yes

4G8

1:200 IHC

BioLegend

800701

yes

no

DCX

1:50 IHC

Santa Cruz

sc-8066

yes

no

Ki-67

1:50 IHC

Santa Cruz

sc-7846

yes

no

Synapsin-1

1:2000 IHC
1:40000 WB

Stress Gene

VAP-SV060

yes

yes

GAPDH

1:2000 WB

ABCAM

Ab 2485

no

yes

Table 2. Antibodies Used
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2.7

Fluorojade C staining
Fluorojade C staining was performed according to the procedure developed by Schmued

et al. (Schmued et al., 1997). Briefly, sections were mounted on positively charged slides and
dried at 30-45C in the oven for 20 min. They were briefly rinsed in distilled water followed by
incubation in 100% alcohol for 3 min, 70% alcohol for 1 min, 1 min in 30% alcohol and then
rinsed 1 min in distilled water. To enhance the Fluorojade C staining, sections were first
incubated in 0.06% potassium permanganate (KMnO4) for 15 min (for 200 ml of distilled water,
120 mg KMnO4 was added and then stored at 4C) then rinsed with distilled water for 1 min. A
stock solution of 0.01% of Fluorojade C was prepared (25 mg of Fluorojade C powder was
added to 250 ml of distilled water), then a working solution of 0.001% from the stock solution
was used for the staining (20 ml of Fluorojade C stock solution and 180 ml of 0.1% acetic acid).
After incubation of 30 min the sections were then washed 3 times in distilled water and dried for
20 min at 30-45C in the oven. The dry sections were incubated 3 times in xylene for 2 min each
before mounting with DPX Fluka (Milwaukee, WI). Images for the Fluorojade C positive signals
were captured using a Nikon 90i fluorescent confocal microscope. The percent of area occupied
was quantified using the Image J. All the pictures were taken using a 20X objective.

2.8

Statistical analysis
Statistical analyses were conducted using Stata and GraphPad Prism. Tests of scalar

predictors were done with regression models; in Stata 13 (StataCorp, College Station, Tx;
(Liang and Zeger, 1986, Zeger and Liang, 1986)). For multiple group comparisons one-way or
two-way ANOVAs followed by post-hoc tests were used. T-tests were used for all other inter-
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group comparisons. Data are presented as mean±SD. For all analyses p < 0.05 was considered to
be significant.

2.9

Study design.
In order to study the synaptic compensation phenomenon which represents Specific Aim

1 of this study, 27 WT and 25 3xTg-AD-vh mice were chosen for immunohistochemical and
biochemical studies. Six different age groups were used: 10, 12, 13, 14, 15, and 16 weeks.
Another set of animals, 29 3xTg-AD-vh and 20 WT, went through general behavioral studies and
the Morris Water Maze task at around the age of 12-14 weeks. Right after completion of the
Morris Water Maze task, the mice that were used for behavioral studies were divided into three
groups, 20 WT, 15 3xTg-AD-vh and 14 3xTg-AD-P021, and another set of mice that did not go
through behavioral studies, 21 WT, 20 3xTg-AD-vh, and 22 3xTg-AD-P021, were employed for
immunohistochemical and biochemical analyses. For Specific Aim 2 studies, the mice that were
employed for behavioral analyses were used to study the effect of P021 on cognition. At 9
months after treatment with P021 the Morris Water Maze task was conducted .Then at 15- 17
months after treatment the mice were tested by the object location and the object recognition
tasks. For Specific Aims 3 and 4, brain samples from mice that were not tested behaviorally were
taken at the age of 3 months just before the start of the treatment as a baseline measure and then
at 9, 15 and 18 months after treatment with P021 (Fig. 7). P021 was given in food diet at a
concentration of 60 nmol/g feed; food consumption was  2.7/mouse/day. Food intake and body
weight were measured biweekly and monthly, respectively.
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Fig. 7. Study design.
IHC, immunohistochemical; 3xTg-AD-P021, P021-treated 3xTg-AD mice; 3xTg-AD-vh, vehicle
diet treated mice; WT, wild type control mice.
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Chapter 3. Synaptic Compensation
3.1

Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the most

common form of dementia in elderly people. It is characterized by two histopathological
hallmarks: β-amyloidosis and neurofibrillary degeneration, maximal densities of which are seen
at moderate to severe stages of dementia. However, at a very early stage synaptic dysfunction
and memory loss are observed in AD. Synaptic loss is the best correlate of dementia, especially
the loss of the presynaptic marker synaptophysin (Terry et al., 1991). In fact, synaptophysin
immunoreactivity was reported to decrease by 25% in the cortex of mild AD patients compared
to normal cases (Masliah et al., 1995, Masliah et al., 2001). Degeneration of the whole synaptic
element, seen as simultaneous loss of presynaptic proteins synaptophysin and Rab 3A and
postsynaptic protein synaptopodin, was found in the cortex of AD patients (Davidsson and
Blennow, 1998). All laminas of the neocortex in AD patients suffer from a synaptic loss of
approximately 50% (Masliah et al., 1989) and the quantification of the neuronal and synaptic
density in the temporal and frontal cortices in AD showed a decrease of 48% in the synapse to
neuron ratio (Bertoni-Freddari et al., 1996).

The use of transgenic animal models of AD made it convenient to understand the
progression of AD pathology and to develop treatments. Herein, I used the 3xTg-AD mouse
(Oddo et al., 2003b), a widely used model shown to mimic the neuropathological features of AD
such as Aβ and tau pathologies. The Aβ pathology starts at around nine months of age, tau
pathology at around twelve months of age and cognitive impairment as early as three months of
age in this mouse model (Davis et al., 2013). This model was generated by the co-injection of
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two mutated human transgenes, APPswe (KM670/671NL) and tau P301L, into the PS1/M146V
knock-in embryo (Oddo et al., 2003b). The two mutated transgenes are under the control of
Thymine 1.2 promoter, which is activated during the embryonic days 11 and 15 in mice
(Campsall et al., 2002).
In the present study I show that in a manner reminiscent of AD, in 3xTg-AD mice
cognitive impairment is associated with a transient synaptic compensation, which is followed by
synaptic deficit.

3.2

Results

3.2.1 At three months the 3xTg-AD mice are impaired in spatial reference memory
Since AD is characterized by loss of short-term memory in the early stages of the disease
as well as loss of long-term memory at later stages, I investigated if young adult 3xTg-AD mice
are cognitively impaired. Because the hippocampus is the main brain structure implicated in
memory formation, storage, consolidation and retrieval I employed the Morris Water Maze
behavioral task, which is hippocampal-dependent, to test 3xTg-AD mice. In this task, mice are
required to learn the position of a hidden platform using distal spatial reference cues. At the end
of the learning trials mice have to form a spatial navigation map using the spatial cues to
determine the position of the platform.
The analysis of the swim speed revealed no significant difference between the wild type
and the 3xTg-AD mice (Fig. 8a). For this reason, the learning performance of the animals was
analyzed as the latency time to reach the escape platform. I found that animals from the two
different groups learned the task well. This was evident from the decrease in the latency to
escape across training sessions. However, when I compared the escape latency curve across time,
I found that the 3xTg-AD learned slower than the WT across the training days (Fig. 8b, p =
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0.016). These data revealed that at 12-14 weeks 3xTg-AD mice were impaired in spatial
reference memory.
To evaluate the memory retention in the 3xTg-AD and WT mice, a probe trial 24 h after
the last training session was conducted. The 3xTg-AD mice spent significantly less time in the
target quadrant (Fig. 8c; p<0.001) and visited the target zone less (Fig. 8d; p<0.005) than WT
animals. These results suggest that memory retention was compromised in 3xTg-AD mice and
further corroborate our findings that these mice were cognitively impaired.
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Fig. 8: At 12-14 weeks the 3xTg-AD (Tg-AD) mice show spatial reference memory
impairment in Morris Water Maze test when compared with control WT animals.
a) Swim speed, b) Escape latency, c) Percent of time in target quadrant, d) Number of platform crossings.
*p < 0.05; **p < 0.01; ***p < 0.001. (WT, n = 20; Tg-AD, n = 29). Data are shown as mean ± SD.

3.2.2 3xTg-AD mice have higher locomotivity and motor coordination than WT mice
The Rota-rod and prehensile traction tests were employed to evaluate locomotivity and
motor coordination. The 3xTg-AD mice had significantly higher latency time to fall in the Rotarod test (Fig. 9a-b; p<0.001) and prehensile traction test (Fig. 9c; p<0.001) than WT.
Furthermore, the difference increased over trials, showing that the 3xTg-AD mice had enhanced
motor coordination and motor learning. Similar findings were reported previously (Blanchard et
al., 2010b, Oore et al., 2013, Stover et al., 2015).
3.2.3 Anxiety level of 3xTg-AD mice is similar to WT mice
In the Elevated Plus Maze task the open arm is considered to be more anxiogenic than the
closed arm. Although I found previously that at 6 to 9 months of age the 3xTg-AD mice show
more anxiety than WT, in the present study the 12-14 week old 3xTg-AD mice did not show any
increase in anxiety compared to WT in the Elevated Plus Maze (Fig. 9d).
I also measured the level of anxiety by open field test in 3xTg-AD and WT mice.
Animals are considered to be anxious if they spend less time in the center than in the periphery
of the arena. There was no significant difference between the two groups in the distance covered
during exploration or in time spent in the center zone (Fig. 9e-f).
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Fig. 9: At 10-12 weeks of age the Tg mice had markedly higher locomotor activity than WT
controls.
a) Rota-rod, b) Prehensile traction test, c) Elevated plus maze, d) Open field. *p < 0.05; **p <
0.01; ***p < 0.001. (WT, n = 20; Tg-AD, n = 29). Data are shown as mean ± SD.
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3.2.4 Impairment in spatial reference memory is accompanied by an increase in neuronal
and synaptic markers to compensate for synaptic loss in 3xTg-AD mice
Synaptic loss is an established phenomenon and an early event in AD. Synaptophysin
loss in the frontal cortex strongly correlates with dementia and cognitive impairment (Masliah et
al., 2001). To examine synaptic loss at very early stages of the disease in different brain regions,
3xTg-AD mice aged 10, 12, 13, 14, 15, and 16 weeks were studied. Brain sections from these
animals were immunohistochemically stained using four different antibodies: antisynaptophysin, anti-GluR1, anti-MAP2, and anti-beta-III tubulin.
3.2.5 CA1 region
Longitudinal changes in mean pixel intensity showed that the synaptophysin expression
in 3xTg-AD mice from 10-16 weeks of age was best modeled by a cubic regression model. In
this model synaptophysin expression diminished at 12 weeks of age and was then compensated
for from 13 to 16 weeks of age (Fig. 10a; Table 3). Similarly, Western blots of synaptophysin
expression were best fit by a cubic model, with a significant decrease in synaptophysin level in
the hippocampus at 12 weeks, followed by an increase by 13-14 weeks and then a decrease by
15-16 weeks in 3xTg-AD mice (Fig. 11a-b, F (3, 18) = 5.47, p = 0.0075).
The examination of GluR1 expression in the CA1 region showed no significant
difference across time (Fig. 10b). Similarly, Western blots showed no change of the expression
level in the hippocampus.
The level of expression of the dendritic marker MAP2 was best fit by a linear model,
though the actual level of MAP2 decreased at 12 weeks of age and then increased from 13-16
weeks (Fig. 10c; Table 3).
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The level of expression of β-III tubulin dropped at 12 weeks and then increased from 1316 weeks (Fig. 10d; Table 3), though again the best fit was obtained with a linear model.

Longitudinal Tg-AD
Cornis Ammonius 1 (CA1)
Synaptophysin
GluR1
MAP2
-III tubulin
Cornis Ammonius 3 (CA3)
Synaptophysin
GluR1
MAP2
-III tubulin
Dentate gyrus (DG)
Synaptophysin
GluR1
MAP2
-III tubulin
Parietal Cortex (PC)
Synaptophysin
GluR1
MAP2
-III tubulin
Frontal Cortex (FC)
Synaptophysin
GluR1
MAP2
-III tubulin

F

Df

p

Adj. R2

Model

4.19
1.72
3.38

(3, 20)
(1, 23)
(1, 23)

0.0188
0.05
0.0789

0.385
0.11
0.12

cubic
linear
linear

5.88
2.62

(3, 20)
(3, 21)

0.0048
0.0775

0.39
0.17

cubic
cubic

4.71
5.44
4.27

(3, 16)
(2, 22)
(2, 22)

0.0154
0.012
0.0272

0.37
0.27
0.2139

cubic
quadratic
quadratic

4.46
6.13
5.7

(3, 20)
(2, 21)
(2, 21)

0.0149
0.008
0.01

0.31
0.3
0.29

cubic
quadratic
quadratic

7.89
3.15

(3, 20)
(1, 22)

0.0011
0.0896

0.47
0.0856

cubic
linear

Table 3. Longitudinal best-fitting regression models for immunohistochemistry of Tg-AD
across time.
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Fig. 10: In the CA1 region, Tg mice showed a decrease in synaptophysin, MAP2 and -III
tubulin at 12 weeks which was compensated by 13 weeks.
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections were immunostained and
analyzed by confocal microscopy in a single experiment under identical conditions and settings
so that they could be directly compared across the six age groups. *p<0.05; **p<0.01;
***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group). Quantification
is shown as mean ± SD.
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Fig. 11: Expression levels of synaptophysin and GluR1 in the hippocampus in Western
blots.
Longitudinal analysis of synaptophysin (10-16 weeks). (a, b) and (c, d) cross-sectional (10-13 weeks, Tg
and WT mice). a, c are Western blots. *p<0.05; **p<0.01; ***p<0.001. (WT, n = 28; Tg-AD, n =

26, n = 3 to 5/group).

3.2.6 CA3 region
The level of expression of synaptophysin in the CA3 region was best fit by a cubic model
(Fig. 12a; Table 3). As in the CA1 region, the expression of synaptophysin dropped at 12 weeks
and increased from 13 to 16 weeks of age. No significant change was detected in the GluR1 and
MAP2 levels in the CA3 region (Fig. 12b, c; Table 3). -III tubulin was best modeled by a cubic
regression with a decrease in the level of expression at 12 weeks and increase from 13-16 weeks
of age (Fig. 12d; Table 3).
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Fig. 12: Tg mice showed a decrease in the level synaptophysin and -III tubulin in the CA3
region at 12 weeks, followed by a compensatory increase by 13 weeks.
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections were immunostained and
analyzed by confocal microscopy in a single experiment under identical conditions and settings
so that that they could be directly compared across the six age groups. *p<0.05; **p<0.01;
***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group ). Quantification
is shown as mean ± SD.
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3.2.7 DG region
In the DG the level of synaptophysin dropped at 12 weeks of age and then increased from
13 to 16 weeks. The changes followed a cubic model (Fig. 13a; Table 3). No change was found
in the expression of GluR1 (Fig. 13b). The level of expression of MAP2 followed a quadratic
model (Fig. 13c, Table 3); -III tubulin expression was best fit by a quadratic model with a drop
at 12 weeks and increase from 13-16 weeks (Fig. 13d; Table 3).
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Fig. 13: Synaptophysin, MAP2 and -III tubulin in the DG region decreased at 12 weeks
for synaptophysin and 13 weeks for MAP2 and -III tubulin with compensatory increase at
later ages.
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections were immunostained and
analyzed by confocal microscopy in a single experiment under identical conditions and settings
so that that they could be directly compared across the six age groups. *p<0.05; **p<0.01;
***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group ). Quantification
is shown as mean ± SD.
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3.2.8 Parietal cortex region
Expression of synaptophysin, MAP2, and -III tubulin showed a drop in the expression
level across time at 12 weeks and an increase from 13-16 weeks. A cubic model best fit the
expression of synaptophysin, while -III tubulin and MAP2 followed a quadratic model (Fig.
14a, c, d; Table 3). The level of expression of GluR1 did not change significantly (Fig. 14b;
Table 3).
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Fig. 14: The levels of synaptophysin, -III tubulin and MAP2 in the parietal cortex showed
a decrease at 12 weeks, followed by a compensatory increase by 13-16 weeks.
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections were immunostained and
analyzed by confocal microscopy in a single experiment under identical conditions and settings
so that that they could be directly compared across the six age groups. *p<0.05; **p<0.01;
***p<0.001. Scale bar: 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group). Quantification is
shown as mean ± SD.
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3.2.9 Frontal cortex region
The level of expression of synaptophysin and MAP2 changed across time. Synaptophysin
followed a cubic model (Fig. 15a; Table 3) while for -III tubulin a linear model fit best (Fig.
15d; Table 3). Both markers decreased at 12 weeks of age and increased from 13-16 weeks. No
significant change was detected in the expression of GluR1 (Fig. 15b; Table 3) or MAP2 (Fig.
15c; Table 3).

76

Fig. 15: In the Frontal cortex, the levels of synaptophysin and -III tubulin significantly
changed at 12 weeks. No change was detected for the GluR1 level. Compensation happened
from 13-16 weeks.
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections were immunostained and
analyzed by confocal microscopy in a single experiment under identical conditions and settings
so that that they could be directly compared across the six age groups. *p<0.05; **p<0.01;
***p<0.001. Scale bar: 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group ). Quantification is
shown as mean ± SD.

3.3

Cross-sectional comparison between 3xTg-AD and control mice confirms
synaptic compensation in the former

3.3.1 CA1 region
Cross-sectional comparison of 3xTg-AD with WT mice revealed a comparative synaptic
loss at 12 weeks followed by compensation in different brain regions at different ages. In the
CA1 region there was a non-significant trend toward decrease in synaptophysin expression at 12
weeks and a relative increase from 13 to 15 weeks (Fig. 16a; Table 4). Western blots showed
changes in synaptophysin expression best fit by a quadratic model with synaptic loss at 12 weeks
compensated from 13 weeks (Fig. 11c-d, F (2, 7) = 12.56; p < 0.005).
GluR1 non-significantly increased in 3xTg-AD mice compared to WT at 13 weeks of
age, although there was no decrease at 12 weeks (Fig. 16b; Table 4).
Similarly, MAP2 expression was comparable in 3xTg-AD and WT mice, though the level
of MAP2 decreased at 13 weeks, increasing at 14 weeks (Fig. 16c; Table 4).
-III tubulin did not change significantly but the lowest level was at 13 weeks of age with
a slight compensation from 14-16 weeks of age (Fig. 16d; Table 4).
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Cross-sectional WT vs
Tg-AD
Cornis Ammmonius 1
(CA1)

week 10

week 12

week 13

week 14

week 15

week 16

p

p

p

p

p

p

Synaptophysin

-

-

-

-

-

-

GluR1

-

-

0.08

-

-

-

MAP2

-

-

-

-

-

-

-

-

-

-

-

-

Synaptophysin

-

-

-

-

-

-

GluR1

-

-

-

-

-

-

MAP2

-

0.07

-

-

-

0.0066

-III tubulin

-

-

-

-

-

-

-

-

-

-

-

-

MAP2

-

0.0009

-

-

-

0.03

-III tubulin

-

-

-

-

-

-

Synaptophysin

-

0.03

-

-

-

-

GluR1

-

-

-

-

-

-

MAP2

-

-

-

-

-

-

-III tubulin

-

-

-

-

-

-

Synaptophysin

-

0.03

0.02

0.0033

-

-

GluR1

-

-

0.08

-

-

-

MAP2

-

-

-

-

-

-III tubulin

-

-

-

0.06

-

-

-III tubulin
Cornis Ammonius
(CA3)

3

Dentate gyrus (DG)
Synaptophysin
GluR1

Parietal Cortex (PC)

Frontal Cortex (FC)

Table 4: The cross-sectional analysis of WT vs Tg-AD immunohistochemically across time.
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Fig. 16: Cross-sectional comparison of Tg and WT mice for the relative expression of
synaptophysin, GluR1, MAP2 and -III tubulin in the CA1 region from 12 to 16 weeks
showed a decrease at 12-13 weeks, followed by compensation at different ages in different
brain regions in Tg mice.
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections from WT and Tg mice at
each age were immunostained and analyzed by confocal microscopy under identical conditions
and settings to enable comparison between the two groups of animals. *p<0.05; **p<0.01;
***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 25, n = 3 to 5/group). Quantification
is shown as mean ± SD. This experiment was repeated 3 times.
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3.3.2 CA3 region
Synaptophysin expression did not differ significantly between 3xTg-AD and WT. The
lowest level of synaptophysin was detected at 12 weeks in 3xTg-AD mice with an increase at 14
weeks (Fig. 17a; Table 4).
GluR1 expression did not change significantly, decreasing at 13 weeks and increasing
only at 14 weeks (Fig. 17b; Table 4).
MAP2 decreased at 12 weeks, increased at 15 weeks, then dropped significantly at 16
weeks (Fig. 17c; Table 4).
-III tubulin expression in the CA3 did not change significantly. The lowest level was at
13 weeks of age with a slight increase from 14-15 weeks and a decrease at 16 weeks (Fig. 17d;
Table 4).
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Fig. 17: Cross-sectional comparison of Tg and WT mice for relative expression of all the
markers in the CA3 region from 12 to 16 weeks showed a non-significant decrease in the
MAP2 level at 12 weeks followed by a compensation and then a decrease again at 16 weeks.
No significant changes were found for the other three markers. a) synaptophysin; b) GluR1; c)
MAP2; and d) -III tubulin. Sections from WT and Tg mice at each age were immunostained
and analyzed by confocal microscopy under identical conditions and settings to enable
comparison between the two groups of animals. *p<0.05; **p<0.01; ***p<0.001. Scale bar =
100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group ). Quantification is shown as mean ± SD.
This experiment was repeated 3 times.
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3.3.3 DG region
Synaptophysin in the DG did not differ significantly between WT and Tg-AD across
time, though some compensation occurred at 15 weeks (Fig. 18a; Table 4).
Overall there was no significant difference in the expression of GluR1; it was lowest at
12 and 13 weeks followed by compensation at 15 weeks (Fig. 18b; Table 4).
MAP2 decreased at 12 weeks, increased from 13-15 weeks, and then dropped again at 16
weeks (Fig. 18c; Table 4).
Overall -III tubulin did not change significantly. The lowest level was at 13 weeks with
an increase at 15 weeks (Fig. 18d; Table 4).
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Fig. 18: Cross-sectional comparison of Tg and WT mice for relative expression of synaptophysin,
GluR1, MAP2 and -III tubulin from 12 to 16 weeks in the DG region showed a non-significant
decrease for the MAP2 level at 12 weeks, a compensation from 13-15 weeks and a decrease again at
16 weeks. No significant changes for the other three markers occurred. a) synaptophysin; b)

GluR1; c) MAP2; and d) -III tubulin. . Sections from WT and Tg mice at each age were
immunostained and analyzed by confocal microscopy under identical conditions and settings to
enable comparison between the two groups of animals. *p<0.05; **p<0.01; ***p<0.001. Scale
bar: 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group). Quantification is shown as mean ± SD.
This experiment was repeated 3 times.
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3.3.4 Parietal cortex region
Synaptophysin decreased significantly at 12 weeks and increased from 13-16 weeks (Fig.
19a; Table 4).
GluR1 did not differ significantly; the lowest level was at 12 weeks with an increase at 14
weeks (Fig. 19b; Table 4).
MAP2 change was not significant; the lowest level was at 13 weeks with an
increase at 14 weeks (Fig. 19c, Table 4).
-III tubulin was lowest at 13 weeks and increased at 14 weeks (Fig. 19d. Table 4). The
changes were not significant.
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Fig. 19: Cross-sectional comparison of Tg and WT mice for relative expression of
synaptophysin, GluR1, MAP2, and βIII tubulin from 12 to 16 weeks in the parietal cortex.
Only synaptophysin showed a decrease at 12 weeks followed by compensation at later time
points.
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections from WT and Tg mice at
each age were immunostained and analyzed by confocal microscopy under identical conditions
and settings to enable comparison between the two groups of animals. *p<0.05; **p<0.01;
***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group ). Quantification
is shown as mean ± SD. This experiment was repeated 3 times.

3.3.5 Frontal cortex
Synaptophysin decreased at 12 weeks and increased at 14 weeks. The compensation for
synaptic loss occurred from 13 to 15 weeks (Fig. 20a; Table 4).
GluR1 non-significantly decreased at 13 weeks and rose from 14-16 weeks (Fig. 20b;
Table 4).
MAP2 did not change significantly. The lowest level was at 13 weeks, rising at 14 weeks
(Fig. 20c, Table 4).
-III tubulin in Tg-AD mice was lowest at 12 weeks and increased non-significantly at 14
weeks of age. Compensation for synaptic loss happened mainly at 14 weeks (Fig. 20d; Table 4).
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Fig. 20: Cross-sectional comparison of Tg and WT mice for relative expression of
synaptophysin, GluR1, MAP2, and βIII tubulin from 12 to 16 weeks of age in the frontal
cortex.
The levels of synaptophysin, MAP2, and -III tubulin decreased from 12-13 weeks and then
increased at 14-16 weeks. a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections
from WT and Tg mice at each age were immunostained and analyzed by confocal microscopy
under identical conditions and settings to enable comparison between the two groups of animals.
*p<0.05; **p<0.01; ***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to
5/group). Quantification is shown as mean ± SD. This experiment was repeated 3 times.
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3.4

Changes in expression levels of neuronal and synaptic proteins in WT mice

3.4.1 CA1 region
Synaptophysin and GluR1 did not change significantly in WT mice (Fig. 21a; Table 5).
MAP2 and -III tubulin significantly changed over time in the CA1 region, best modeled with a
cubic regression (Fig. 21a; Table 5). MAP2 decreased from 12 to 13 weeks and came back to
normal level at 14 to 15 weeks. -III tubulin decreased at 12 weeks and then increased at 13
weeks.
3.4.2 CA3 region
No significant changes were detected in synaptophysin, MAP2 or -III tubulin (Fig. 21b;
Table 5). GluR1 followed a cubic pattern, with the lowest level at 15 weeks and an increase at 16
weeks (Fig. 21b; Table 5).
3.4.3 DG region
No significant changes for any of the markers were detected in the DG area (Fig. 21c;
Table 5).
3.4.4 Parietal cortex
The only change that was seen in this region was in the expression level of GluR1. It
followed a quadratic fit with a decrease from 12-15 weeks and then an increase by 16 weeks
(Fig. 21d; Table 5). All the other markers showed no differences.
3.4.5 Frontal cortex
No significant change was seen for any markers in this brain region (Fig. 21e; Table 5).
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Longitudinal WT
Cornis Ammmonius 1 (CA1)
Synaptophysin
GluR1
MAP2
-III tubulin
Cornis Ammonius 3 (CA3)
Synaptophysin
GluR1
MAP2
-III tubulin
Dentate gyrus (DG)
Synaptophysin
GluR1
MAP2
-III tubulin
Parietal Cortex (PC)
Synaptophysin
GluR1
MAP2
-III tubulin
Frontal Cortex (FC)
Synaptophysin
GluR1
MAP2
-III tubulin

F

df

P

Adj. R2

Model

5.35
4.82

(3, 20)
(3, 20)

0.007
0.011

0.36
0.33

cubic
cubic

2.47
-

(3, 22)
-

0.08
-

0.15
-

cubic
-

-

-

-

-

-

5.81
-

(2, 22)
-

0.009
-

0.28
-

quadratic
-

-

-

-

-

-

Table 5: Longitudinal comparison of WT immunohistochemically across time.
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Fig. 21: Longitudinal comparison of relative expression of synaptophysin, GluR1, MAP2
and βIII tubulin in WT mice showed some changes but no overall decrease from age 10
weeks to 16 weeks.
a) CA1; b) CA3; c) DG; d) parietal cortex and frontal cortex. Sections were immunostained and
analyzed by confocal microscopy in a single experiment under identical conditions and settings
so that that they could be directly compared across the six age groups. *p<0.05; **p<0.01;
***p<0.001. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group). Quantification is shown as mean ± SD.
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Cross-sectional comparison between 3xTg-AD and control mice shows that synaptic
compensation happened at different time points in different brain regions

The comparison of the changes in the expression of the different synaptic and neuronal
markers mentioned above in the 3xTg-AD mice as % of WT showed that synaptic compensation
happened in different brain regions at different time points (Fig. 22, table 5). Indeed, for the
synaptic marker synaptophysin for example synaptic compensation in the CA3 region happened
at 14 weeks (Fig. 22, table), while in the parietal cortex compensation happened at 13 weeks
(Fig. 22, table 5). Table 5 shows all the regional changes for all the synaptic and neuronal
markers at different time points.
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Fig. 22: Change in Tg mice as % of WT showed that synaptic compensation occurred at
different time points in different brain regions. A summary of data taken from Figures 1620. Sections from WT and Tg mice at each age were immunostained and analyzed by confocal
microscopy under identical conditions and settings to enable comparison between the two groups
of animals. WT (n = 28, 3xTg-AD, n = 26, n = 3 to 5/group).
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3.5

Discussion
Dementia status in AD is preceded by a relatively long and variable period of MCI. In

some individuals the MCI stage does not progress to AD. This variable MCI stage is probably
due to the compensatory neuroregenerative response of the AD brain which, because of an
insufficient neurotrophic environment, does not succeed completely (Li et al., 2008, Iqbal et al.,
2014a). Histopathological studies have shown that the compensatory phenomenon does occur in
the AD brain (Mukaetova-Ladinska et al., 2000).
The present study revealed that the spatial reference memory impairment in the young
adult 3xTg-AD mice seen at around 12-14 weeks of age is accompanied by a decrease in the
presynaptic marker synaptophysin, the postsynaptic marker GluR1, the dendritic marker MAP2
and the neuronal marker β-III tubulin. However, reminiscent of the AD brain, the 3xTg mice
showed a decrease in synaptic and neuronal markers at 12 weeks followed by a transient increase
from 13 to 16 weeks of age. I speculate that this increase is a failed attempt of the brain to
compensate for synaptic loss. Beyond the age of 4 months, the 3xTg-AD mice are known to have
a decrease in synaptophysin as well as an apparent synaptic dysfunction (Oddo et al., 2003b,
Blanchard et al., 2010b). Most importantly, when I expressed the data of 3xTg-AD mice as a
percent of control (WT) for different ages from age 10-16 weeks, different brain regions
compensated for the synaptic loss at different time points. Although the WT mice also showed
changes in these markers from 10-16 weeks of age, the changes seen in WT mice were totally
different from those seen in 3xTg-AD mice.
The present study showed that there was an upregulation in the level of expression of
different synaptic, dendritic and neuronal markers, especially the increase in the expression level
of synaptophysin in cognitively impaired 3xTg-AD mice. Previous studies reported an increase
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in glutamatergic buttons in the midfrontal gyrus in MCI patients and an increase in
synaptophysin immunoreactivity and cholinergic buttons in the plaque proximity areas in the
APP

K670N,M671L+

PSlM146L double transgenic mice which, however, decreased with the

progression of the disease (Hu et al., 2003, Bell and Cuello, 2006, Bell et al., 2007). Similarly,
spatial reference memory impairment in aged rats was shown to be associated with an increase in
the levels of expression of PSD95 and GluR1 compared to control animals (Nyffeler et al.,
2007).
Consistent with the present study, a previous study reported an increase in the level of
expression of synaptophysin and SNAP-23 in AD brains at Braak stage 3 with minimal to mild
clinical grades of dementia compared to normal controls and an increase in the expression levels
of MAP2 and α-synuclein at Braak stage 4 in the neocortex in AD (Mukaetova-Ladinska et al.,
2000). However, a sharp decrease in synaptophysin expression in AD was seen only at Braak
stages 5 to 6 with the full spectrum of amyloid beta and tau pathologies and moderate to severe
clinical grades of dementia. Similarly, an increase in the level of PSD-95 expression in the
entorhinal cortex of AD cases (Leuba et al., 2008a; Leuba et al., 2008b) and a decrease in the
level of synaptophysin expression compared to age-matched controls was previously reported
(Leuba et al., 2008b). The agreement between human and animal studies indicates that the
upregulation in synaptic, dendritic and neuronal markers found in the present study is most
probably due to a compensatory phenomenon initiated by the diseased brain to save the
remaining intact synapses.
In light of what was found previously in human subjects, findings of the present study in
3xTg-AD mice could be mimicking what happens in AD patients at early stages of the disease.
For instance, at the age of 12-14 weeks the 3xTg-AD mice are considered to be in the early
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stages of AD-like disease. They have only intracellular amyloid beta (A) and cognitive
impairment; A plaque and tau pathologies are seen only at 9-12 months onwards.
It is believed that synaptic compensation could happen at different levels: at the activity
level, at the network level and at the synaptic level. At the activity level compensation occurs
when a neuron senses its own spiking activity level through calcium-dependent sensors and
adjusts it accordingly by the phenomenon of synaptic scaling, mainly through adjusting the
abundance of glutamate receptors postsynaptically. The neuron can also self-adjust by local
synaptic compensation through a change in the efficacy of neurotransmitter release
presynaptically. At the level of the neuronal network, when target neurons are denervated they
inform afferent neurons via signaling about the need for synaptic input. Remaining intact
neurons compensate by increasing the synaptic area so that the total synaptic contact area per
unit volume of the cortex remains intact (Scheff, 2003).
Coupling between astrocytes and neurons can also contribute to global synaptic
homeostasis because glial cells are well placed to sense the overall activity of neurons
(Stellwagen and Malenka, 2006). Using random synaptic deletions to simulate global synaptic
compensation, computational studies showed that all the remaining intact synapses would
increase their activity (or scaling) in a similar way by multiplying their weight by the same factor
(Horn et al., 1993). From a neurobiological perspective, synaptic compensation could happen by
the upregulation of the expression levels of certain presynaptic and postsynaptic markers, e.g.,
the increase in the expression levels of synaptophysin, PSD95 and GluR1 reported previously
(Leuba et al., 2008a, Leuba et al., 2008b, Hu et al., 2003, Nyffeler et al., 2007) as well as the
findings of the present study. The synaptic compensation could result from neuritic outgrowth.
Indeed, it has been proposed that after their death affected neurons liberate growth factors that
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could be used by surviving neurons for growing new neurites (Uylings and de Brabander, 2002).
Another mechanism of synaptic compensation could be activation of silenced synapses following
the death of inhibitory neurons and an increase in neurogenesis in the dentate gyrus (Jin et al.,
2004b).
There are three major points of view concerning the mechanism of synaptic
compensation. One view considers the phenomenon to be beneficial, helping to slow down the
progression of the disease (Iacono et al., 2008). The second view considers it as detrimental
because it affects the brain network and drives disease progression (Nyffeler et al., 2007,
Abuhassan et al., 2014, Berchtold et al., 2014). The third one considers compensation as
beneficial at the early stage of the disease because it slows down its progression (Mesulam,
2000, Small, 2008). However, in the long run it is detrimental because it becomes the driving
force to affecting the whole neuronal network.
I speculate that in the present study the decrease in synaptophysin, MAP2 and -III
tubulin at 12 weeks of age in the 3xTg-AD animals compared to WT and the transient increase in
these three markers from 13 to 16 weeks of age is due to a compensatory mechanism in which
the diseased brain attempts to repair itself. Because the disease is not fully developed in the
young 3xTg-AD mice, the brain still has the capacity to compensate for the synaptic loss. This
compensatory mechanism may be the biological basis of slowing down the development of the
AD-like pathological features in this mouse model. Indeed, it is known that the 3xTg-AD mouse
develops Aβ and tau pathologies only at an advanced age: Aβ pathology at ~9 months and tau
pathology at around 12 months. Thus, it takes several months for these pathological features to
develop and this is considered a long enough period for the progression of the pathologies. I
speculate that a similar phenomenon may be occurring in asymptomatic AD or MCI patients’
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brains. In fact, the mild cognitive impairment period is relatively long, lasting several years, and
this may be due to the compensation or the self-repair attempt of the brain. However, as the
disease progresses the brain is overwhelmed and synaptic loss reaches a certain threshold level
beyond which the brain cannot compensate any more. Perhaps this is why the acceleration of
cognitive decline and the appearance of clinical features of AD occur at an advanced stage.
For this reason, prevention strategies starting at an early stage of the disease could be
more effective than intervention at a later stage after a drastic synaptic and neuronal loss is
reached. Once the brain has undergone a severe insult of synaptic and neuronal loss, repair
would be more difficult than prevention at an early stage of the disease. Acting when synaptic
compensation is most active would likely be more effective.
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Chapter 4. Effect of early treatment with P021 on cognitive
impairment
4.1

Introduction
The cumulative incidence of AD is estimated to increase from ~5% at the age of 70 to

~50% at the age of 90 (Jahn, 2013). AD interferes with the process of memory formation from
the molecular level to the level of the whole brain network. In most cases of AD, slow cognitive
deterioration occurs several years before the clinical symptoms are brought to attention. During
the very early stages of AD, short-term memories are severely affected and patients have
difficulties remembering new information and familiar people’s names. Executive functions such
as judgment and problem solving and organizational skills are also affected; long-term and
declarative memories, however, are less deteriorated. Small personality and behavioral changes
are reported. Agitation, anxiety and psychosis are not reported in the initial stages. In contrast,
during moderate to severe stages cognitive deterioration becomes more pronounced and newly
learned material is rapidly lost with patients described as “living in the past”. Difficulties in
spatial navigation and disorientation in the familiar environment become marked symptoms as
well as the inability to recognize family members and close relatives. Executive function and
logical reasoning are severely deteriorated while behavioral symptoms such as hallucinations,
delusions and illusionary misidentification become more common. Sleep disruption, agitation
with temper tantrums, physical and verbal aggression and anxiety are also common in this stage.
Apathy, however, is the most persistent and frequent symptom exhibited by 72% of the patients
through all stages of AD (Mega et al., 1996). Behavioral disturbances represent the major burden
and source of distress to the caregiver and lead to elder abuse in the US. This results in the
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institutionalization of patients to nursing homes, which leads to an increase in the financial cost
(Binetti et al., 1998). At the most severe stages almost all the cognitive functions are gone, with
patients becoming totally dependent on caregivers and having difficulties even in chewing and
swallowing food. Most patients become bedridden at this stage and the major cause of death is
pneumonia (Lyketsos et al., 2011, Tarawneh and Holtzman, 2012). Women are known to be at a
higher risk than men to suffer from AD. This may be because of the decrease in the level of
estrogen after menopause (Irvine et al., 2012).
The severity of cognitive impairment directly correlates with the density of NFT. NFT
formation starts in the memory-associated areas such as the entorhinal cortex and the
hippocampus, then spreads to parietal, temporal and finally frontal cortices. Indeed, findings
from the Nun Study and the Adult Changes in Thought (ACT) study reported a strong correlation
between the BRAAK stages and the status of dementia (SantaCruz et al., 2011). Furthermore, the
NFT density in the entorhinal cortex and the temporal lobe showed a strong correlation with
cognitive scores in non-demented people. Another study also suggested that the accumulation of
NFT may be responsible for memory loss associated with normal aging as well as the memory
deficit seen in MCI (Guillozet et al., 2003). In contrast, A plaque deposition did not correlate
either with neuronal loss and NFT or with the severity of the disease (Gomez-Isla et al., 1997).
The number of senile plaques in the cerebral cortex also tends to stay stable with the severity of
the disease stages. The fact that A plaque deposition does not correlate with cognitive scores, is
not specific for memory related lesions and is found in many cognitively normal individuals
(Tomlinson et al., 1970, Alafuzoff et al., 1987, Arriagada et al., 1992b, Guillozet et al., 2003)
strongly suggests that A burden does not play a significant role in memory impairment during
the early stages of the disease (Guillozet et al., 2003). However, the spatial and temporal
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distribution of the NFT and the numerical density better match the clinical features of dementia
than the A plaque burden (Tomlinson, 1982, Alafuzoff et al., 1987, Arriagada et al., 1992a,
Berg et al., 1993, Gomez-Isla et al., 1997, Berg et al., 1998, Giannakopoulos et al., 2003). The
severity of cognitive symptoms was found to be even more correlated with the severity of
neuronal loss (Gomez-Isla et al., 1997) and even more with synaptic deficit, especially with
synaptophysin loss (DeKosky and Scheff, 1990, Terry et al., 1991).
Medical intervention delaying disease onset by 5 years could reduce the number of AD
patients by 57% and decrease the projected Medicare financial costs from $627 billion to $344
billion (Sperling et al., 2011). Once a reliable screening instrument is developed and a treatment
that slows the progression of the disease by 50% is discovered, the risk of having AD in people
aged 65 and older would decrease from 10% to 5.7%. Furthermore, even delaying the onset of
the disease by 6 months would, it is estimated, decrease the number of people developing AD by
half a million by 2050 (Brookmeyer et al., 1998). Currently approved drugs produce only modest
improvements of cognitive symptoms, resulting mostly in stabilization rather than alleviation of
the cognitive symptoms (O'Hara et al., 2001).
The use of transgenic mouse models greatly helped to understand the molecular
mechanisms of AD and facilitated preclinical studies that could lead to development of potential
AD drugs. The 3xTg-AD mouse model has proven to be a biologically relevant model to AD
pathology. Unlike other transgenic mice, 3xTg-AD mice develop A plaques and
hyperphosphorylated tau without NFT, resembling rarer cases of AD (Tiraboschi et al., 2004). It
is even recently reported that these mice develop a deficiency in episodic memory as early as 3
months of age that deteriorates similarly to the deterioration seen in patients. In the present study
I found (Chapter 3) that, similar to the visuospatial impairment seen in AD, the 3xTg-AD mice
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are impaired in spatial memory as examined by the Morris Water Maze task. The aim of this
study is to investigate the effect of P021 on preventing or delaying the cognitive impairment by
initiating the treatment at 3 months, which is around the period of synaptic compensation. P021
and its parent molecule Peptide 6 were previously shown to be effective in reversing cognitive
impairment in 3xTg-AD mice when the treatment was started at later stages of the disease
(Blanchard et al., 2010b, Kazim et al., 2014). P021 was also found to rescue cognitive
impairment in aged Fisher rats (Bolognin et al., 2014) and in a rat model of the sporadic form of
AD (Bolognin et al., 2012).
In the present study, I investigated the effect of P021 treatment starting at around the
period of synaptic compensation and lasting for ~18 months in 3xTg-AD mice. I found that,
reminiscent of AD, cognitive deterioration in 3xTg-AD mice starts very early in the disease
process and lasts for the lifetime. Furthermore, P021 treatment right after the onset of cognitive
impairment and very early in the disease process can completely prevent cognitive impairment in
3xTg-AD mice. Treatment with P021 decreases the mortality rate without apparent side effects
such as weight loss or decrease in food consumption in 3xTg-AD mice.

4.2

Results

4.2.1 Treatment with P021 can rescue reference memory deficit
As described in Chapter 3, I found that the 3xTg-AD mice were cognitively impaired as
determined by the Morris Water Maze task very early in the disease process at ~3 months of age.
Since the Morris Water Maze task measures spatial reference memory that is purely hippocampal
dependent and spatial reference memory is affected early in AD patients, I sought to study the
effect of P021 treatment on preventing or reversing this impairment. The Morris water Maze task
was conducted after 9 months of treatment with P021, when the animals were aged 12 months.
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During the task animals went through four training trials per day for four days for a total of 16
trials. There was no difference in the swim speed during the four training days (Fig. 23a).
Analysis of the latency to escape showed that the learning curve of the 3xTg-AD-vh was slower
compared to WT (Fig. 23b, p < 0.001) and 3xTg-AD-P021 mice (Fig. 23b, z = 4.78 p = 0.031).
All three groups of mice learned the task, however. The analysis of distance by day showed also
that the learning curve of 3xTg-AD-vh mice was slower than WT (Fig. 23c, p <0.0001) and
3xTg-AD-P021 animals (Fig. 23c, p = 0.039) and they traveled farther to find the escape
platform. These data showed that the 3xTg-AD-vh mice were impaired and that P021 was able to
reverse this impairment.
To evaluate retention memory in the 3xTg-AD mice three probe trials were conducted.
The first one (PT1) was twenty-four hours after the last training trial. The second probe trial
(PT2) and the third probe trial (PT3) were separated by twenty days from each other and from
the first probe trial. The percent of time spent in the target quadrant and the number of crossings
of the previous place of the platform were determined to evaluate the performance of the
animals. During PT1, the 3xTg-AD-vh spent significantly less time in the target quadrant
compared to WT (Fig. 23d, post-hoc Bonferroni-adjusted test, p<0.05) and P021 treatment was
able to reverse this impairment (Fig. 23d, p<0.01). A similar trend was seen in the number of
visits to the previous place of the platform but there was no significant difference between the
three groups (Fig. 23g). During PT2, the analysis of the percent of time in target quadrant
showed that the 3xTg-AD-vh spent less time compared to the WT (Fig. 23e, p<0.05).
Furthermore, the analysis of the number of crossings of the previous place of the platform
showed that the 3xTg-AD-vh had made fewer visits compared to the WT and that P021 reversed
this impairment (Fig. 23h, p = 0.094). For PT3, the percent of time in target quadrant and the
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number of platform crossings showed a similar trend to PT1 and PT2 but were not significant
(Fig. 23f, i). These results suggest that memory retention was compromised in 3xTg-AD-vh mice
and that the 9 month treatment with P021 rescued this impairment.

Fig. 23: At 12 months of age after 9 months of treatment the 3xTg-AD-vh mice were
impaired in the Morris Water Maze task and P021 prevented this impairment.
a) Swim speed, b) Latency to escape, c) Distance traveled, d) percent of time in target quadrant
in PT1, e) percent of time in target quadrant in PT2, f) percent of time in target quadrant in PT3,
g) number of platform crossings PT1, h) number of platform crossings PT2, and i) number of
platform crossings PT3. Tq: target quadrant, AL: adjacent left, AR: adjacent right, Oq: opposite
quadrant. *p<0.05; **p<0.01, ***p<0.001. (WT, n = 20; Tg-AD-vh, n=15; Tg-AD-P021, n = 14). Data
are shown as mean ± SD.
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4.2.2 Treatment with P021 can rescue short-term reference memory impairment
The neophobia test is used to measure the rodent’s fear of discovering novelty, in this
case a novel object. This test was conducted during the first habituation session before the object
location test. The statistical analysis of the percent of time spent in the center exploring the novel
object showed that both the WT and 3xTg-AD-vh mice spent similar time exploring the new
object, while the P021-treated spent significantly more time exploring the novel object compared
to the two previous groups (Fig. 24a, p = 0.0086). The novel object location in the open field
was conducted twenty four hours after the last habituation session. The Object location test
comprised a sample phase and a test phase. The analysis of the data from the sample phase
showed that, as expected, there was no difference in exploring the two identical locations
between the three groups of mice (Fig. 24b). However, the data from the test phase showed that
3xTg-AD-vh mice spent more time investigating the familiar location than the novel one, while
the WT and 3xTg-AD-P021 groups spent more time exploring the novel location than the
familiar one (Fig. 24c, p = 0.0072).
Together these data showed that the 3xTg-AD-vh at the age of 18 months had impairment
in short-tem spatial memory and that the ~15 months treatment with P021 reversed this
impairment.
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Fig. 24. At 18-19 months of age after 15-16 months of treatment, when compared to WT, the 3xTgAD-vh showed impairment in short-term spatial reference memory in the object location task and
P021 was able to prevent this impairment as well as decrease neophobia in 3xTg-AD mice. a)
Neophobia test, b) sample phase, and c) test phase. *p<0.05; **p<0.01, ***p<0.001. (WT, n = 20; TgAD-vh, n=15; Tg-AD-P021, n = 14). Data are shown as mean ± SD.

4.2.3 P021 can rescue episodic memory impairment
The Novel object recognition task is based on a rodent’s preference to explore novelty. It
is thought to depend solely on the entorhinal cortex, hippocampus and frontal cortex. This test is
considered to test only some aspects of the episodic memory because the experimenter has no
access to the temporal dimension of the episode. The only accessible components are the
memory, the place and the context in which an object is encountered and thus the test is
considered to be a test of short-term memory (Ennaceur, 2010). The sample phase was conducted
twenty-four hours after the last habituation phase and the analysis of the data showed, as
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expected, no difference between the three groups in exploring the two identical objects (Fig.
25a). The trial test was conducted 15 min after the sample phase. I found that the 3xTg-AD-vh
mice were impaired and that the WT mice were also impaired because of the effect of aging.
They either spent a similar amount of time near the familiar and the novel objects or spent more
time near the familiar one. However, the 3xTg-AD-P021 spent more time exploring the novel
object than the familiar one (Fig. 25b, p = 0.0234). These data suggest that at 19-20 months of
age the 3xTg-AD-vh and WT mice were impaired and that the chronic treatment with P021
rescued this impairment.

Fig. 25: The object recognition task at 19-20 months of age (after 16-17 months of P021 treatment)
showed that the WT and 3xTg-AD-vh were impaired in episodic-like memory and that P021
rescued this impairment in 3xTg-AD mice. a) Sample phase and b) test phase. *p<0.05; **p<0.01,
***p<0.001. (WT, n = 20; Tg-AD-vh, n=15; Tg-AD-P021, n = 14). Data are shown as mean ± SD.

4.2.4 Prevention of cognitive impairment across time
Data from all three cognitive tests were converted to cognitive scores. Cognitive scores
from each test were calculated as: mean of each mouse - mean of all mice) / SD (all mice). The
cognitive score represents the number of SD from the mean. Then cognitive scores from all tests
were compared across time with the two-way ANOVA. The results showed that very clearly
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across time there was a decrease in cognitive performance in 3xTg-AD mice compared to WT (p
= 0.017). However, in 3xTg-AD-P021 there was a marked enhancement of cognitive
performance (Fig. 26, p = 0.001) especially at 15-17 months post-treatment.

Fig. 26. Comparison of cognitive scores over time in all the behavioral tests. *p<0.05; **p<0.01,
***p<0.001. (WT, n = 20; Tg-AD-vh, n=15; Tg-AD-P021, n = 14). Data is shown as mean ± SEM.

4.2.5 P021 treatment can decrease mortality and has no effect on body weight or food
consumption.
Analysis of survival rates at the end of the study showed that P021 treatment decreased
the mortality rate in 3xTg-AD-P021 mice. Indeed, the survival rate of 3xTg-AD-vh at week 71
was significantly less (41%) than the survival rate of 3xTg-AD-P021 (87%) (2[1, df] = 9.437, p =
0.0021) (Fig. 27a). The body weight analysis showed no difference among the three groups (Fig.
27b). Similarly there was no difference in the food consumption among the groups (Fig. 27c).
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Together these data suggest that the delay of the onset of cognitive impairment in 3xTgAD - P021 may have been able to decrease the mortality rate in the treated animals without
causing any serious side effects such as decrease in body weight or food consumption.

Fig. 27: Survival curve analysis showed an increase by 87% in 3xTg-AD-P021 compared to
only 41% in 3xTg-AD-vh mice survived by 71 weeks with no side effects of P021 on food
intake or body weight. a) survival curve, b) body weight, and c) food intake. *p<0.05;
**p<0.01, ***p<0.001. (WT, n = 20; Tg-AD-vh, n=15; Tg-AD-P021, n = 14). Data are shown as
mean ± SD.
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4.3

Discussion
The clinical diagnosis of AD relies mainly on the appearance of signs of cognitive

impairment and memory loss, especially loss of short-term and declarative memories. The severe
decline in mental abilities, or what is referred to as dementia, is the major burden in AD. Indeed,
it compromises daily activities for the patient and makes him/her totally dependent on caregivers
in the severe stages. Delaying the onset of dementia and cognitive deterioration would be of
major importance in AD. Furthermore, preventing AD would result in the decrease in the
mortality rate due to this disease, since it is the sixth leading cause of death in the USA. Thus, a
drug that could delay or reverse cognitive deterioration would be ideal because it could prevent
AD and decrease the death rate due to this disease.
The present study showed that, reminiscent of AD, the 3xTg-AD mice are impaired in
spatial reference memory as tested by the Morris Water Maze task. I further show that the
initiation of treatment with the neurogenic/neurotrophic compound P021 right after the start of
the cognitive impairment, around the period of synaptic compensation, for 9 months is able to
prevent cognitive impairment completely in the 12 month old 3xTg-AD mice. Our results also
show that impairment in short-term spatial memory, as tested with the novel object location task,
is completely prevented after 15 months of treatment with P021 when the 3xTg-AD mice are 18
months old. Using the novel object recognition task that measures episodic-like memory, I show
complete prevention of cognitive impairment after treatment of ~3 month old mice with P021 for
16-17 months. Most importantly, the analysis of survival rates shows that P021 treatment is able
to increase the survival rate from 41% in 3xTg-AD-vh to 87% in 3xTg-AD-P021. These
beneficial effects of long-term treatment with P021 on cognition and survival rate in 3xTg-AD
mice are seen in the absence of any apparent side effects such as decrease in the food
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consumption or body weight.
All of these data collectively suggest that initiation of the treatment with P021 very early
in the disease process can delay the onset of cognitive impairment and decrease the mortality rate
without apparent side effects in the 3xTg-AD mice. Thus, P021 could potentially delay the onset
of cognitive impairment in AD patients.
The present findings that the 3xTg-AD mice are impaired at 3 months of age (Chapter 3)
was also reported previously in the literature (Davis et al., 2013). The three-month time point
apparently overlaps with the onset of cognitive impairment in these mice, since it was previously
reported that at 2 and 2.5 months the 3xTg-AD mice are cognitively normal and that they were
not born with cognitive impairment (Billings et al., 2005, Gimenez-Llort et al., 2007). Our
findings are consistent with the previous report that the 3xTg-AD mice are cognitively normal
until 3 months of age and then cognitive deterioration happens in an age-dependent manner due
to the transgenic products or their derivative (Billings et al., 2005). According to the findings of
this study and previous findings, the 3xTg-AD mice remained impaired throughout their lifespan
as assessed by the Morris Water Maze and other behavioral tasks (Gimenez-Llort et al., 2007,
McKee et al., 2008, Filali et al., 2012). It is very difficult in AD patients to detect the onset of
cognitive impairment because of the lack of a reliable biomarker. In contrast, mice can be
assessed behaviorally by a battery of tests to detect the early signs of cognitive impairment and
correlate it with molecular and cellular changes. This then emphasizes the usefulness of this
study, first because I was able to detect the very early onset of cognitive impairment and follow
cognitive deterioration across time in 3xTg-AD mice, and second because I was able to study the
effect of early therapeutic intervention in preventing cognitive deterioration.
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The results of this study show that the oral treatment of 3 month old 3xTg-AD mice for 9
months with P021 can prevent cognitive deficit, and this is consistent with our previous reports,
where we started the treatment with P021 or Peptide 6 later during the disease process
(Blanchard et al., 2010b, Kazim et al., 2014). We previously showed that P021 is a
neurogenic/neurotrophic compound that increases synaptic plasticity, neurogenesis and BDNF
expression and decreases tau and possibly A pathologies (Blanchard et al., 2010a, Blanchard et
al., 2010b, Li et al., 2010, Bolognin et al., 2012, Bolognin et al., 2014). Since the cognitive
impairment reported in this study starts very early in the disease process with the onset of
synaptic loss without apparent A and tau pathologies, I speculate that the preventive effects of
P021 on cognition at 12 months of age are mainly mediated by its beneficial effects on synaptic
plasticity and neurogenesis. Similarly, it was reported previously that the neurogenic and
neurotrophic effects of Amitriptyline (FDA approved tricyclic antidepressant drug) are able to
reverse cognitive impairment in 3xTg-AD mice at 14 months of age (Chadwick et al., 2011).
Furthermore, it is well documented that BDNF is an essential effector of spatial learning and that
its level increases three and six days after training in the hippocampus and the entorhinal cortex
(Kesslak et al., 1998, Harvey et al., 2008). The fact that P021 acts by increasing BDNF
expression could also explain the rescue of the cognitive deterioration seen at 12 months of age
in 3xTg-AD mice in the present study.
The present study shows that in the novel object location task at 18 months of age the
3xTg-AD mice are impaired. Furthermore, the 15 month treatment with P021 can rescue this
impairment. The impairment in the novel object location task in the 3xTg-AD mice found in this
study is consistent with previous findings in 15-18 month old 3xTg-AD mice (Gulinello et al.,
2009). Since at this stage A and tau pathologies are prominent as well as synaptic loss, I
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speculate that the beneficial effects of P021 could be also because of its preventive effects on A
and tau pathologies; the effect of BDNF on prevention of cognitive impairment in 12-14 month
old 3xTg-AD mice has been reported (Corona et al., 2010). Our previous studies showed that
P021 acts by decreasing the hyperphosphorylation of tau through the GSK3 pathway (Kazim et
al., 2014). P021 acts by increasing BDNF expression that acts through the PI3k-Akt pathway to
increase the phosphorylation of GSK3 on serine 9 and inhibits its activity. Since GSK3 is a
major tyrosine kinase that phosphorylates tau, that is most likely why we see the decrease in tau
phosphorylation. The partial decrease in A is also suggested to be through inhibiting GSK3
activity, since it has been shown previously that GSK3 mediates A neuritic damage
(DaRocha-Souto et al., 2012) and that its inhibition decreases both A and tau pathologies and
rescues cognitive impairment in other AD mouse models (Noble et al., 2005, Hu et al., 2009,
Sereno et al., 2009, Onishi et al., 2011).
Since episodic memory is severely affected during the AD pathological process, I
investigated the impairment in episodic-like memory in 3xTg-AD mice and the effect of 16-17
month treatment with P021 on alleviating it. This study showed that the 19-20 month 3xTg-ADvh mice were impaired in episodic memory, but surprisingly I found that the WT mice were also
impaired because of the effect of aging. The treatment with P021 rescued the episodic-like
memory deficit seen at this age. Our findings are corroborated by previous findings that showed
that at 12 months of age both WT and 3xTg-AD mice were impaired in an episodic-like memory
task, the WWWhich occasion (What-Where-Which occasion) task (Davis et al., 2013). Most
importantly, episodic memory impairment has been reported previously in cognitive aging
because it is sensitive to gray and white matter loss as well as to subtle changes in dendritic
spines that affect synaptic plasticity (Burke and Barnes, 2006, Charlton et al., 2010, He et al.,
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2012). The present finding that the WT mice were spared in short-term spatial memory and
impaired in episodic like memory was also reported previously in rats (Winters et al., 2004).
Indeed, depending on the place of the lesions, rats can be impaired in the novel object
recognition but not the novel object location and vice versa. The hippocampus is believed to be
essential for object location but not object recognition. However, the entorhinal cortex was
shown to be important in object recognition but not object location, and this suggests a functional
dissociation between the two regions (Winters et al., 2004).
To our knowledge this is the first study showing that P021 treatment for 18 months can
dramatically increase the survival rate in 3xTg-AD mice by more than 40%. The 3xTg-AD-vh
mice showed a low level of survival, especially from 12-18 months of age at the peak of A and
tau pathologies. Our findings are in agreement with previous literature that showed a decrease in
the long term survival rate in AD patients during a 14 year period from an expected rate of
16.6% to 2.2%. Furthermore, the decrease in the survival rate becomes more dramatic in AD
with multi-infarct dementia: 1.7% versus an expected 13.3% (Molsa et al., 1986). The increase in
disease severity was found to be associated with an increase in the level of mortality similar to
what I reported here, i.e., that the highest mortality level was registered at the peak of A and tau
pathologies. The increase in the long-term survival rate seen after P021 treatment further
emphasizes that a therapeutic drug that would be able to delay the onset of cognitive impairment
and underlying pathologies in AD could decrease the level of death due to this disease. The lack
of a therapeutic drug makes AD the sixth major leading cause of death in the USA and the most
common cause in people aged 65 years or older.
Since P021 is derived from the CNTF, and CNTF in clinical trials showed serious side
effects such as muscle pain, anorexia, loss of appetite and weight loss (see Chapter 1), I
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measured body weight and food consumption throughout the study. The results revealed no
effect of P021 on food intake or body weight; this further emphasizes that P021 is a potentially
safe drug that can be developed to treat AD.

4.4

Conclusion
In conclusion, our data show that early treatment with P021 right after the onset of

cognitive impairment during the period of synaptic compensation can prevent cognitive
impairment for the different stages of the disease, mild (12 months) and moderate to severe (1820 months), in 3xTg-AD mice. I also found that P021 treatment for the 18 month period can
dramatically decrease the mortality level by more than 40% in 3xTg-AD mice. The beneficial
effects of oral treatment with P021 can occur in the absence of severe side effects such as loss of
appetite or weight loss. These findings show that P021 is a promising therapeutic compound for
the treatment of AD and related neurodegenerative conditions.
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Chapter 5. Effect of P021 on A and tau pathologies

5.1

Introduction
AD is caused by severe neuronal loss in the limbic and neocortical areas but the real

cause of neurodegeneration is still unknown. AD accounts for 60-80% of dementia cases; multiinfarct dementia or vascular dementia comes in second place, accounting for 20-30% of
dementia cases (www.alz.org; Ott et al., 1995). Multi-infarct dementia is caused when the brain
tissue loss reaches 100-150 ml. The risk of multi-infarct dementia usually increases with the
number of infarctions that occur over time. Small infarcts usually occur because of the decrease
in blood flow to the brain. Decrease in the blood flow to the brain leads to a decrease in the
brain’s oxygen level, which leads to brain tissue loss due to ischemia. The decrease in the blood
flow, it is suggested, results from the increase in A deposition in the brain’s blood vessels,
called cerebral vascular angiopathy. According to the A hypothesis, the excess production of
A or its soluble forms is the trigger for the neurofibrillary degeneration and dementia associated
with AD.
A is a metabolic product of the cleavage of the amyloid precursor protein (APP). The
APP transcript is alternatively spliced into three different mRNAs: APP770 and APP751, which
each contain a Kunitz-type serine protease inhibitor domain (APP-KPI), and APP695, which
lacks this domain. APP 695 is expressed primarily in neurons, whereas APP 770 and 751 are
expressed in neurons and glia. In AD the mRNA levels of the three APPs have been shown to be
increased, but in neurons there was a shift from the APP 695 mRNA into APP-KPI mRNAs,
APP770 and APP751 (Matsui et al., 2007). There are two pathways for APP processing, either
amyloidogenic or non-amyloidogenic (Fig. 28). In the amyloidogenic pathway APP is cleaved by
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-secretase to produce the C99 fragment that is later processed by the γ-secretase to produce A
peptides, including A 40 and 42, the most abundant fragments in A plaques (Robakis, 2010).
The non-amyloidogenic pathway involves cleavage with -secretase within the A-sequence on
the APP, followed by γ-secretase, to produce the APP C-terminal fragment, thus inhibiting secretase and the formation of A peptides.

Fig. 28. Amyloidogenic and non-amyloidogenic pathways (Zhang, 2012).

Currently the A hypothesis, which postulates amyloid deposition and soluble A as
causing disease, represents the basis of several therapeutic strategies, especially several
prevention studies such as DIAN and API (see Chapter 1). However, this hypothesis remains
controversial because the A load fails to correlate with the severity of dementia or neuronal and
synaptic loss (Terry et al., 1981, Braak and Braak, 1991, Neve and Robakis, 1998). Furthermore,
around 30% of normal aged people express as much amyloid deposition as in a typical AD brain
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(Crystal et al., 1988, Arriagada et al., 1992a, Davis et al., 1999). Behavioral abnormalities in Tg
mice were also shown to be independent of A deposition (Robakis, 2010). Several transgenic
mice that express high levels of A deposition failed to show significant neurodegeneration. A
has been shown to exacerbate tau pathology in Tg mice. However, these Tg mouse models were
generated overexpressing mutated tau, while to date no tau mutations have been found in AD
(Iqbal and Grundke-Iqbal, 2010). Furthermore, in the familial cases of FTDP-17 caused by tau
mutations in chromosome 17 there is only tau pathology and no -amyloidosis. In other
dementia cases such as hereditary cerebral hemorrhage with amyloidosis of Dutch origin
(HCHWA-D) and sporadic cerebral amyloid angiopathy (SCAA) -amyloidosis is extensive in
the absence of any tau pathology (Coria et al., 1987, van Duinen et al., 1987). Moreover, a recent
study reported that there is no colocalization between A deposition and tau NFT in most AD
brain regions, suggesting that A is a poor variable to explain the development of tau pathology
(Lace et al., 2009). The successive failures in anti-A therapeutic approaches in phase II and
phase III clinical trials makes it unlikely that A is the major trigger of AD dementia and
neurofibrillary degeneration, especially as the anti-A therapies were successful in clearing A
from the parenchyma of the brains of AD patients, as shown with postmortem studies, and yet no
cognitive improvement or halting of the disease progression was observed (Holmes et al., 2008).
A main support of the A hypothesis is the presence of presenilin (PS) mutations in the
FAD cases, which is believed to cause the increase in the generation of the neurotoxic A
fragment 1-42 and increase the ratio of A 42/40. PS1 is a transmembrane protein involved in
the γ secretase processing of APP and the production of A peptide. In FAD cases more than 130
PS1 mutations were reported. To explain the mechanism of neurodegeneration in FAD cases the
A hypotheses suggests that the PS1 mutations favor the cleavage of APP by γ-secretase. This
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leads to an increase in the generation of the neurotoxic A fragment that promotes cerebral
amyloidosis and formation of A oligomers (Hardy and Selkoe, 2002, Koo and Kopan, 2004).
However, a recent study reported that only three out of eight PS1 mutations showed an increase
in A production. This shows that mutation in the PS is not always accompanied by an increase
in A 42 generation or even increases the ratio of A 42/40. Some PS mutations even cause a
loss instead of a gain of function in γ-secretase activity (Shioi et al., 2007). Indeed, it has been
reported that PS2 mutations are not accompanied by an increase in A42 production or an
increase in A42/A40 ratios (Walker et al., 2005). The increase in A production also does not
correlate with the age of the onset of disease in AD cases with PS1 mutations (Citron et al.,
1997, Mehta et al., 1998). Furthermore, even though the APPSwe mutation increases the
production of A40 and A 42 it does not result in a change in the A42/A40 ratio (KumarSingh et al., 2006). Thus it was suggested that the FAD mechanism of neurodegeneration may be
independent of the effect of presenilins on A production (Shioi et al., 2007).
A peptides are expressed by all cells. They are normal components of human serum and
CSF, there is little evidence of disease associated abnormalities of A and no toxic oligomers are
specific to AD. It is unclear under what conditions these peptides become toxic. Several studies
currently suggest that A deposition could be secondary to neuronal dysfunction of AD but not a
primary agent that causes the disease (Robakis, 2010). The FAD mutations in PS1, PS2, and
APP may not cause neurodegeneration because of their effect on increasing the generation of Aβ
but by altering the signal transduction pathways, especially those involving protein phosphatase2A (PP2A) and glycogen synthase kinase-3β (GSK-3β) (Iqbal et al., 2014b). In a recent study
another mechanism of cell death was shown to be promoted by APP. Indeed, one fragment of
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APP was shown to interact with the cell death receptor 6 to promote neurodegeneration in mice
(Nikolaev et al., 2009).
Hyperphosphorylation of tau, on the other hand, is a major cause of neurodegeneration in
tauopathies (Table 6) (Lee et al., 2001, Brandt et al., 2005, Goedert and Jakes, 2005, Brunden et
al., 2010). NFT are one of the earliest pathological substrates of aging and a neuropathological
continuum from aging to MCI and AD (Arriagada et al., 1992b, Guillozet et al., 2003). In the
rare form of AD with plaques only and hyperphosphorylated tau without tangles (POAD)
cognitive deterioration is slower and the onset of the disease tends to start later than typical AD
patients with NFT and amyloid plaques (PTAD). Patients in the POAD group tend to die at older
ages and there is a trend toward shorter duration of the disease (Tiraboschi et al., 2004).
Furthermore, the severity of cognitive impairment is directly correlated with the number of NFT
(Arriagada et al., 1992a). In contrast, A plaque deposition does not correlate either with
neuronal loss and NFT or with the severity of the disease (Gomez-Isla et al., 1997).
Tau is a major microtubule-associated protein in the brain. Tau’s normal function is to
interact with microtubule binding domains to stabilize and maintain their structure. In the normal
brain tau contains 2-3 moles of phosphate per mole of the protein; in the AD brain it is 3-4-fold
hyperphosphorylated. The hyperphosphorylation of tau leads to its binding and sequestration of
normal tau and the other two microtubule associated proteins (MAP1 and MAP2), which causes
disruption of microtubules (Kopke et al., 1993, Alonso et al., 1994, Alonso et al., 1996, Alonso
et al., 1997). Hyperphosphorylation of tau is suggested to happen because of an imbalance
between tau protein kinase and phosphatase activities. In AD two main features are observed in
tau pathology: either there is microtubule destabilization, which is considered to be a loss of
function, or tau oligomerization, which is considered to be a gain of toxic function (Avila, 2000).
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Tau is synthesized in the human brain as six isoforms generated by alternative splicing of
its pre-mRNA at exons 2, 3, and 10, generating the protein with 352 to 441 amino acids in
length. Variation in the splicing of exons 2/3 inclusion/exclusion are called 0N (no inclusion of
exons 2 and 3), 1N (inclusion of exon 3), and 2N (inclusion of exons 2 and 3). The alternative
splicing of exon 10 generates tau isoforms either with three (3-R) or four (4-R) carboxyl-terminal
MT-binding repeat motifs. The six isoforms are 4R2N, 4R1N, 4R0N, 3R2N, 3R1N, and 3R0N
(Iqbal et al., 2005, Brunden et al., 2010, Wolfe, 2012). In human tau expression is under
developmental control: in the fetus tau is exclusively 3R0N but in adults all six isoforms are
expressed.
Neither A nor NFT are specific to AD. They are also found in normal individuals in
small numbers. Previous reports emphasized that a better correlate of cognitive impairment in
AD is synaptic and neuronal loss (DeKosky and Scheff, 1990, Terry et al., 1991, Gomez-Isla et
al., 1997). Thus, a combination of a drug that could inhibit A and tau pathologies and
neurodegeneration and increase the regenerative capacities of the brain would be ideal to treat
AD and related neurodegenerative diseases.
We previously reported that P021 has a neurogenic/neurotrophic effect and it can
decrease A and tau pathologies in 3xTg-AD mice in the severe stages of the disease. In the
present study I investigated the effect of P021 on preventing tau phosphorylation and A plaque
formation by starting the treatment before the onset of these two pathologies in 3xTg-AD mice.
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Tauopathies

Frontotemporal
dementia with
Parkinsonism linked to
chromosome-17 tau
(FTDP-17)

Pick’s disease

Cortico-basal
degeneration

Progressive
Supranuclear Palsy
(PSP)

Dementia
Pugilistica/traumatic
brain injury/chronic
traumatic
encephalopathy

Areas of the Brain
Mainly Affected

Cause
Missense mutation in tau
that makes it a more
favorable substrate for
hyperphosphorylation by
protein kinases,
characterized by
abnormal accumulation
of 3R tau
Missense mutation of tau
(9 are known)
Presence of tau filaments
Presence of tauimmunoreactive Pick
bodies
Increase in the
expression of
hyperphosphorylated tau
in astrocytes and glia
cells
Overexpression of the
4R repeat tau that
aggregates into filaments
Extensive accumulation
of tau-immunoreactive
neuropil threads
throughout gray and
white matter
Caused in part by a
variant in the tau gene
called H1 haplotype
Overexpression of the
4R repeat tau that
aggregates into filaments
mainly neuropil threads
and NFT
Tau pathology mainly as
NFT

Signs

Frontal and temporal
lobe

Irrational decisions
and socially
inappropriate
behaviors

Frontotemporal lobar
and limbic atrophy

Dementia and loss of
language

Cerebral cortex, deep
cerebellar nuclei, and
substantia nigra, in
association with
prominent neuronal
achromasia

Clinical signs very
similar to PSP. Marked
disorder in movement
and cognitive
dysfunction

Atrophy of basal
ganglia, Subthalamus
and brain stem, with
corresponding neuronal
loss and gliosis

Supranuclear gaze
palsy and prominent
postural instability

Multiple concussions or
other head injuries to
the brain

Neurodegeneration
with dementia and
Parkinson’s diseaselike symptoms

Table 6. Major tauopathies where tau pathology occurs in the absence of Aβ pathology.
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5.2

Results

5.2.1 Prevention of A and tau pathologies by P021 in 3xTg-AD mice
Since A and tau pathologies are the two hallmarks of AD I investigated the effect of
P021 on the prevention of these two pathologies. The effect of P021 was studied by the treatment
of 3 month old 3xTg-AD mice for 9 months. A and tau pathologies in the 3xTg-AD mouse are
localized in the CA1 and the subiculum regions as reported previously (Oddo et al., 2003a). The
immunohistochemical staining with 4G8 antibody was used to detect A pathology but it also
recognizes APP. Immunohistochemical staining with AT8 antibody was used to detect tau
hyperphosphorylation in the Ser202/Thr 205 site.
I found that at 12 months of age in the CA1 region only APP immunostaining could be
seen and the analysis of the mean pixel intensity showed that P021 had no significant effect (Fig.
29a). In the subiculum region the staining, however, was both for APP and A plaques. During
the analysis the gain was lowered for each picture so that only the A plaque load appeared.
Then A load was quantified and analyzed as percent of area occupied. I found that at 9 months
after treatment the P021 was able to completely prevent A pathology in the subiculum region
(Fig. 29a, t-test, p = 0.0037).
The AT8 staining in the CA1 region was quantified as percent of area occupied. The
results showed a trend toward a significant effect of P021 on preventing tau pathology in this
region (Fig. 29b, t-test, p = 0.05). In the subiculum, however, the data were analyzed as mean
pixel intensity and there was no apparent effect of P021 treatment at this time point (Fig. 29b).
The PHF1 staining in the CA1 region and the subiculum was quantified as percent of area
occupied.

The

results

showed

a

significant

effect

of

P021

on

preventing

hyperphosphorylation in both regions (Fig. 29c, t-test, p = 0.03 and p < 0.0001, respectively).
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tau

Fig. 29. Effect of P021 on the prevention of A and tau pathologies at 12 months.
a) 4G8 staining CA1 (upper panel) and subiculum (lower panel). b) AT8 staining in the CA1
(upper panel), and subiculum (lower panel). c) PHF1 staining in the CA1 (upper panel) and the
subiculum (lower panel). *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar = 100m. (Tg- AD-vh, n =
5; Tg-AD-P021, n = 5). Data are shown as mean ± SD.
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5.2.2 Preventive effects of P021 on A and tau pathologies after 15 months of treatment
(at 18 months of age)
The analysis of the percent of area occupied by the A load in the CA1 region (Fig. 30a)
showed no difference between the 3xTg-AD-vh and Tg-AD-P021. However, there was a strong
preventive effect of P021 in the subiculum region seen as a decrease in the percent of area
occupied by the A load (Fig. 30a, t-test, p = 0.0028).
The analysis of the effect of P021 treatment after 15 months on tau hyperphosphorylation
using the AT8 staining showed that there was a strong significant effect both in CA1 (Fig. 30b, ttest, p = 0.0015) and subiculum (Fig. 30b, t-test, p = 0.0024) regions. Similarly the analysis of
the percent of area occupied by PHF1 positive immunohistochemical staining showed that P021
was able to prevent tau pathology in the CA1 region (Fig. 30c, t-test, p = 0.0018) and the
subiculum (Fig. 30c, t-test, p = 0.0001).
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Fig. 30: Effect of P021 on the prevention of A and tau pathologies at 15 months posttreatment.
a) 4G8 staining CA1 (upper panel) and subiculum (lower panel). b) AT8 staining in the CA1
(upper panel), and subiculum (lower panel). c) PHF1 staining in the CA1 (upper panel), and
subiculum (lower panel). *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar = 100m. (Tg-AD-vh, n =
4; Tg-AD-P021, n = 5). Data are shown as mean ± SD.
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5.2.3 Prevention of A and tau pathologies after 18 months of treatment with P021 (21
months of age)
At 18 months after treatment, P021 was able to prevent A pathology in the CA1 (Fig.
31a, t-test, p = 0.0018) and in subiculum (Fig. 31a, t-test, p< 0.0001) in the 3xTg-AD.
When analyzing the percent of area occupied for tau hyperphosphorylation using AT8
staining I found that P021 was able to prevent tau pathology in the CA1 (Fig. 31b, t-test, p =
0.0002) and the subiculum (Fig. 31b, t-test, p = 0.0002). The analysis of the PHF1 positive
staining as percent of area occupied showed a significant effect of P021 on preventing tau
pathology in the CA1 (Fig. 31c, t-test, p < 0.0001) and the subiculum (Fig. 31c, t-test, p <
0.0001). Western blots of the hippocampus showed similar findings (Fig. 31d, p = 0.0003).
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Fig. 31: Effect of P021 on the prevention of A and tau pathologies at 18 months posttreatment.
a) 4G8 staining CA1 (upper panel) and subiculum (lower panel). b) AT8 staining in the CA1
(upper panel), and subiculum (lower panel). c) PHF1 staining in the CA1 (upper panel) and
subiculum (lower panel) and d) Western blots of the hippocampus developed with PHF1 and
134d and quantification. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar = 100m. (WT, n = 5; TgAD-vh, n = 5; Tg-AD-P021, n = 5). Data are shown as mean ± SD.
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5.2.4 Effect of P021 treatment across time on A and tau pathologies
Regression analysis of the A pathology across time in the subiculum showed that the A
load increased with age in the 3xTg-AD-vh (Fig. 32a; t = 4.61, p < 0.0001, AdjR2 = 0.42) and
that P021 treatment was able to decrease it across time starting from 12 months until 21 months
(Fig. 32a; t = -4.32, p <0.0001, AdjR2 = 0.38).
The analysis of AT8 as a percent of area occupied across time in the CA1 area with the
regression analysis showed that the AT8 load increased over time from 12-21 months of age in
the 3xTg-AD-vh (Fig. 32b; t=5.48, p <0.0001, AdjR2 = 0.42). However, P021 treatment was able
to lower the AT8 load across time (Fig. 32b, t= -3.24, p = 0.003, AdjR2 = 0.26). Furthermore, I
found that the AT8 load increased at a slower rate in the 3xTg-AD-P021 compared to the 3xTgAD-vh (Fig. 32b, t = -2.37, p = 0.027, AdjR2 = 0.86).
The analysis of the PHF1 load across time as percent of area occupied in the CA1 area
showed that it increased over time in the 3xTg-AD-vh (Fig. 32c, t = 6.64, p < 0.0001, AdjR2
=0.61) and that P021 treatment was able to inhibit it (Fig. 32c, t = -2.51, p < 0.02, AdjR2 = 0.16).
Furthermore, P021 treatment was able to slow down the rise of the PHF1 curve across time (Fig.
32c, t = -4.23, p < 0.0001, AdjR2 = 0.92). In the subiculum area the PHF1 load was higher in the
3xTg-AD-vh versus 3xTg-AD-P021 across time (Fig. 32d, t = -12.59, p < 0.0001, AdjR2 = 0.85).
Furthermore, P021 treatment was able slow down the rise of the PHF1 curve across time (Fig.
32d, t = -2.24, p = 0.034, AdjR2 = 0.93).
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Fig. 32: Analysis of the preventive effects of P021 across time.a) 4G8 staining in the subiculum in

3xTg-AD-vh (upper panel) and in Tg-AD-P021 (lower panel). b, c, d) AT8 (b) and PHF1 (c, d)
staining in CA1 (b, c) and subiculum (d) in 3xTg-AD-vh (upper panel) and in Tg-AD-P021
(lower panel) *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar = 100m. (Tg-AD-vh, n = 5; Tg-ADP021, n = 5). Quantification are shown as mean ± SD.
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5.3

Discussion
Several drug driven therapeutics in AD have aimed to clear either A plaques or NFT

from the brain in a hope to stop the progression of AD pathologies. Since all the attempts to
develop therapeutics based solely on removing A from the brain have failed, and since AD is
known to be a multifactorial disease, finding a drug that could affect both pathologies as well as
increasing neurogenesis and neuronal plasticity could be promising. We showed previously that
P021 increased neurogenesis and neuronal plasticity and rescued cognitive impairment in several
AD models (Blanchard et al., 2010b, Bolognin et al., 2012, Kazim et al., 2014), a Down
Syndrome mouse model (Blanchard et al., 2011) and a cognitive aging animal model (Bolognin
et al., 2014). Here I show that P021, when administered early during the period of synaptic
compensation before any overt A or tau pathologies, can prevent them at 9, 15, and 18 months
post-treatment and also limit the progression of the pathologies across time in 3xTg-AD mice.
To our knowledge this is the first report of a neurotrophic/neurogenic compound that is able to
prevent both A and tau pathologies and slows their progression with time.
The appearance of senile plaques in the brain along with NFT is one of the diagnostic
features of AD. I investigated the progression of A pathology at three different time points —
12, 18, and 21 months — and the preventive effect of P021 on it in 3xTg-AD mice. At 12
months of age I showed a prevention of A pathology in the subiculum but not in the CA1. The
pathology in the CA1 region was not robust; I saw only APP staining. This may explain the
effect of P021 on the subiculum and not on CA1. At 18 months and 21 months, however, the
pathology was more robust and almost the whole CA1 and subiculum areas were involved. I
found that P021 has a strong effect in preventing A pathology. This finding is not in agreement
with what we reported previously using this peptide. Indeed, when we started the treatment of
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3xTg-AD mice after the disease onset (6-7 months of age) for 6 weeks, we found no effect of
P021 on A (Blanchard et al., 2010b). Treatment of 3xTg-AD mice starting at 9-10 months of
age for 12 months showed that P021 was able to reduce A generation (Kazim et al., 2014). The
findings of the present study emphasize the importance of early treatment for prevention of A
pathology. The curve of the progression of A pathology across time showed that the A load
increased across time in 3xTg-AD-vh. However, in P021 treated animals the progression of the
disease was slowed down, especially from 18-21 months of age in the subiculum region.
Since tau hyperphosphorylation correlates with synaptic loss in animal models (Kimura
et al., 2010) and the density of NFT correlates with the severity of dementia in AD patients
(Arriagada et al., 1992a, Bierer et al., 1995, Dickson et al., 1995, Giannakopoulos et al., 2003,
Guillozet et al., 2003) I studied the effect of chronic P021 treatment on tau phosphorylation with
the phospho-specific tau antibodies AT8 and PHF1. P021’s potential preventive effects were also
studied across three different time points: 9, 15, and 18 months post-treatment.
I found that at 12 months of age in the 3xTg-AD the NFT formation starts in the
subiculum and only a very small area of the CA1 region is occupied. When I analyzed the
immunohistochemical staining with AT8, I found a high variation from animal to animal but
after 9 months of treatment 3xTg-AD-P021 showed a trend toward an effect in the CA1 but none
in the subiculum; however, using the PHF1 immunohistochemical staining, I found that P021
was able to prevent tau pathology in the CA1 and the subiculum.
At 18 months of age in 3xTg-AD mice the pathology is already prominent in the
subiculum and covers a large area in the CA1 region. I found that 15 months of continuous
treatment with P021 significantly prevented tau pathology. These findings are in agreement with
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a previous study in which we showed that at 15-16 months of age P021 treatment for six months
was able to reverse tau pathology in 3xTg-AD mice (Kazim et al., 2014).
At 21 months of age treatment with P021 for 18 months prevented tau pathology both in
the CA1 region and the subiculum. At this stage AT8 load was evident in the two regions in
3xTg-AD-vh mice. These results are consistent with our previous findings (Kazim et al., 2014).
The most important finding of the present study, though, is that P021 was able to slow the
progression of the disease across time. This finding is of major importance because this shows
that P021 could be a potential drug for AD that could stop or halt the progression of the disease.
I speculate that the preventive effects of P021 on A and tau pathologies are through the
inhibition of GSK3, as we reported previously (Kazim et al., 2014). P021 acts by increasing the
expression of BDNF, which leads to the increase in the phosphorylation of GSK3 on serine 9,
which results on its inhibition. Since GsK3 is a major tau protein kinase for phosphorylation of
the proline-directed sites, its inhibition results in a decrease in tau phosphorylation (MunozMontano et al., 1997). GSK3β also is implicated in A mediated neuritic damage (DaRochaSouto et al., 2012), APP processing and A deposition (Phiel et al., 2003). Its inhibition is shown
to reduce both A and tau pathologies, neuronal survival and cognitive impairment (Sereno et
al., 2009).

5.3

Conclusion
Collectively our data show that chronic early oral treatment with P021 results in

prevention of A and tau pathologies. I also show, by the analysis of its effect across time, that
P021 is able to slow down the progression of the disease in the 3xTg-AD mouse model. This
presents P021 as a potential disease modifying drug for AD.
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Chapter 6. Effect of early treatment with P021 on
neuroregeneration and neurodegeneration
6.1

Introduction
Increasing evidence suggests that the beginning of the pathological cascade of AD starts

many years before the appearance of the clinical symptoms of cognitive impairment. The very
early stages of AD are thought to start with synaptic dysfunction, followed by neuronal loss, A
and tau pathologies and cognitive impairment (Selkoe, 2002). Although the severity of dementia
has been shown to correlate with the density of NFT or NFT plus senile plaques, neither of the
two pathologies is specific to AD. They are also reported in normal aged individuals. For
instance, in the oldest old people dementia is associated with very little pathology, while the
absence of dementia was reported in the presence of high levels of Aβ and tau pathologies
(Green et al., 2000, Silver et al., 2002). Furthermore, it has been shown that there is a significant
overlap in the BRAAK stages between demented and non-demented patients (Gold et al., 2000,
Riley et al., 2002). Synaptic loss, on the other hand, has been shown to be a consistent feature
that differentiates demented and non-demented people and significantly correlates with the
severity of dementia (DeKosky and Scheff, 1990, Terry et al., 1991, Scheff and Price, 2003).
Synaptic loss correlates well with other types of dementia and age-associated decrease in
cognitive performance, called normal cognitive aging (Coleman et al., 2004).
Postmortem analysis has revealed a drastic decrease in presynaptic and postsynaptic
markers in very early AD stages, suggesting the degeneration of the whole synaptic element
(Davidsson and Blennow, 1998). A decrease in the number of synapses of ~ 25-30% was
reported in temporal and frontal cortical biopsies and around 15-35% loss in the number of
synapses per neuron within 2-4 years of the onset of AD (Davies et al., 1987). Synaptic loss is
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even more pronounced in the hippocampus, reaching 44% to 55% (Scheff et al., 2007). Synaptic
degeneration is thought to start in the entorhinal cortex, with the dendrites as the first to undergo
degeneration, since they make up to 90% of synaptic contact. Dendritic loss is found to occur in
parallel with synaptic loss, and major synaptic loss occurs very early in AD (Davies et al., 1987,
Masliah et al., 2001). It has been previously shown that the ratio of synapses to neurons
decreases by 48%, suggesting that synaptic loss is not happening only in the degenerated neurons
but also in the remaining neurons (Coleman and Yao, 2003). Thus, in AD neurons may survive
for a long period of time with a progressive deterioration of structure and function (Coleman et
al., 2004). Surviving neurons account for as much as 38% of synaptic loss in AD. Cognitive
deficit is thus suggested to occur not only because of synaptic loss but because of the impaired
capacity of the still surviving synapses.
In spite of the reduced capacity of synaptic plasticity there is still a residual plastic
capacity, as shown by the synaptic compensation phenomenon that happens in the early AD
stages and in transgenic mice (see Chapter 3). In a previous study, although synaptophysin was
reported to decrease in the frontal cortex of demented people, an increase was found in
cognitively impaired non-demented 90+ year old individuals. This suggests that synaptic
compensation counteracts synaptic loss and accounts for preserved cognition in these individuals
in the presence of extensive pathology (Head et al., 2009). In the Rush Religious Orders Study
an increase in the level of synaptophysin in the superior frontal cortex of MCI patients was
reported compared to normal individuals (Counts et al., 2006). Furthermore, an increase in the
level of synaptophysin in elderly people with extensive pathology and normal cognition was
found compared to patients diagnosed with clinical and pathological AD (Lue et al., 1996, Lue et
al., 1999). However, the increase in synaptophysin expression does not necessarily mean an
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increase in the number of synapses, since an increase in the synaptic size to keep an intact total
synaptic contact area in the very early stages of the disease has been found (Scheff and Price,
2003).
Brain mass loss/year is estimated to be ~ 0.5% in normal aged individuals and ~5-fold
higher in AD (Fox et al., 1996). During the period of 7-10 years of disease progression, brain
loss is estimated to be 200–400 g (Chan et al., 2001). The hippocampus is the major brain region
that undergoes neuronal loss in AD and the atrophy is as drastic as 10% per year. More than
50% of the neurons in the brain are lost and the loss increases with the severity of the disease.
Neuronal loss in the cortical association areas is thus directly correlated with memory loss
(Gomez-Isla et al., 1997). It was shown previously that neuronal loss is prominent in layer II of
the entorhinal cortex in mild AD, which distinguishes it from that layer in non-demented aged
individuals. Furthermore, the number of neurons is inversely correlated with the number of NFT
but not with senile plaques (Gomez-Isla et al., 1996). Neuronal loss has been linked to the
abnormal hyperphosphorylation of tau. As stated previously (chapter 5), hyperphosphorylated
tau sequesters normal tau, which causes the breakdown of microtubules. This would compromise
axonal transport and lead to retrograde degeneration and synaptic loss (Iqbal and Grundke-Iqbal,
2002). These events are believed to lead to brain volume loss and dementia.
A key mechanism of deficient neurogenesis, neuronal loss and synaptic plasticity could
be the imbalance of neurotrophic factors (Li et al., 2008). It has been shown that neurons
maintain two pools of NGF: a constitutive pool in the soma that may maintain neuronal survival
and a regulatable pool in the dendrites to maintain plasticity. A small change in the NGF level in
transgenic mice is linked to impaired synaptic plasticity and cognitive performance.
Furthermore, in AD the BDNF polymorphism from Valine to Methionine occurs with high

134

frequency and it has been shown to inhibit the cleavage of Pro-BDNF to BDNF (Coleman et al.,
2004). An imbalance of neurotrophic factor is suggested to be the cause of the deficit in
neurogenesis (Li et al., 2008).
I postulated that providing the diseased brain with neurotrophic activity could boost the
process of neuroregeneration to counteract synaptic and neuronal loss and enhance neurogenesis.
Since synaptic and neuronal loss and the compensation phenomenon happen very early during
the disease process, I attempted to intervene at this early age in the 3xTg-AD mice (~3 months)
with the neurogenic/neurotrophic peptide P021 to learn if I could prevent the disease progression
to advanced stages.
The purpose of this study is thus to investigate the effect of P021 on prevention of
synaptic and neuronal loss, neurogenesis deficit and neurodegeneration in 3xTg-AD mice by
starting the treatment at 3 months of age and maintaining it for several months. Synaptic loss was
studied immunohistochemically and biochemically using different synaptic markers such as
synaptophysin, synapsin 1, GluR1, PSD-95, NR1 and MAP2 at 3 months of age just before
treatment with P021, at 12 months (9 months after treatment), at 18 months (15 months after
treatment), and at 21 months (18 months after P021 treatment). Neurodegeneration at the above
time points was also studied using Fluorojade C staining. Neurogenesis was studied at 12 months
of age using DCX and Ki-67 staining.

6.2

Results

6.2.1 Preventive effect of P021 on synaptic plasticity
Synaptic loss in 3xTg-AD at 3 months of age before the start of the treatment
Since my aim was to start the treatment with P021 very early in the disease process at
around the period of synaptic compensation, I analyzed brain tissues of 3xTg-AD mice before
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treatment. Based on my findings described in chapter 3, the onset of synaptic loss and its
compensation starts at around three months in 3xTg-AD mice. I analyzed the level of expression
of MAP2 immunohistochemically and I found a trend toward a decrease in the CA1 (Fig. 33a, e,
p = 0.05) and a significant decrease in the DG (Fig. 33a, e, p = 0.0429). Similarly, Western blot
analysis of the hippocampus showed a significant decrease in the protein expression level of
MAP2 (Fib. 34b, c, t-test, p = 0.01). I found that the synaptophysin expression level decreased
both in CA3 (Fig. 33b, e, p = 0.0209) and DG (Fig. 33b, e, p = 0.0044). The PSD-95 expression
showed a significant difference between the WT and 3xTg-AD mice in the parietal cortex (Fig.
33c, e, p = 0.0395). In the cortex the level of synaptophysin (Fig. 34a, c, p = 0.0014) was
reduced significantly while that of GluR1 showed a trend toward decrease in 3xTg-AD mice
(Fig. 34a, c, p = 0.06) as shown by Western blots. The level and the expression of synapsin 1
were also investigated immunohistochemically and biochemically but there was no significant
difference between the 3xTg-AD and the WT. Furthermore, the level and the expression of NR1
in the parietal cortex decreased significantly in the 3xTg-AD mice compared to WT, as shown by
immunohistochemical analysis (Fig. 33d, e, p = 0.0014) and by Western blots of the cortex (Fig.
34a, c, p = 0.004). The analysis of the level of the ratio of pCreb and Creb in the cortex by
Western blots showed a significant decrease in the 3xTg-AD mice compared to WT (Fig. 34a, c,
p = 0.002). No significant difference was found in the level of PSD95 between the two groups by
Western blots in the cortex and the hippocampus (Fig. 34a, c). Human-specific monoclonal
antibody 43D to tau was used to check the 3xTg-AD mice genotype compared to WT by
Western blots (Fig. 34a, b).
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Fig. 33: Synaptic deficit at 3 months of age in 3xTg-AD mice.
a) Immunohistochemical analysis of the MAP2 level in the CA1 region (upper panel) and the
DG (lower panel). b) Level of expression of synaptophysin in the CA3 region (upper panel) and
the DG (lower panel). c) Level of expression of PSD-95 in the parietal cortex. d) Expression of
NR1 in the parietal cortex and e) quantification of immunohistochemical staining. t-test.
*p<0.05; **p<0.01; ***p<0.001. Scale bar = 100m. (WT, n = 5; Tg-AD vh, n= 5).
Quantification is shown as mean ± SD.
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Fig. 34: Analysis of the protein level in 3 months old 3xTg-AD mice by Western blots.
a) Cortex, Western blots b) Western blots analysis of the protein level in the hippocampus and c)
quantification, t-test, *p <0.05; **p <0.01; ***p <0.001. (WT, n = 6; Tg-AD vh, n= 6).
Quantification is shown as mean ± SD.
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Effect of P021 on synaptic plasticity after 9 months of treatment in 3xTg-AD
I investigated the effect of 9 months of treatment with P021 on synaptic plasticity
immunohistochemically and biochemically. The immunohistochemical analysis of the
expression of PSD-95 showed that there was a significant increase in 3xTg-AD-P021 compared
to WT and 3xTg-AD-vh in the CA1 (Fig. 35a, e, p = 0.0038) and CA3 regions (Fig. 35a, e, p =
0.0010). In the DG (Fig. 35a, e, p = 0.0314) and parietal cortex (Fig. 35a, e, p = 0.0169) a
significant difference was found between 3xTg-AD-vh and 3xTg-AD-P021. Similarly, Western
blot analysis of the hippocampus showed a trend toward a decrease in the level of PDS-95
expression in the 3xTg-AD-vh mice compared to WT (Fig. 36b, c, p = 0.07) and a trend toward
an increase in 3xTg-AD-P021 compared to 3xTg-AD-vh (Fig. 36b, c, p = 0.07). I found also that
the NR1 expression in the CA3 region increased in 3xTg-AD-P021 compared to WT and 3xTgAD-vh (Fig. 35c, e, p = 0.0091).
A trend toward a decrease was found in the MAP2 expression in the CA3 region (Fig.
35b, e, p = 0.09), DG (Fig. 35b, e, p = 0.0416) and the parietal cortex (Fig. 35c, e, p = 0.0392) in
the 3xTg-AD-vh compared to WT. However, no apparent effect of P021 to prevent this deficit
was detected. The analysis of the expression of synapsin 1 immunohistochemically showed a
trend toward a decrease in the DG in the 3xTg-AD-vh compared to WT (Fig. 35d, e, p = 0.07).
Similarly, no difference was detected by Western blots (Fig. 36a, c) and no apparent effect of
P021 was detected either immunohistochemically or by Western blots. I analyzed the level and
the expression of synaptophysin both immunohistochemically and biochemically and I found a
significant decrease in 3xTg-AD-vh compared to WT by Western blots (Fig. 36a, c, p = 0.0339).
However, I did not detect any effect of P021 on synaptophysin expression. I confirmed the
genotype of 3xTg-AD-vh and 3xTg-AD-P021 mice with Western blots using the human-specific
tau antibody 43D (Fig. 36a, b).
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Fig. 35: Effect of P021 on synaptic deficit, 9 months post-treatment in 3xTg-AD mice.
a) Immunohistochemical analysis of the level of expression of a) PSD-95 in the CA1, CA3, DG,
and parietal cortex b) MAP2 in the DG (upper panel), CA3 (middle panel), and parietal cortex
(lower panel) c) NR1 in the CA3 region. d) Analysis of the synapsin 1 level of expression in the
DG. e) quantification of immunohistochemical staining. One Way ANOVA post hoc test.
*p<0.05; **p<0.01; ***p<0.001. Scale bar = 100m. (WT, n = 5; Tg-AD-vh, n = 5; Tg-ADP021, n = 5). Quantification is shown as mean ± SD.
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Fig. 36: Effect of P021 at 12 months of age in 3xTg-AD mice.
a) Analysis of the protein expression level in the cortex by Western blots. b) Analysis of the
expression level of protein in the hippocampus and c) quantification of the blots. One Way
ANOVA post hoc test. *p<0.05; **p<0.01; ***p<0.001. (WT, n = 5; Tg-AD-vh, n = 5; Tg-ADP021, n = 5). Quantification is shown as mean ± SD.

Effect of P021 on prevention of synaptic loss after 15 months of treatment
The analysis of the expression of MAP2 immunohistochemically showed that there was a
trend toward a decrease in the CA1 between WT and 3xTg-AD-vh mice (Fig. 37a, f, p = 0.06). A
significant effect of P021 was detected at this time point to prevent synaptic loss in the CA1
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region (Fig. 37a, f, p = 0.0065). In the CA3 region a trend toward a significant decrease was
detected in 3xTg-AD-vh as compared with WT mice (Fig. 37a, f, p = 0.09). P021 was found to
rescue this deficit (Fig. 37a, f, p = 0.0226). In the DG (Fig. 37a, f, p = 0.0239) and the parietal
cortex (Fig. 37a, f, p = 0.0491) a significant preventive effect of P021 was found in 3xTg-ADP021 compared with 3xTg-AD-vh mice.
The analysis of the synapsin 1 expression immunohistochemically showed a decrease of
the expression in 3xTg-AD-vh and no apparent effect of P021 treatment. Immunohistochemical
analysis showed a significant decrease in the CA1 region (Fig. 37b, f, p = 0.0395), a trend toward
a decrease in the CA3 region (Fig. 37b, f, p = 0.07) and trend toward a decrease in the parietal
cortex (Fig. 37b, f, p = 0.06) in the 3xTg-AD-vh compared to WT.
Immunohistochemical analysis of the expression of GluR1 showed a significant increase
in the 3xTg-AD-P021 mice in the CA1 region compared to the 3xTg-AD-vh (Fig. 37c, f, p =
0.0365).
Immunohistochemical investigation of the expression of synaptophysin in the CA1 region
showed a significant increase in the 3xTg-AD-P021 compared to WT (Fig. 37d, f, p = 0.0450)
and a trend toward an increase in the level of synaptophysin in the parietal cortex in 3xTg-ADP021 compared to WT (Fig. 37d, f, p = 0.0623). The analysis of the expression of NR1 showed
that it increased in the DG (Fig. 37e, f, p = 0.0306) and the parietal cortex (Fig. 37e, f, p =
0.0476) of the 3xTg-AD-P021 compared to WT.
Western blot analyses of synapsin1 level in the cortex showed a significant preventive
effect of P021 (Fig. 38a, c, p = 0.0003) in 3xTg-AD-P021 mice. Similarly, I found an increase in
the level of synaptophysin in the cortex of the 3xTg-AD-P021 mice compared to 3xTg-AD-vh
(Fig. 38a, c, p = 0.0045). The NR1 expression level shows a trend toward an effect of P021 (Fig.
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38a, c). In the hippocampus Western blot analysis showed a trend toward an effect of P021 in
increasing the level of MAP2 and synapsin1 (Fig. 38b, c, p = 0.05 and p = 0.06, respectively).
The 3xTg-AD-vh and 3xTg-AD-P021 genotypes were determined biochemically using the 43D
antibody which recognizes only human tau (Fig. 38a, b).

Fig. 37: Preventive effects of P021 on synaptic deficits at 15 months post-treatment by
immunohistochemistry in 3xTg-AD mice.
a) Investigation of the level of expression of MAP2 in the CA1, CA3, DG, and parietal cortex. b)
Synapsin 1 level of expression in the CA1, CA3, and parietal cortex. c) Level of expression of
GluR1 in the CA1 region. d) Level of expression of synaptophysin in the CA1 and the parietal
cortex. e) Level of expression of NR1 in the DG and the parietal cortex and f) quantification of
immunohistochemical staining. One Way ANOVA post hoc test. *p<0.05; **p<0.01;
***p<0.001. Scale bar = 100m. (WT, n = 5; Tg-AD-vh, n = 3; Tg-AD-P021, n = 5).
Quantification is shown as mean ± SD.
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Fig. 38: Preventive effect of P021 after 15 months post-treatment by Western blots in 3xTdAD mice.
a) Analysis of protein expression in the cortex. b) Analysis of protein expression in the
hippocampus and c) quantification of the blots. One Way ANOVA post hoc test. *p<0.05;
**p<0.01; ***p<0.001. (WT, n = 5; Tg-AD-vh, n = 3; Tg-AD-P021, n = 5). Quantification is
shown as mean ± SD.

Effect of P021 on synaptic loss after 18 months of treatment
A significant increase of the synapsin 1 expression immunohistochemically in the CA1
region was found in the 3xTg-AD-P021 compared to WT (Fig. 39a, c, p = 0.0384) and a trend
toward an increase compared to the 3xTg-AD-vh (Fig. 39a, c, p = 0.0791). The expression of
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NR1 in the parietal cortex decreased in the 3xTg-AD-vh compared to WT (Fig. 39b, c, p =
0.0305) and a trend toward an increase in 3xTg-AD-P021 compared to 3xTg-AD-vh (Fig. 39b, c,
p = 0.05) was found.
Western blot analysis showed a significant increase in the level of synaptophysin in the
cortex (Fig. 39d, f, p = 0.03). In the hippocampus, synaptophysin showed a trend toward a
decrease in the 3xTg-AD-vh compared to WT (Fig. 39e, f, p = 0.07). In the cortex, a trend
toward a decrease in the ratio of pCreb and Creb was detected in the 3xTg-AD-vh compared to
WT and 3xTg-AD-P021 (Fig. 39d, f). The MAP2 level showed a significant increase in the
P021-treated group compared to 3xTg-AD-vh in the cortex (Fig. 39d, f). The level of PSD-95 in
the hippocampus showed a trend toward an increase for the 3xTg-AD-P021 compared to the
3xTg-AD-vh (Fig. 39e, f, p = 0.09). The GluR1 expression showed a significant decrease in the
3xTg-AD-vh (Fig. 39e, f, p = 0.02) and a trend toward an effect of P021 (Fig. 39e, f, p= 0.06) in
the hippocampus, no changes were detected in the cortex (Fig. 39d, f). The level of the ratio of
pCreb and Creb showed a significant increase in the 3xTg-AD-P021 compared to the other two
groups (Fig. 39e, f, p = 0.0007). The GluR2/3 level showed a significant increase in the WT
compared to the other two groups (Fig. 39e, f, p = 0.0002).
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Fig. 39: Preventive effect of P021 on synaptic deficit at 18 months post-treatment in 3xTgAD mice.
a) Immunohistochemical analysis of synapsin 1 level in the CA1 region and b) NR1 level of
expression in the parietal cortex. c) Immunohistochemical quantification. d) Western blot
analysis of level of expression of synaptic proteins in the cortex and e) in the hippocampus and f)
quantification of the blots. One way ANOVA post hoc test. *p<0.05; **p<0.01; ***p<0.001.
Scale bar = 100 m. (WT, n = 5; Tg-AD-vh, n = 5; Tg-AD-P021, n = 5). Quantification is shown
as mean ± SD.
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6.2.2 Preventive effects of P021 on neurodegeneration
Effect of P021 on prevention of neurodegeneration after 9 months of treatment in 3xTgAD mice
Neurodegeneration was analyzed using Fluorojade C staining and the data were analyzed
as percent of area occupied by the degenerated neurons. The degenerated neurons were stained
as bright green on a dark green background. The quantification of the percent of area occupied
revealed that the area occupied by degenerated neurons was significantly higher in the 3xTg-ADvh compared to WT and 3xTg-AD-P021 in the CA3 (Fig. 40a, d, p = 0.0066), DG (Fig. 40a, d, p
< 0.0001), parietal (Fig. 40a, d, p = 0.0351), and frontal (Fig. 40a, d, p = 0.0121) cortices. P021
treatment for 9 months showed a complete rescue of the neurodegeneration.
Preventive effect of P021 on neurodegeneration at 15 months post-treatment in 3xTg-AD
mice
Neurodegeneration was found to increase in the 3xTg-AD-vh compared to WT, and the
P021 treatment for 15 months was able to prevent this impairment. These changes were seen in
the CA1 (Fig. 40b, d, p = 0.0039), CA3 (Fig. 40b, d, p = 0.0431), DG (Fig. 40b, d, p = 0.0021),
and parietal cortex (Fig. 40b, d, p = 0.0001).
Preventive effect of P021 on neurodegeneration at 18 months post-treatment in 3xTg-AD
mice
At 21 months of age the percent of area occupied by the degenerated neurons was higher
in 3xTg-AD-vh compared to WT, and P021 treatment was able to completely prevent this deficit
in CA1 (Fig. 40c, d, p = 0.0011), CA3 (Fig. 40c, d, p = 0.0133), DG (Fig. 40c, d, p = 0.0013),
and parietal cortex (Fig. 40c, d, p = 0.0056).
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Fig. 40: Preventive effect of P021 on neurodegeneration in 3xTg-AD mice.
a) At 9 months post-treatment in the CA3, DG, parietal and frontal cortices (WT, n = 5, Tg-ADvh, n = 5; Tg-AD-P021, n = 5). b) At 15 months post-treatment in the CA1, CA3, DG, and
parietal cortex (WT, n = 5, Tg-AD-vh, n = 3; Tg-AD-P021, n = 5). c) At 18 months posttreatment in the CA1, CA3, DG, and parietal cortex and (WT, n = 5, Tg-AD-vh, n = 5; Tg-ADP021, n = 5). d) quantification of immunohistochemical staining. One way ANOVA post hoc
test. *p<0.05; **p<0.01; ***p<0.001. Scale bar = 100 m. Quantification is shown as mean ± SD.

6.2.3 Effect of P021 on boosting neurogenesis
The effect of P021 on boosting neurogenesis was investigated at 9 months post-treatment
(12 month old 3xTg-AD) by immunohistochemical staining for Ki-67, a cell proliferation marker
that measures early stages of the neurogenesis and DCX a marker for immature adult-born
neurons whose expression levels reflect neurogenesis. As expected, I found that the number of
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DCX+ cells was significantly reduced in the 3xTg-AD-vh compared to WT (Fig. 41a, c, p =
0.0009) and that P021 rescued this deficit (Fig. 41a, c, p < 0.0001). Remarkably, the level of
neurogenesis was rescued to more than WT level (Fig. 41a, c, p < 0.001). Similarly, a decrease in
the number of Ki-67+ cells was observed in the 3xTg-AD-vh mice compared to WT (Fig. 41b, c,
p = 0.0057) and it was rescued with the P021 treatment (Fig. 41b, c, p < 0.0001).

Fig. 41: Preventive effects of P021 on neurogenesis in DG at 9 months post-treatment in
3xTg-AD mice.
a) DCX and TOPRO staining in WT (left panel), 3xTg-AD-vh (middle panel), and Tg-AD-P021
(right panel). b) Ki-67 and TOPRO staining in WT (left panel), 3xTg-AD-vh (middle panel), and
Tg-AD-P021 (right panel). c) Densiometric quantification of the number of DCX+ and Ki-67+
cells. Arrow heads indicate positive cells. One way ANOVA post hoc test. *p<0.05; **p<0.01;
***p<0.001. Scale bar = 100 m. Quantification is shown as mean ± SD.
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6.3

Discussion
Since synaptic and neuronal losses occur very early in the disease process and are the

best correlates of cognitive impairment and dementia in AD, I postulated that an efficient
treatment for AD would be one that starts early in the disease process and is able to achieve
synaptoprotection and neuroprotection and thus halt the disease progression. I further postulated
that a treatment that is initiated during the period of synaptic compensation would make this
phenomenon successful and help slow down synaptic and neuronal loss as well as boosts
neurogenesis and consequently cognitive deterioration. Herein, I applied such a strategy: I
administered the P021 in diet during the synaptic compensation period and I followed its effect
at 9, 15, and 18 months post-treatment.
In the present study I found that at 3 months of age, before the start of the P021
treatment, there was a synaptic loss, as seen by the decrease in the level of MAP2,
synaptophysin, PSD-95, NR1, and the ratio of pCreb and Creb. At 9 months post-treatment I
found a synaptic deficit in the 3xTg-AD-vh mice compared to the WT, as shown by a decrease in
the level of MAP2 and synapsin 1. While I found a rescue of synaptic deficit post-9 month
treatment as seen immunohistochemically with PSD-95 and NR1, the strongest effect of P021 on
rescuing synaptic deficit was at 15 months post-treatment on the MAP2, synaptophysin, synapsin
1, GluR1 and NR1 expression levels as shown immunohistochemically and biochemically. At 18
months post-treatment P021 was able to prevent synaptic deficit, as shown by
immunohistochemistry and Western blots.
Our data showed that at exactly 3 months of age, before I started the treatment with P021,
there was synaptic loss, as shown by a decrease in the synaptophysin, MAP2, PSD-95 and NR1
expression levels, the ratio of pCreb and Creb, as well as a trend toward a decrease in the GluR1
level in the 3xTg-AD mice compared to the WT. These data further corroborate our findings
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described in Chapter 3. An early drop in the synaptophysin level of expression is also known in
early AD patients and this decrease is correlated with early cognitive impairment and the severity
of dementia (Heffernan et al., 1998, Masliah et al., 2001, Callahan et al., 2002). Similarly, I
found here and in Chapter 3 an early reduction in the synaptophysin level as well as cognitive
impairment in the 3xTg-AD mice.
At 9 months post-treatment the analysis of the expression level of PSD-95
immunohistochemically showed that P021 treatment was able to rescue the decrease in the
expression in 3xTg-AD mice in the CA1, CA3, DG and parietal cortex. Similarly, with Western
blots I found a trend toward a decrease in the level of PSD-95 in the 3xTg-AD-vh and a trend
toward an effect of P021 in the hippocampus. The expression of NR1 decreased also in the
3xTg-AD-vh in the parietal cortex and a trend toward an effect of P021 was seen. I found a
synaptic deficit, as seen in the drop of MAP2 expression in the DG, CA3, and parietal cortex and
the synapsin 1 expression in the DG in 3xTg-AD mice. These data showed that P021 at 12
months of age was effective in restoring synaptic loss, as seen in a restored expression level of
PSD-95 and NR1. Our immunohistochemical findings were further corroborated with the
Western blot analysis of the cortex.
At 15 months post-treatment P021 showed the strongest effect on preventing synaptic
loss. This may be because at 18 months of age the 3xTg-AD-vh mouse brain has already
undergone extensive synaptic loss so the effect of P021 becomes quite apparent. Indeed, P021
rescued

the

decrease

in

MAP2

expression

in

all

the

brain

regions

analyzed

immunohistochemically (CA1, CA3, DG and parietal cortex). Synaptophysin loss was also
prevented in the CA1 and the parietal cortex. A decrease in the GluR1 expression was also
prevented in the CA1 region of the hippocampus. Western blot analysis of the protein level of
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synaptophysin further corroborated our data. Similar data was reported in other P021 studies
(Blanchard et al., 2010a, Blanchard et al., 2010b, Li et al., 2010, Blanchard et al., 2011, Chohan
et al., 2011, Bolognin et al., 2012, Kazim et al., 2014). The preventive effect of P021 on rescuing
synapsin 1 expression was seen by Western blot analysis. This strong effect of P021 should be
interpreted in light of our previous data on Aβ and tau pathologies and cognition. I showed
previously (Chapter 4) that there was a strong effect of P021 on preventing cognitive impairment
and A and tau pathologies (Chapter 5), thus P021 would be expected to prevent synaptic
pathology as well.
At 18 months post-treatment an effect of P021 on rescuing the synapsin1 expression was
seen immunohistochemically in the CA1 region of the hippocampus. A trend toward a rescuing
effect of P021 on the expression of NR1 in the parietal cortex was found. Western blot analysis
of the cortex and the hippocampus revealed a preventive effect of P021 on rescuing the level of
synaptophysin and MAP2 in the cortex and the ratio of pCreb and Creb in the hippocampus. A
trend toward an effect of P021 on rescuing PSD-95 and GluR1 expression was also found in the
hippocampus. Thus, collectively, our data show that early chronic treatment with P021 can be
effective even until later age in rescuing neuronal plasticity deficits in 3xTg-AD mice.
In the present study I found that the different brain regions of the 3xTg-AD-vh mice had
undergone massive degeneration compared to WT mice, and P021 treatment was able to rescue
this impairment at 12, 18 and 21 months of age.
The level of neurogenesis in the present study was investigated by the quantification of
the number of DCX+ cells and Ki-67+ cells in the DG area at 9 month post-treatment with P021.
My results show that neurogenesis was defective in 3xTg-AD-vh mice and that the treatment
with P021 was able to rescue this deficit. This neurogenic effect of P021 could be through the

152

inhibition of the LIF signaling pathway or the increase in the BDNF expression. My results are
in agreement with what was shown previously when P021 was injected subcutaneously to
normal adult C57Bl6/J mice (Li, et., 2010) or by oral gavage to a rat model of cognitive aging
(Bolognin et al., 2014).

6.4

Conclusion
My data showed that there was a synaptic loss in 3 month old 3xTg-AD mice. After 9,

15, and 18 months of treatment, P021 was able to prevent synaptic loss. Furthermore,
neurodegeneration analysis using Fluorojade C staining showed that P021 completely prevented
neurodegeneration at the three different time points. At 12 month of age (9 month posttreatment) P021 was also able to rescue the deficit in neurogenesis. These data showed that P021
could be a potential drug to restore synaptic loss, boost neurogenesis and prevent
neurodegeneration.

153

Chapter 7. Discussion
Taken together, the results of the present project demonstrate for the first time that the
administration of the neurogenic/neurotrophic peptidergic compound P021 at a very early stage
of the disease can prevent synaptic and neurogenesis deficit, cognitive impairment and A and
tau pathologies in 3xTg-AD mice. Behavioral analysis of 3xTg-AD mice with the Morris Water
Maze task showed that the 3xTg-AD mice were already cognitively impaired prior to the
initiation of the treatment with P021. Impairment in cognition was accompanied by a decrease in
the level of several synaptic markers such as synaptophysin and compensation at later time
points. The P021 provided during this compensation period showed that it can prevent synaptic
loss, neurogenesis deficit, cognitive impairment and A and tau pathologies. Most importantly,
the analysis across time of the effect of P021 on A and tau pathologies demonstrated a strong
effect on slowing down the progress of A and tau pathologies, as shown by a decrease in the
4G8 and AT8 load at 9 months, 15 months and 18 months post-treatment. Furthermore, I
unexpectedly found that P021 was able to increase the survival rate in the 3xTg-AD to 87%
compared to only 41% for 3xTg-AD-vh. Analysis of body weight and the food intake showed
that P021 had no apparent side effects.

7.1

Synaptic compensation
I found that at 12-14 weeks of age the 3xTg-AD mice were impaired. The

immunohistochemical and biochemical analysis of the brain tissues of 3xTg-AD mice from 10,
12, 13, 14, 15, and 16 weeks of age demonstrated the level and the expression of several synaptic
markers, most importantly synaptophysin, dropped sharply at 12 weeks, then came back almost
to the level of normal WT from 13 to 16 weeks because of the synaptic compensation
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phenomenon. The synaptic compensation phenomenon was reported previously in AD patients at
very early stages of the disease (Counts et al., 2006) and in cognitive aging (Bertoni-Freddari et
al., 1988, Barnes, 1994, Brown et al., 1998). My data further showed that when I compared the
expression levels of synaptic markers in the 3xTg-AD to those of WT the compensation
appeared to be region specific and time specific. Similarly, synaptic compensation in cognitive
aging was shown to be region specific and it was suggested to account for the spared cognition in
elderly people (Bertoni-Freddari et al., 1988, Barnes, 1994). In AD, however, synaptic
compensation seems to be unsuccessful, which is why cognitive deterioration occurs. This is in
agreement with our finding that the 3xTg-AD mice were impaired in the presence of the
compensation phenomenon. It could be suggested, however, that synaptic compensation in
humans is what accounts for a relatively long period of MCI in which cognitive deterioration and
neuronal and synaptic loss happen very slowly for up to 10 years. Likewise, in the 3xTg-AD
mice mutations are carried in their genes from embryonic day 11 but the appearance of the A
and tau pathologies starts only at around 9 months of age for A and 12 months for tau. Several
reports in the literature emphasize the importance of the compensation phenomenon at the level
of the synapse and at the level of the new born neurons to boost the efficiency of the therapeutic
intervention. Thus a drug that could be provided during this period would help the brain to
counteract the disease progression.

7.2.

Effect of P021 on cognitive impairment and survival rate
Previously, many attempts were made to use neurotrophic factors as therapeutic agents

for AD. However, most of them failed because of their short half-life, poor BBB permeability
and several side effects such as loss of appetite, weight loss, muscle pain, anorexia and
hyperplasia (Saragovi and Gehring, 2000). All of these side effects hinder the use of
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neurotrophic factors in Alzheimer’s therapy. To overcome these problems, several studies shift
to peptide mimetics, which are derived from the most active region of the neurotrophic factors.
Since they are very small peptides they have a better ability to cross the BBB, better half-life and
lesser side effects. The same approach was used in this study. I used P021, which is derived from
the most active region of the CNTF. We then added the adamantane group to increase its
lipophilicity and make it BBB permeable and decreased its degradation with peptidases (Li et al.,
2010). We showed previously that P021 has no apparent side effects (Blanchard et al., 2010b,
Kazim et al., 2014).
The present study is solely preventive; My aim was to provide P021 in the mouse diet
very early at 3 months of age, during the period of synaptic compensation and before the onset of
A and tau pathologies, and most importantly before severe synaptic or neuronal loss. The
chronic administration of P021 in this study from 3 months to 21 months of age showed that
P021 was able to prevent cognitive impairment completely in the mild and severe stages of the
AD-like pathological progress in 3xTg-AD mice. I showed that at 12 months of age, after
treatment with P021 for 9 months, spatial reference memory impairment was prevented in the
3xTg-AD-P021. Furthermore, at 18-19 months of age, after 15-16 months of P021 treatment, I
showed that short-term spatial memory impairment was prevented in the 3xTg-AD-P021, as seen
in a better performance in the object location task compared to 3xTg-AD-vh. Impairment in
episodic memory was prevented in the object recognition task in the 3xTg-AD-P021 while both
the 3xTg-AD-vh and WT were impaired. The WT mice were impaired because of the effect of
aging and this was further corroborated from the literature (Davis et al., 2013). Since spatial
navigation and episodic memories are severely affected in AD at early stages and I showed in
this study that P021 was able to prevent the impairment, this shows its potential therapeutic
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effects in AD. Cognitive impairment followed by dementia is one of the major clinical symptoms
that render AD patients totally dependent on others and bedridden at later stages of their life, so
if I can prevent cognitive deterioration I will be able to halt or slow down the disease process.
Not only was early treatment with P021 able to prevent the onset of cognitive impairment, but
also I unexpectedly found that it increased the survival rate of the 3xTg-AD-P021 compared to
3xTg-AD-vh. It is well documented in the literature that AD decreases the survival rate of
patients. For instance, over 14 years the survival rate of AD patient is only 2.4% versus an
expected rate of 16.6% (Molsa et al., 1995). In our study, the 3xTg-AD-P021 survival rate was
87% compared to only 41% in 3xTg-AD-vh. This shows that delaying the onset of cognitive
impairment and the other pathologies in AD patients would help to increase their survival rate.

7.3

Effect of P021 on A and tau pathologies
A and tau pathologies are the two major hallmarks of AD. Cognitive impairment is

known to correlate with NFT counts but not with A plaques (Arriagada et al., 1992a, GomezIsla et al., 1997). The spatial distribution of tau pathology follows a stereotypic pattern that starts
in the limbic system and then spreads to the neocortical regions. Since the limbic regions are the
primary targets of NFT pathology and they are known for their important role in memory it is
reasonable to expect a correlation between tau pathology and cognitive impairment. Since tau
pathology correlates with cognitive impairment its prevention could help to stop cognitive
deterioration. Indeed, in my study I found that early treatment with P021 in 3xTg-AD mice was
able to slow down the progression of A and tau pathologies across time from the time of their
onset until the progression to severe stages. Slowing down the pathologies could be the
biological correlate to slowing down cognitive deterioration and the rescue of cognitive
impairment seen in my study at different time points. My data are in agreement with reports in
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the literature that the use of plasma rich growth factors is able to decrease A deposition, tau
phosphorylation and cognitive impairment in APP/PS1 mice (Anitua et al., 2014).

7.4

Effect of P021 on neurodegeneration and neuroregeneration
Synaptic deficit is widely reported to correlate with cognitive impairment (DeKosky and

Scheff, 1990, Terry et al., 1991). Furthermore, it has been shown that synaptic loss correlates
with the increase in NFT counts. Synaptic loss was found to follow a similar pattern to NFT
pathology, in which neurons in the entorhinal cortex are first affected and then the hippocampus
(Coleman et al., 2004). The hippocampus in AD has been shown to have the greatest synaptic
loss, from 44% to 55% (Scheff et al., 2007). Early intervention within the onset of synaptic loss
or before was suggested to be effective on preventing and slowing down the progression of the
neuropathological features of AD. In this study P021 was provided in food diet just at the onset
of synaptic loss for nearly the whole mouse lifespan. I found that P021 was able to prevent
synaptic loss, especially at 18 and 21 months of age. Our data are in agreement with our previous
studies using P021 in AD mouse models (Blanchard et al., 2011, Bolognin et al., 2012, Kazim et
al., 2014) as well as other animal models of neurodegenerative diseases (Blanchard et al., 2011)
and cognitive aging (Bolognin et al., 2014). Similarly, P021 treatment was able to prevent
neurodegeneration at the three time points.

7.5

Effect of P021 on neurogenesis
Since it is well established that neurogenesis contributes to information storage and

retrieval as well as the plasticity of the hippocampus, its disruption most likely will affect
memory and cognitive abilities. Indeed, in AD neurogenesis is disrupted very early in the disease
process. The impaired neurogenesis in AD was shown to be due to an imbalance of neurotrophic
factors in the brain biochemical milieu with a decrease in the BDNF and NT-4 expression levels
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and an increase in the expression level of FGF-2. We previously reported an increase in
neurogenesis in AD postmortem brains in the DG (Li et al., 2008). However, the self-repair
attempt of the brain remains unsuccessful as the newly born neurons cannot make it to become
fully mature and integrate into the surviving circuitry in AD brains. I thought that providing the
brain with the trophic support would help the brain to compensate for the deficit in neurogenesis.
In this study the effect of P021 to boost neurogenesis was studied at 9 month-post-treatment in
the DG area. I found that neurogenesis was defective in the 3xTg-AD-vh compared to WT and
that P021 was able to prevent this deficit and boost neurogenesis to a level more than WT. This
was seen by the increase in the number of the DCX+ and Ki-67+ cells in the P021 treated group
in the DG. The fact that neurogenesis decreased in the 3xTg-AD-vh mice was in agreement with
what was found previously using this mouse model (Hamilton et al., 2010).

7.6

Possible mechanism of prevention of cognitive impairment and pathological
features with P021
Previous investigation of the possible mechanisms of P021 showed that P021 acts by

competitively inhibiting leukemia inhibitory factor (LIF) signaling. In neuronal cell culture P021
was shown to weakly inhibit LIF signaling through a slight inhibition of the phosphorylation of
STAT3 in a dose dependent manner (Li et al., 2010). Furthermore, we showed previously that
P021 acts by increasing the expression level of BDNF. Together the inhibition of LIF signaling
and the increase in BDNF expression would inhibit stem cell proliferation and promote their
maturation (Fig. 42a). Furthermore, BDNF has been shown to increase synaptic plasticity,
neurogenesis and cell survival. The effect of P021 on preventing synaptic plasticity and cognitive
impairment that I found here is probably due in part to the increase in BDNF expression. It is
well established in the literature that an increase in BDNF expression leads to an increase in the
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phosphorylation of GSK3β on its Serine 9 site, which is inhibitory. The prevention of A and tau
pathologies with P021 in this study may be through the inhibition of GSK3 signaling (Fig.
42b). Indeed, it has been shown that GSK-3 is a major tau kinase (Kosik, 1992) and its
overexpression leads to hyperphosphorylation of tau and microtubule disruption in mice (Lucas
et al., 2001). In AD, GSK3β is known to mediate A induced neuritic damage (DaRocha-Souto
et al., 2012). Moreover, the GSK 3 isoform is known to increase APP processing (Phiel et al.,
2003) and A production. So inactivation of GSK3 would result in a reduction of the A load
and tau hyperphosphorylation, as seen in the present study. In the neurogenic niches
hyperactivation of GSK3 leads to impaired neurogenesis in mice. Thus, by decreasing GSK3β
activity, neurogenesis can be rescued. Since it has been shown that GSK3 promotes apoptosis,
its inhibition also would lead to the inhibition of neurodegeneration (Beurel et al., 2010).
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a)

b)

Fig. 42: Mechanism of action of P021. a) Neurogenic/ neurotrophic effect of P021. b) Mechanism of
inhibition of Aβ and tau pathologies by P021. (Kazim et al, Neurbiol. Dis., 2014).
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7.7

Future directions
My findings (chapter 3) suggest that in 3xTg-AD mice the brain attempts to self-repair by

the synaptic compensation phenomenon as a reaction to the early synaptic loss. However, even in
the presence of synaptic compensation this attempt is unsuccessful and does not prevent
cognitive impairment, as seen in human cognitive aging. Future work should then focus on
answering the question of what is lacking in this compensation.

Is it insufficient or is it

abnormal so that it cannot reverse cognitive impairment? An approach to answer this question
would be to investigate the morphology of the spines with the lipophilic staining DiI to
determine if they have a normal shape or large and stubby spines that are pathological. Since it is
reported that in AD patients the compensation in the surviving synapses happens by increasing
the synapse size so that the total contact surface area is preserved, a measure of the size of the
synapses could be another approach to investigate in future studies. Future work could also focus
on determining whether the number of synapses really increased, causing the observed increase
in synaptic markers, or if it was simply a result of an increase in synaptic size. Furthermore, I
could investigate the electrophysiological component of this compensation. For example, I could
record from a single cell with a patch clamp method to detect an increase in the level of the
excitatory post-synaptic potential. Then I could study it at the level of the neuronal network. If
there is an increase in the amplitude of neuronal firing would this result in an increase in the
whole neuronal firing? Would an increase in neuronal firing result in a compensation for the
whole neuronal network or disrupt it? If the latter was the case, instead of compensating for the
synaptic loss compensation would become the driving force for synaptic loss and
neurodegeneration.
Since our study is of secondary prevention because it was initiated after the onset of
cognitive impairment and synaptic loss, future directions would be to start the treatment of mice
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in utero by providing the drug in the food to the mothers from conception until weaning and then
later on to pups after weaning. Since the expression of the mutated transgenes in 3xTg-AD mice
starts from embryonic day 11 and since an early treatment before the onset of synaptic loss and
cognitive impairment would be more effective, I can consider the data from our study as
encouraging the start of treatment in utero. Considering all ages together, P021 was able to
decrease the A and tau loads and it was able to prevent cognitive impairment as well as
synaptic loss. I expect that in utero treatment would be stronger in preventing the A and tau
pathologies as well as synaptic loss. This study would be of great importance to human
preclinical trials, especially those of the familial form of the disease. If toxicological testing
shows that P021 is safe to use for humans from the embryonic stage then I could prevent AD in
people who carry the mutated genes in their genome and are destined to develop it later on in
their life.

7.8

Conclusion
Together the results of this study showed for the first time that secondary prevention

using P021 in 3xTg-AD mice is able to prevent cognitive impairment, A and tau pathologies
and synaptic and neuronal loss and can boost neurogenesis. Taking advantage of the synaptic
compensation phenomenon and the ability of the brain to self-repair very early in the disease
process I was able to show that P021 treatment was able to prevent cognitive impairment at three
different time points at 9, 15-16, and 16-17 months post-treatment. Most importantly I showed
that P021 treatment increases the survival rate of 3xTg-AD mice and can prevent A and tau
pathologies. Lastly I found that P021 was able to prevent synaptic loss by increasing the level
and the expression of different synaptic markers as I showed biochemically as well as
immunohistochemically at 9, 15, and 18 months post-treatment. Thus, together these data
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suggest P021 as a potential drug for AD treatment in future prevention trials, since prevention
trials now use only anti-A therapy which, to date, has proven in human clinical trials to be
ineffective.
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